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Thyroid cancer is the most common endocrine cancer, with a rising incidence. The 
proto-oncogene PBF is over-expressed in thyroid tumours, and the degree of over-expression 
is directly linked to patient survival. PBF causes transformation in vitro and tumourigenesis in 
vivo, with PBF-transgenic mice developing large, macro-follicular goitres, effects partly 
mediated by the internalisation and repression of the membrane-bound transporters NIS and 
MCT8. NIS repression leads to a reduction in iodide uptake, which may negatively affect the 
efficacy of radioiodine treatment, and therefore prognosis. 
Work within this thesis describes the use of tandem mass spectrometry to produce a list 
of potential binding partners of PBF. This will aid further research into the pathophysiology 
of PBF, not just in relation to thyroid cancer but also other malignancies. From this list, the 
interaction with three proteins was further investigated and validated by GST pull-down 
assays and/or co-immunoprecipitation. Thyroglobulin is an essential component of thyroid 
hormone synthesis. Preliminary studies suggested co-localisation with PBF within intra-
cellular vesicles, although further research is needed to explore this functionally. Cortactin 
has a role in the cellular transport of proteins, and also promotes invadopodia formation and 
metastases in cancer. Co-localisation was observed in vesicles and at the membrane, with PBF 
additionally demonstrated in cell membrane projections – indicating a potential mechanism 
for the shuttling of PBF to and from the cell membrane, and its secretion. SRC is a tyrosine 
kinase intimately linked to cancer. SRC phosphorylated PBF, an effect abrogated by treatment 
with specific inhibitors, including PP1. Importantly, PP1 treatment was then found to increase 
iodide uptake in human primary thyroid cultures over-expressing PBF. 
Overall, these data describe a list of possible binding partners for PBF, and specifically 
identify a novel potential therapeutic strategy for iodide-refractory thyroid cancer.
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Chapter 1 General Introduction  




1.1 The Physiological Role of the Thyroid Gland 
1.1.1 Thyroid structure and development 
The thyroid is an important endocrine organ located in the anterior neck and is found in 
all vertebrates.  In humans, it originates from the base of the tongue in the 3rd to 4th week 
gestation and migrates into the neck over the next few weeks.  Macroscopically, it is 
composed of two lobes lying on either side of the trachea and connected by an isthmus 
(McGlashan 2008).  Microscopically, the thyroid consists of many follicles - spheres of 
cuboidal follicular epithelial cells (Figure 1.1).  
 
Figure 1.1 A -­‐ Cross-sectional structure of a thyroid follicle. B -­‐ Detail of a thyroid follicular 
cell, showing the process by which the follicle produces thyroid hormones. I = Iodine, Tyr = 
Tyrosine, MIT/DIT = Mono/Di-­‐iodotyrosine, T3 = Triiodothyronine, T4 = Thyroxine, MCT8 
= Monocarboxylate transporter 8, NIS = Sodium iodide symporter, Lys = Lysosome, BL = 
baso-­‐lateral, mb = membrane. 




There are around 3 million follicles in a healthy adult thyroid, each surrounding an area 
of protein-rich colloid which forms the bulk of the mass of the thyroid.  The most abundant 
protein within the colloid is thyroglobulin, a 660 kDa dimeric protein synthesised in the 
endoplasmic reticulum.  Each follicle is surrounded by a network of capillaries and clusters of 
parafollicular cells. 
1.1.2 Thyroid hormone synthesis 
The predominant role of the thyroid is to produce the thyroid hormones triiodothyronine 
(T3) and tetraiodothyronine   (“thyroxine”  or  T4).  The synthetic pathway is complex (Figure 
1.1B) and dependent on the influx of iodide into the thyroid via the sodium-iodide symporter 
(NIS), a transmembrane glycoprotein located at the basolateral membrane of the thyroid 
follicular cell. NIS actively transports 2 sodium ions with 1 iodide ion, resulting in an 
intracellular iodide concentration up to 50 times higher than the plasma. Iodide diffuses across 
the cell, and is then transported across the apical membrane into the colloid by pendrin, where 
it is oxidated to iodine by thyroid peroxidase at the outer surface of the membrane. The 
reactive species liberated from this reaction iodinates thyroglobulin at its tyrosyl residues. The 
products of this iodination are monoiodotyrosine and diiodotyrosine, which in turn can 
combine to form the thyroid hormone triiodothyronine (T3) and thyroxine (T4), still bound to 
thyroglobulin. Thyroid-stimulating hormone (TSH), released from the anterior pituitary gland, 
binds to the TSH receptor on the basolateral membrane, stimulating endocytosis of thyroid 
hormones. T3 and T4 are liberated from thyroglobulin following the fusion of the endosomes 
with lysosomes, and subsequently transported across the basolateral membrane into the 
bloodstream via monocarboxylate transporter 8 (MCT8) (Di Cosmo et al. 2010; Trajkovic-
Arsic et al. 2010).  




The control of thyroid hormone production and secretion is via the hypothalamic-
pituitary-thyroid axis, an endocrine negative feedback loop where low circulating levels of 
T3/T4 stimulate the hypothalamus to release thyrotropin releasing hormone (TRH).  This 
stimulates the anterior pituitary to release thyroid stimulating hormone (TSH). As well as the 
effects on the secretion of T3 and T4, TSH also stimulates expression of NIS, thus acting 
throughout the pathway of thyroid hormone synthesis (Dohan et al. 2003). 
 
Figure 1.2 Hypothalamic-Pituitary-Thyroid axis. The release of TRH and TSH is under the 
control of a negative feedback loop by T3 and T4. TRH - Thyrotropin Releasing Hormone, 
TSH - Thyroid Stimulating Hormone. 
1.1.3 The role of the thyroid gland in health 
Both T3 and T4 are transported in the bloodstream bound primarily to thyroxine-binding 
globulin, with a smaller amount bound to either thyroxine-binding albumin or para-albumin. 
In the bound state, the hormones are inactive and it is therefore the free T3 and T4 (< 0.5 % of 




total) that exert a cellular effect. T4 has a long half-life and acts as a pro-hormone for the 
biologically active T3. T4 is converted in the periphery to T3 by iodothyronine deiodinases, 
and then actively transported across the cell membrane by a small number of identified 
transporters, namely OATP1C1, monocarboxylate transporter (MCT) 8 and MCT10 (Visser et 
al. 2011). Thyroid hormone has a wide range of effects across the body, in general increasing 
metabolic rate and development, as summarised in Table 1.1. 
 










Muscle Increase protein breakdown. 
Adipose Stimulate lipolysis. 
Developmental 
Central nervous system Promote brain development. 
Bone Promote skeletal growth. 
Metabolic 
Gastrointestinal tract Increase carbohydrate absorption. 
General 
Increase oxygen 




Table 1.1 Table detailing the systemic effects of thyroid hormone (Ganong 1997). 
  




1.2 Thyroid Cancer 
1.2.1 Incidence of Thyroid Cancer 
Thyroid cancer is the commonest endocrine cancer, with an incidence of 3.6 cases per 
100,000 per year in the UK. Women have a 2.5 times greater risk of developing thyroid 
cancer than men (5.6 vs 2.2 per 100,000), with a peak incidence during the 4th decade (Figure 
1.3A) (Cancer Research UK 2013). The incidence of differentiated thyroid cancer (DTC) has 
almost tripled in the United States between 1975 and 2009, and the disease has the fastest 
rising incidence of any cancer in the USA (Figure 1.3B and C) (Howlader N 2012). The exact 
cause for this rise in incidence is unknown, but has been attributed to the increase in the 
detection   of   small,   early   tumours   (“incidentalomas”)   during   investigations   for   other 
conditions (Leenhardt et al. 2004; Cooper et al. 2009), and interestingly the rise is not 
associated with a corresponding rise in mortality (Figure 1.3D) (Howlader N 2012). However,  
the fact that the incidence of later stage cancers is also increasing implies that more 
sophisticated detection methods cannot account for the increase alone (Chen et al. 2009; Sipos 
and Mazzaferri 2010). 





Figure 1.3 Thyroid cancer demographic data. A – Incidence of thyroid cancer per 100,000 
across age groups by gender (CRUK 2013). B – USA age-adjusted incidence per 100,000 
between 1975 and 2009. C – US annual percentage change in incidence of malignancy across 
all cancer sites. D – USA age-adjusted mortality rate per 100,000 between 1975 and 2009 (B 
– D from SEER data (Howlader N 2012)). 
 
1.2.2 Risk factors for developing DTC 
There are several well documented risk factors for developing thyroid cancer. One of the 
most widely studied is the effect of ionising radiation on the thyroid gland in childhood. First 
considered in a report of 28 childhood thyroid cancers, of whom 11 received radiation to the 
thymus for respiratory obstructive symptoms (Duffy and Fitzgerald 1950), the association was 
further explored over the subsequent decades (Kaplan et al. 2009). The atomic bomb 




survivors of Hiroshima provided a long term cohort that have been extensively studied; a 
recent study has shown that the excess thyroid cancer risk of those exposed as children has 
continued for over 50 years after exposure (Furukawa et al. 2013). The more recent disaster at 
Chernobyl in 1986 led to a sharp increase in the number of cases of DTC in the surrounding 
areas (Stsjazhko et al. 1995). Papillary carcinomas are the most frequent DTC to be associated 
with radiation exposure, with chromosomal rearrangements (principally RET/PTC (35 %) and 
occasionally   PAX8/PPARγ (3 %)) most common, and point mutations (BRAF (15 %) and 
RAS (8 %)) also present (Leeman-Neill et al. 2013). The effects of the Fukoshima disaster 
following the Japanese earthquake and tsunami on the health of the surrounding prefecture 
will be monitored closely over the following decades, with the World Health Organisation 
predicting a 70 % increase risk of thyroid cancer in females exposed as infants (WHO 2013). 
A previous history of benign hyperplastic thyroid disease increases the risk of thyroid 
cancer (relative risk (RR) 14.5, P < 0.01) (Preston-Martin et al. 1987), as does a family 
history of thyroid cancer. The lifetime risk of thyroid cancer in a patient with a first degree 
relative diagnosed with a non-medullary thyroid cancer is 2 % (standardised incidence ratio 
(SIR) 2.9, 95 % CI 2.4 to 3.4, p < 0.00001) for women and 1 % (SIR 2.5, 95 % CI 1.9 to 3.3, 
p < 0.00001) for men. When 2 or more family members are affected, the SIR rises to 23.2 (95 
% CI 10.6 to 44.0, p< 0.00001). The younger the family member was diagnosed with DTC, 
the higher the risk of developing the disease (Fallah et al. 2013). 
Thyroid cancer is more common in association with certain hereditary diseases. Familial 
adenomatous polyposis coli (FAP) is an autosomal dominant pre-malignant disease caused by 
mutations in the tumour suppressor gene APC. Affecting 3 to 10 per 100,000 (Half et al. 
2009), patients develop a large number of colonic polyps, and there is a 100 % progression to 
colorectal cancer. It is also associated with a number of extra-colonic manifestations, of which 




the cribriform morular variant of papillary thyroid cancer is one. The rate of thyroid cancer 
amongst patients with FAP ranges from 0.4 to 11.8 % (Steinhagen et al. 2012), with a relative 
risk of 7.6 (95 % CI 2.5 to 17.7) (Giardiello et al. 1993). A specific mechanism for this 
association has not, as yet, been described. Cowden, and Cowden-like, syndrome, are 
characterised by the development of multiple cutaneous hamartomas, and due to autosomal 
dominantly inherited mutations in one or more of the PTEN, SDHx and KLLN gene. In a 
cohort of 2723 patients with the syndrome, for those with a PTEN mutation the SIR for 
thyroid cancer was 72 (95 % CI 51 to 99, p < 0.001) and this was disproportionally follicular 
thyroid cancer. The SIR for SDHx and KLLN mutations was 63 (95% CI 42 to 92, p < 0.001) 
for SDHx variants, and 45 (95% CI, 26 to 73, p < 0.001) respectively (Ngeow et al. 2011). 
Chronic   lymphocytic   (Hashimoto’s)   thyroiditis leads to an increased risk of thyroid 
lymphoma (as well as systemic myeloproliferative and lympho-proliferative neoplasms 
generally) but not DTC, with an estimated relative risk of 67 (p < 0.000001) (Holm et al. 
1985). 
1.2.3 Types of thyroid cancer 
The majority of thyroid cancers arise from follicular cells and are termed differentiated 
thyroid cancers (DTCs). The commonest sub-type is papillary thyroid cancer (PTC), which 
accounts for approximately 70 % of all thyroid cancer and is further split into pure papillary, 
follicular and mixed PTC. PTC metastasis is usually via lymphatic spread, and an involved 
cervical lymph node may be the first sign of the disease in some patients (Lim et al. 2012). 
Follicular thyroid cancer (FTC) accounts for around 10 – 20 % of thyroid cancers. 
Unlike PTC, lymph node metastasis is rare, with blood borne spread to lungs and bone being 
more common. The 2 subtypes are Minimally Invasive Follicular Carcinoma (MIFC), which 
although macroscopically appearing the same as a follicular adenoma demonstrates capsular 




and/or vascular invasion microscopically, and Widely Invasive Follicular Carcinoma (WIFC), 
which demonstrates diffuse infiltration of the thyroid gland, and a consequently poorer 
survival rate. 
Medullary thyroid cancer (MTC) originates from the parafollicular cells and represents 
5% of thyroid cancers. There is a strong hereditary component to the disease; 25% of MTC 
cases are caused by germline mutations in the RET proto-oncogene that result in multiple 
endocrine neoplasia (MEN) 2A (80%), MEN 2B (5%) and familial MTC (5-15%) (Ceolin et 
al. 2012). The cancers secrete calcitonin (used as a serum marker for the disease), which can 
cause the characteristic flushing and diarrhoea associated with the disease. 
Anaplastic, or de-differentiated, thyroid cancer typically presents later in life and is 
associated with rapid mitosis and high rate of lympho-vascular invasion. It accounts for 
around 5 % of all thyroid cancers and is almost universally fatal (Ain 1998).  
The histological distribution of thyroid cancers, as well as their mode of presentation and 
primary treatment is summarised in Table 1.2 . 
Subtype Proportion Mode of presentation Primary Treatment 
Papillary 71.5 % Thyroid mass or cervical lymphadenopathy 
Surgery +/- 
131I 
Follicular 19.6 % Thyroid mass or distant metastases 
Surgery +/- 
131I 
Medullary 6.1 % Thyroid mass or evidence of MEN Surgery 
Anaplastic 1.5 % Rapidly enlarging thyroid mass Palliative 
Table 1.2 Subtypes of thyroid cancer including mode of presentation and primary treatment 
modality (British Thyroid Association and Royal College of Physicians 2007; British 
Association of Endocrine and Thyroid Surgeons 2009). 




1.2.4 Diagnosing thyroid cancer 
The commonest presentation of DTC is a solitary thyroid nodule (STN), which may 
have been identified by the patient or their general practitioner, or incidentally when the 
patient was being investigated for an unrelated problem. Once identified, the usual method of 
assessment of a STN is via ultrasonography and fine needle aspiration cytology (FNAC). 
There are a number of ultrasound characteristics that suggest a malignant nodule as opposed 
to a benign diagnosis: microcalcifications, irregular nodule margins, parenchymal 
hypoechogenicity, increased nodule vascularity and abnormal neck lymphadenopathy 
(Alexander 2008). However, none of these are definitive. 
FNAC aims to provide a cellular sample from the nodule in question, thus allowing a 
cytological analysis with the aim of determining if the nodule is benign or malignant. FNAC 
can be performed using palpation alone or via ultrasound guidance; the latter is associated 
with  higher  “hit”   rates  and  more  reliable  diagnosis,  as   the  ultrasonographer   is  able   to   target  
the needle to the most suspicious area.  FNAC results are split into 5 broad categories (see 
Table 1.3),  known  as  the  “Thy”  classification.   











Thy1 Non-diagnostic (virtually acellular) 
0-10 
Thy1c Non-diagnostic- Cystic lesion 
Thy2 
Non-neoplastic (Consistent with a benign 
follicular nodule or lymphocytic thyroiditis or 
subacute thyroiditis) 0-3 
Thy 2c Non-neoplastic, cystic lesion 
Thy3a Neoplasm possible- atypia 5-15 
Thy3f Neoplasm possible- suggestive of follicular neoplasm 15-30 
Thy4 Suspicious for papillary/ medullary/ metastatic/lymphoma/carcinoma 60-75 
Thy5 Malignant 97-100 
Table 1.3 Current recommendations for the reporting of thyroid FNAC specimens, with the 
associated risk of malignancy for each category (British Thyroid Association and Royal 
College of Physicians 2007; RCPath 2009). 
 
In general, if a Thy2 result is obtained from FNAC, the patient will go on to have a 
repeat sample taken, usually at an interval of 3 to 6 months, and only if this is again benign 
will this be taken as a valid result. On the other end of the scale, a Thy5 result mandates at 
least a hemi-thyroidectomy (see section 1.2.5.2). Difficulties arise in the problematic area of 
the Thy3 result. It is not possible for a cytologist to determine whether follicular cells in a 
sample represent a benign follicular adenoma or the malignant follicular carcinoma, and 
therefore these results are classed as indeterminate. Most centres will proceed with a 
“diagnostic   lobectomy”,   removing   the   half   of   the   thyroid   gland   containing   the   suspicious  
nodule and thereby allowing a full histological diagnosis. The rate of malignancy in Thy3 
FNACs is approximately 28 %, although the risk increases at ages less than 30 and greater 
than 60 years, in males, and for larger nodules (Mihai et al. 2009). This results in a large 




number of patients undergoing surgery for what is in fact a benign disease, and over a quarter 
of patients requiring a second operation for what proves to be malignancy. At present, studies 
are underway to utilise biomarkers or mutation analysis of FNAC samples in an attempt to 
improve the diagnostic accuracy of these indeterminate results. 
1.2.5 Management of differentiated thyroid cancer 
1.2.5.1 Staging 
In the UK, thyroid cancer is staged according to the TNM classification (Table 1.4), 
which takes into account Tumour factors, Nodal status and Metastases.  
Stage Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1a Tumour 1 cm or less in greatest dimension, limited to the thyroid 
T1b Tumour 1–2 cm in greatest dimension, limited to the thyroid 
T2 Tumour more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid 
T3 
Tumour more than 4 cm in greatest dimension, limited to 
the thyroid or any tumour with minimal extrathyroid 
extension (e.g. extension to sternothyroid muscle or 
perithyroid soft tissues) 
T4a 
Tumour of any size extending beyond the thyroid capsule 
and invading any of the following: subcutaneous soft 
tissues, larynx, trachea, oesophagus, recurrent laryngeal 
nerve 
T4b Tumour invades prevertebral fascia, mediastinal vessels, or encases carotid artery 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
N1a Metastasis in Level VI (pretracheal and paratracheal, including prelaryngeal and Delphian lymph nodes) 
N1b Metastasis in other unilateral, bilateral or contralateral cervical or upper/superior mediastinal lymph nodes. 
cM0 Clinically no distant metastasis 
cM1 Distant metastasis clinically 
Table 1.4 TNM staging classification for DTC (from AJCC Cancer Staging Manual, 2009). 




In  DTC,  the  disease  is  further  staged  by  the  patient’s  age  to  allow  prognostication  (see 
section 1.2.6). 
1.2.5.2 Surgery 
At present, the only definitive way of treating DTC is with surgery to remove all or part 
of the thyroid gland, affected lymph nodes and metastases. In the past, there was a tendency to 
perform sub-total thyroidectomy (leaving a significant portion of the gland behind in an 
attempt to preserve the recurrent laryngeal nerve (RLN)) but this was shown to increase 
recurrence rates when compared to total or near-total thyroidectomy. The main complications 
from the surgery are damage to the RLNs (resulting in voice change or in extreme cases 
airway compromise and respiratory embarrassment requiring tracheotomy) and/or parathyroid 
glands (resulting in temporary or permanent hypoparathyroidism); although in experienced 
hands these should occur in only a small number of cases. As more DTCs (in particular PTCs) 
with a diameter less than 10 mm are diagnosed, more centres are treating these with thyroid 
lobectomy. While this undoubtedly reduces complications, studies have shown that between 
30 and 46 % of PTCs are multifocal and contralateral (Ricci and Alfonso 2012; Lee et al. 
2013), meaning that some of these patients will have residual foci of malignancy in the neck 
following surgery. 
1.2.5.3 Radioiodine ablation 
Given  the  thyroid’s  ability  to  concentrate  iodine,  radioiodine  ablative  therapy  has  been  
used since the 1940s to treat thyroid disease (Miller and Soley 1948). The isotope used in 
thyroid cancer treatment is iodine-131 (   I). This has a decay half-life of around 8 days, and 
emits both gamma (10 %) and beta (90 %) radiation. The isotope can therefore be imaged 
using gamma-readers, although it is not possible to detect the beta emissions. It is the latter 
that facilitates the death of thyroid tissue where it is taken up. 




Over the past few years, there has been a move away from treating all thyroid cancers 
greater than 1 cm with post-operative    I, instead only giving treatment to targeted patients 
who will show a predicted benefit (Table 1.5). There is still a group in whom there is no clear 
evidence one way or the other, and for these patients the decision to give or withhold 
treatment must be made on an individual basis by the multi-disciplinary team. 
No indication for ¹³¹I ablation 
(low risk of recurrence) 
x Complete surgery 
x Favourable histology 
x No extra-thyroidal extension 
x PTC:  unifocal.  ≤  1cm  diameter,  N0,  M0.  
Minimally invasive FTC: no vascular 
invasion,  ≤  2cm  diameter 
Definite indications 
x Distant metastases 
x Incomplete resection 
x High risk of tumour recurrence 
Table 1.5 Indications for ¹³¹I ablation post-surgery (British Thyroid Association and Royal 
College of Physicians 2007). 
The efficacy of radioiodine treatment for thyroid cancer is directly related to the action 
of the sodium-iodide symporter, NIS. In well-differentiated malignancies with functioning 
NIS,    I is concentrated within the gland at doses that ensure the destruction of any residual 
thyroid tissue. However, in tumours that show a lesser degree of differentiation, NIS is less 
active and the tumour cells therefore less susceptible to treatment. It is these cancers that are 
not only most likely to recur, but also less amenable to secondary treatments. 
1.2.5.4 TSH suppression 
In order to minimalise the risk of recurrence, most patients will require TSH 
suppression, regardless of initial surgical option or whether they have received    I. By 
administering exogenous T4, the hypothalamic-pituitary-thyroid axis is supressed, thereby 
reducing TSH secretion from the anterior pituitary gland. This ensures that any remaining 
thyroid tissue is receiving little or no activating stimulus, therefore reducing the likelihood of 
further tumour growth. For most patients, doses of levothyroxine will be tailored to achieve a 




serum TSH of less than 0.1 mIU/L, however for lower risk patients a measurable level below 
the reference range (i.e. 0.1 – 0.5 mIU/L) may be maintained with no increase in risk of 
recurrence. 
1.2.6 Prognosis 
The prognosis of appropriately managed DTC is favourable, with many patients being 
classed  as  “cured”.  Unfortunately,   cancers  have  been  known   to   recur  many  years   following  
treatment and therefore lifelong surveillance is mandatory.  
1.2.6.1 Recurrence 
The American Thyroid Association stratifies patients into low, intermediate and high 
risk of recurrence (Table 1.6). Despite the generally good prognosis, the overall recurrence 
rate for DTC is 30 % at 30 years (Mazzaferri and Jhiang 1994), although this risk may be 
reduced by radioiodine ablation, TSH suppression and prophylactic central neck dissection 
(McLeod et al. 2013). 
Low risk Intermediate risk High risk 
x No metastatic spread 
(local/distant) 
x Full macroscopic resection 
x No locoregional invasion 
x Non-aggressive histology 
x No    I uptake outside of 
the thyroid bed 
x Microscopic invasion into 
perithyroidal soft tissues 
x Cervical lymph node 
metastases 
x Aggressive histology 
x Uptake of    I outside of 
the thyroid bed 
x Macroscopic tumour 
invasion 
x Incomplete resection 
x Distant metastases 
x Increase thyroglobulin out 
of proportion to post-
treatment scan 
Table 1.6 Factors influencing risk of recurrence (Cooper et al. 2009). 
Recurrence is most often in the thyroid bed, although the exact cause is often unknown. 
Factors associated with recurrence include extra-thyroidal extension of the primary tumour, 
bulky nodal metastatic lesions, macroscopic local invasion, and aggressive histologic 
subtypes; inadequate primary surgery may also contribute (Shaha 2012). Although recurrent 




DTC are less radioiodine avid than primary tumours, there is still a role for radioiodine, 
especially in combination with surgery, either as a pre-operative debulking tool or a post-
operative ablative technique. Metastases are most common in the neck, either in the central 
and lateral compartment; distant metastases occur predominantly in the lung or bones (79 %) 
(Jin et al. 2013). 
1.2.6.2 Mortality 
The 5 year survival for thyroid cancer is 98.9 % below the age of 65 years, although this 
drops to 91.1 % after this; the mortality rate has risen slightly over the last 15 years in the 
USA from 0.44 to 0.51 per 100,000 per year (Howlader N 2012). The reason behind the 
relatively stable mortality rate despite the rising incidence is that DTC is being diagnosed 
much earlier, allowing more successful treatment. There are, however, a significant cohort of 
patients for whom the diagnosis is made after disease progression, and it is in this group that 
the majority of the early mortality (less than 5 years from diagnosis) occurs. Late mortality is 
often due to an increased aggressiveness, difficulty in resection and lack of response to 
adjuvant therapies of recurrent tumours. 
1.3 The molecular basis of thyroid cancer 
1.3.1 Oncogenes and thyroid cancer 
Most malignant thyroid tumours are monoclonal in origin, meaning that genetic 
alterations in a single cell within an otherwise healthy thyroid gland are responsible for the 
disease. These alterations may reflect activating mutations of oncogenes or inactivation of 
tumour suppressor genes.  




1.3.1.1 Mitogen-Activated Protein Kinase Pathway 
The MAPK pathway, also known as the RAS-RAF-MEK-ERK pathway, is an important 
cascade that allows signalling from a cell surface receptor to trigger nuclear transcription, and 
thereby govern key cellular events (Figure 1.4).  
Uncontrolled activation of the pathway is a feature of many cancers and this is often 
brought about by mutation of its constituent kinases. These mutually exclusive mutations are 
found in approximately 75 % of PTCs and 70 % of FTCs (Figure 1.5) (Bhaijee and Nikiforov 
2011). 
 
Figure 1.4 The Mitogen Activated Protein Kinase pathway. Binding of a growth factor (GF) 
to a receptor tyrosine kinase (RTK) leads to the subsequent interaction with Growth Factor 
Receptor Bound protein (GRB) 2 via its SH3 site. GRB2 then binds Son of Sevenless (SOS), 
which facilitates a guanine exchange, converting RAS-GDP to RAS-GTP. This triggers a 
cascade of phosphorylation reactions culminating in a number of key nuclear events. 





Figure 1.5 Frequency of genetic mutations in papillary and follicular thyroid cancer (Bhaijee 
and Nikiforov 2011). 
1.3.1.2 Point mutations 
1.3.1.2.1 BRAF 
There are 3 RAF genes - A, B and C – the corresponding proteins of which are 
serine/threonine kinases. BRAF mutations have been identified in many human cancers 
(Davies et al. 2002), the commonest of which is the point mutation T1799A, which leads to 
the amino acid change V600E. This leads to oncogenic activation of the BRAF kinase. BRAF 
mutation occurs in 44 % of PTC and  24 % of papillary derived ATC, but does not occur in 
FTC, MTC or benign thyroid disease such as thyroid adenomas or hyperplasia (Xing 2005). 
PTCs displaying the BRAF mutation are more aggressive, showing lymph node spread, extra-
thyroidal invasion, distant metastases (Xing 2007) (Table 1.7) and loss of radioiodine avidity 
(Xing et al. 2005). 






Odds Ratio with BRAF 
mutation (95% confidence 
interval) 
Lymph node metastases 1.83 (1.58-2.13) 
Extra-thyroidal invasion 2.50 (2.11-2.97) 
Disease stage III or IV 2.14 (1.79-2.56) 
Table 1.7 Association of BRAF mutation with the most aggressive characteristics of PTC 
(Xing 2007). 
 Recurrence is also more likely in the presence of BRAF mutation (odds ratio 2.65, p < 
0.001 (Xing 2007)) and is associated with a reduced disease free survival (Figure 1.6) (Kim et 
al. 2006). The increased recurrence rates are valid even when taking into account the poor 
prognostic factors detailed above. 
 
Figure 1.6 Disease free survival from time of diagnosis of thyroid cancer, depending on 
BRAF mutation status, taken from Kim et al. 2006. 




In vivo work also confirms that BRAFV600E induces thyroid enlargement and PTC, with 
one study of transgenic mice expressing this mutation demonstrating carcinomas in 14 of 15 
mice by 12 weeks, most with an aggressive phenotype (Knauf et al. 2005). Further work has 
suggested that TSH plays a key role in inducing BRAFV600E  PTC, with oncogenic BRAF 
knock-in mice requiring the TSH receptor in order to transform thyroid follicular cells 
(Franco et al. 2011). 
This link between BRAF mutation and aggressiveness of tumour phenotype has 
prompted research into both the therapeutic significance and diagnostic and prognostic value 
of the mutation.  Using siRNA, BRAF knockdown in human ATC cell lines in vitro reduced 
the phosphorylation of downstream proteins in the MAPK cascade as well as significantly 
reducing their growth. This was then replicated using BAY 43-9006, a small molecule RAF 
kinase inhibitor (Salvatore et al. 2006), thus demonstrating that these compounds may be 
effective in treatment for ATC containing the BRAFV600E mutation. For diagnostic purposes, 
Xing et al used both direct DNA sequencing and a colorimetric mutation detection method to 
identify the BRAFV600E  mutation in pre-operative FNAC samples from patients undergoing 
thyroidectomy for nodular thyroid disease (Xing et al. 2004). Of those patients with a final 
diagnosis of PTC, 50 % were positive for BRAFV600E, whereas no patients with other 
malignancies or benign thyroid disease harboured the mutation. While this would not be 
useful for those patients in whom a follicular neoplasm is suspected (see Section 1.2.4), it 
may aid the planning of the extent of surgery in patients with a possible or confirmed 
diagnosis of PTC. Yip et al compared 106 BRAF-positive to 100 BRAF-negative PTC 
patients, the majority of which were identified post-operatively. Significantly more of the 
former group required further surgery for persistent/recurrent disease (p = 0.04), with the 




authors suggesting that had the BRAF status been known pre-operatively, 24 % of patients 
would have had more extensive surgery at initial operation (Yip et al. 2009). 
1.3.1.2.2 RAS 
The RAS proteins are another family involved in cell growth and proliferation. Named 
after   the   “Rat   sarcoma”   virus,   they  were   first   discovered   as   proteins   encoded   by   retroviral  
oncogenes. Subsequently, these were shown to be constitutively activated by point mutations. 
The RAS family are GTP-binding proteins, with different subsets controlling different aspects 
of cell behaviour. RAS carries out its normal functions when localised to the cytosolic surface 
of the cell membrane, and is involved in the MAPK cascade (see Figure 1.4). Inactive RAS is 
bound to guanosine diphosphate (GDP) and is converted to the active, GTP bound protein, by 
guanine nucleotide exchange factors, two of the most studied of which are Son of Sevenless 
(SOS) 1 and 2. Following the activation of receptor tyrosine kinases, GRB2 binds via its SH2 
domain to the TKR and then via its SH3 domain to SOS1/2. This brings SOS1/2 into 
proximity with RAS and via nucleotide exchange brings about the conversion of GDP to 
GTP. Activated RAS then continues to signal downstream via the MAPK pathway. 
Approximately 20 % of malignancies involve a mutation in one of the RAS genes (Bos 
1989). The three RAS genes most frequently involved in human tumour formation are HRAS, 
KRAS and NRAS, with point mutations in codons 12, 13 or 61 leading to aberrant activation 
and uncontrolled stimulation of the cellular proliferation pathways. RAS mutations are found 
in both papillary and follicular thyroid cancers, although are more common in FTC. However, 
mutations are also found in almost 50 % of follicular adenomas (Nikiforova et al. 2003); in 
both carcinomas and adenomas the predominant mutation is in NRAS codon 61. This implies 
that RAS activation alone is insufficient to cause malignancy, but does sensitise the tumour to 
other genetic alterations. The high prevalence of RAS mutations in follicular adenomas may 




also suggest that these tumours are not completely benign, but may represent a pre-cancerous 
stage in FTC development. A study of poorly-differentiated thyroid cancers reported that in a 
cohort of 65 patients, NRAS codon 61 mutations were the most common genetic alteration 
present (15/65, 23 %). This was in contrast to the  PTC  “markers”:  BRAF mutations (1/65, < 1 
%), PAX8/PPARγ translocation (0/65, 0 %) and RET/PTC re-arrangement (0/65, 0 %) 
(Volante et al. 2009). The authors suggest that these findings indicate that RAS mutation is a 
key step in the progression to poorly-differentiated thyroid cancer, more so than the other well 
recognised mutations. However, in their cohort there were 49 patients in whom none of the 
above mutations was identified. This implies that their testing was limited, and that wider 
screening may identify an oncogene that is more important, and that again RAS mutation is 
merely acting as a sensitising precursor to progression. 
Studies examining the RAS pathway as a therapeutic target in the treatment of cancer are 
on-going. Farnesyltransferase (FTase) adds the 15-carbon isoprenoid group to the C terminal 
of RAS, thus ensuring its localisation to the plasma membrane, and was therefore an obvious 
target for inhibition. Unfortunately, due to the ability of other transferases to modify RAS, 
inhibition of FTase alone did not result in an inhibition of tumour growth. However, when 
used in combination with the EGFR inhibitor Gefitinib, the FTase inhibitor Tipifarnib 
reduced the viability of C-643 cells (thyroid follicular cells with HRAS point mutations at 
codons 12 and 61), with a corresponding reduction in the phosphorylation of the downstream 
effector ERK (Frasca et al. 2013). As the majority of RAS mutations in thyroid tumours 
involve KRAS and NRAS, with only a few involving HRAS, the clinical relevance of this 
observation may be small. 






RET (REarranged during Transfection) is a proto-oncogene  located on chromosome 
10q11.2 that encodes a receptor tyrosine kinase (RTK), which acts as a receptor for the glial 
cell line-derived neurotrophic factor (GDNF) family of ligands (GFLs). GFLs are involved in 
cell survival, differentiation and migration and specifically in neurite outgrowth. Alteration in 
RET can lead to thyroid cancers in 2 different ways. As wild-type RET in the thyroid gland is 
predominantly found in parafollicular C cells, it follows that activating mutations will result 
in C cell hyperplasia and ultimately medullary thyroid cancer (MTC). Indeed, point mutation 
in exon 16 is found in 95 % of patients with Multiple Endocrine Neoplasia type 2B (MEN 
2B), of which MTC is a feature (Martucciello et al. 2012). The second mechanism is via 
chromosomal re-arrangement. Wild type RET harbours an extracellular, transmembrane, and 
intracellular tyrosine kinase domain. In RET/PTC rearrangements, chromosomal 
translocations in intron 11 fuse the kinase domain with an activating gene. There are three 
major types of RET rearrangement; RET/PTC1 and 3 are paracentric inversions involving 
another gene on chromosome 10q while RET/PTC2 is between chromosomes 10 and 17. An 
additional 8 rearrangements have been described, most of which are associated with radiation 
exposure (Table 1.8). 




Name Activating gene Location 
RET/PTC1 H4 10q21 
RET/PTC2 RIα 17q23 
RET/PTC3 ELE1 10q11.2 
RET/PTC4 ELE1 (different breakpoint) 10q11.2 
RET/PTC5 GOLGA5 14q 
RET/PTC6 HTIF1 7q32 
RET/PTC7 RFG7 1p13 
RET/PTC8 KTN1 14q22.1 
RET/ELKS ELKS 12p13 
RET/RFG8 RFG8 18q21-22 
RET/PCM-1 PCM-1 8p21-22 
Table 1.8 The range of described RET rearrangements, with corresponding activating gene 
and its chromosomal location (Nikiforov 2002). 
As these re-arrangements are lacking the transmembrane domain of RET, the protein 
product can be located in different subcellular locations, and therefore can produce different 
effects. Of the three main re-arrangements, thyroidal over-expression of RET/PTC1 and 3 in 
mice has been shown to result in papillary thyroid cancer formation (Santoro et al. 1996; 
Powell et al. 1998). The prevalence of RET/PTC varies widely by location and this is 
compounded by differences in testing measures. In Caucasian adults and children with no 
history of radiation exposure, the prevalence of RET/PTC in papillary thyroid carcinomas is 
around 35 %, with RET/PTC1 being the most common. Both RET/PTC1 and 3 are present in 
PTCs associated with radiation exposure after the Chernobyl disaster (22 % and 13 % of 
tumours respectively (Leeman-Neill et al. 2013)). RET/PTC3 containing cancers are more 
likely to develop early than RET/PTC1, and are associated with more aggressive clinical 
behaviour (Ciampi and Nikiforov 2007).  




Numerous strategies have been implemented to use RET as a therapeutic target, not just 
in thyroid cancer but in tumourigenesis in general. These have been developed to target 
different steps in the RET pathway, from ligand binding to recruitment of adaptor proteins (de 
Groot et al. 2006), but none are yet in clinical use. 
1.3.1.3.2 PAX8/PPARγ 
The Paired Box Gene 8 (PAX8) / Peroxisome proliferator-activated receptor gamma 
(PPARγ)   fusion   protein   is   brought   about   by   a   translocation   between   chromosomes  2   and  3  
(t(2;3)(q13;p25)). It was identified first in 5 of 8 follicular thyroid cancers (Kroll et al. 2000), 
and the prevalence is thought to be approximately 20 – 60 % in FTC (Dwight et al. 2003; 
Bhaijee and Nikiforov 2011). The prevalence of the translocation in follicular adenoma is 
contentious, with reports ranging from 0 – 4 % (Nikiforova et al. 2002; French et al. 2003; 
Nikiforova et al. 2003; Hibi et al. 2004), although these tumours may represent pre-malignant 
FTCs, merely lacking capsular or vascular invasion (Dwight et al. 2003). FTCs expressing the 
PAX8/PPARγ   fusion   tend   to   affect   younger   patients,   be   smaller   in   size,   and   exhibit   more  
vascular invasion compared to those without (French et al. 2003; Nikiforova et al. 2003). It is 
found in a small number of PTCs, possibly linked to radiation exposure (Leeman-Neill et al. 
2013). 
Given   that   PAX8/PPARγ   is   relatively   specific   to   FTC,   testing   fine   needle   aspiration  
cytology specimens for the re-arrangement, with the aim of differentiating those patients with 
benign and malignant follicular lesions, has been attempted, with mixed results (Ferraz et al. 
2012; Pauzar et al. 2012). While the absence of the re-arrangement does not denote benign 
disease, the presence indicates a much higher probability of malignancy, or at least atypical 
follicular adenoma, and therefore this strategy may prove useful in the future when deciding 
which patients should receive radical, as opposed to diagnostic, surgery. 




As  a  therapeutic  target,  both  PAX8  and  PPARγ  have  shown  promise,  although  the  aim  is  
restoration of function rather than inhibition as both proteins increase the degree of 
differentiation of thyroid follicular cells. In K1 and F133 thyroid cell lines, transfection with 
PAX8 significantly increased 125II uptake and reduced cell survival after radioiodine therapy 
(Mu et al. 2012). Treatment with PPARγ   agonists   increases anaplastic thyroid cancer 
differentiation in vivo (Aiello et al. 2006), and murine studies also support a potential in vivo 
application (Dobson et al. 2011) 
1.3.1.3.3 TRK 
TRK oncogenes are the result of mutation of the NTRK1 gene. This encodes the 
neurotrophic tyrosine kinase receptor type 1 (TRK1), a receptor for nerve growth factor, NGF 
(Kaplan et al. 1991). This plays a role in cell differentiation and sensory neuronal pathway 
development, as well as proliferation of keratinocytes and lymphocytes (Di Marco et al. 
1993). The oncogenes are the result of activating translocations and are associated with 
papillary thyroid cancer. There are 4 described re-arrangements, the most common of which is 
the fusion between NTRK1 and TPM3 (Greco et al. 2010). 
Transgenic mice with the Trk-T1 oncogene under the control of the thyroglobulin 
promoter have been shown to develop hyperplasia and papillary carcinoma at a young age (4 
and 6 of 26 mice respectively under 7 months of age), with 100 % of older mice having either 
hyperplasia or PTC (2 and 7 of 9 mice) (Russell et al. 2000).  Unfortunately this study did not 
comment on the frequency of disease in wild type mice. However, another group examined 
the effect on the thyroid when the Trk-T1 mouse was crossed with the p27-null mouse strain 
(Fedele et al. 2009), which develop multi-organ hyperplasia, lung/GIT/gonadal tumours but 
no thyroid tumours (Fero et al. 1996). An increase in the percentage of papillary thyroid 




carcinomas in both the p27 -/- and p27 +/- genotypes was observed, with a shorter latency 
period, when compared to wild type mice (Figure 1.7).  
 
Figure 1.7 Trk-T1 mice are more prone to PTC, an effect enhanced by p27 knockout. A - 
Kaplan Meier analysis of latency period for developing PTC in Trk-T1 mice with variation in 
p27 genotype. p27 knockout reduces the latency period for developing PTC. B – The 
percentage of Trk-T1 mice developing PTC is incrementally higher for p27 heterozygotes and 
knockouts compared to wild type. Taken from (Fedele et al. 2009). 
Numerous studies have examined NTRK1 mutations in cohorts of patients with papillary 
thyroid cancer, with the reported prevalence varying depending on the population studied; 
however, the commonly accepted figure is in the region of 12 % (Beimfohr et al. 1999; 
Bounacer et al. 2000; Brzezianska et al. 2006; Greco et al. 2010). Unlike RET/PTC, there is 
no association with either environmental (e.g. Chernobyl) or therapeutic radiation exposure 
(Beimfohr et al. 1999; Bounacer et al. 2000). 
 




There are no effective therapies targeting this gene in the treatment of thyroid cancer, 
and there is less focus on their development, likely due to the lower frequency at which it is 
found in both sporadic and radiation induced PTC when compared to RET/PTC. Studies have 
investigated the potential of NTRK1 mutation testing to improve the detection of malignancy 
in thyroid nodule aspirates (Sapio et al. 2007; Cantara et al. 2010). While valid in theory, 
these have not translated into a clinical use due to zero pick up rate of the mutation in patient 
cohorts studied. 
1.3.1.4 p53 
In contrast to many other solid organ malignancies, the tumour suppressor gene p53 is 
rarely mutated in well-differentiated thyroid cancer. It is, however, frequently mutated in 
poorly differentiated and undifferentiated (anaplastic) thyroid cancer (Donghi et al. 1993; 
Fagin et al. 1993). This loss of p53 function is thought to be a trigger of progression from 
well- to poorly-differentiated carcinoma (Nikiforov 2004) (especially if co-existing with a 
mutation such as RET/PTC (Quiros et al. 2005)). Reports are conflicted as to whether re-
introduction of p53 into p53-mutant cells is able to rescue the phenotype (Moretti et al. 1997; 
Blagosklonny et al. 1998), and if not this suggests that other factors continue to drive tumour 
growth once de-differentiation has occurred.  
1.3.1.5 PTEN 
PTEN is a protein phosphatase and acts as a tumour suppressor by inhibiting the 
AKT/PI3K pathway. It dephosphorylates PIP3, an upstream effector in the pathway, thus 
preventing AKT induced cell growth and proliferation (Chu and Tarnawski 2004). Loss of 
PTEN function is associated with a wide range of human malignancies, including follicular 
thyroid cancer. A thyroid specific Pten knockout mouse model (Pten -/-) develops follicular 
adenomas by 10 months of age (Yeager et al. 2007), and when followed up half of all females 




developed invasive follicular carcinomas, while the remainder had either follicular adenomas 
or hyperplasia (Antico-Arciuch et al. 2010). Methylation, and associated inactivation, of 
PTEN is linked with greater degrees of de-differentiation in human thyroid tumours (Hou et 
al. 2008), thus implicating PTEN in the progression of thyroid tumours. 
1.4 PTTG-Binding Factor (PBF) 
1.4.1 Physiology 
PBF was first identified as a binding partner of the pituitary tumor transforming gene, 
PTTG (Chien and Pei 2000). PTTG acts as a securin, inhibiting separase activity and thus 
preventing sister chromatid separation during mitosis (Zou et al, 1999). PTTG stimulates 
expression of fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor 
(VEGF) (McCabe et al. 2002). Given these functions, and that PTTG is involved in DNA 
repair mechanisms (Kim et al. 2005), it is unsurprising that PTTG over-expression has been 
described in several solid organ tumours, including thyroid cancer (Kim et al. 2005). 
In order to determine the mechanism of PTTG action, yeast 2-hybrid assays were 
performed to identify potential binding partners, with PBF as one of the results (Chien and Pei 
2000). In subsequent studies, it was established that PBF was a ubiquitously expressed 180 
amino acid protein, with a mass of 22 kDa. PBF was subsequently matched to a previously 
cloned gene, C21orf3, located on the long arm of chromosome 22 at 22q22.3 (Yaspo et al. 
1998). Although there is no significant homology with other human proteins, PBF is highly 
conserved across species (Figure 1.8). This implies not only a specific and unique function 
but also an evolutionary importance. 





Figure 1.8 Amino acid sequence of PBF, demonstrating high conservation across species. 
1.4.1.1 Structure 
PBF is a type 1a transmembrane glycoprotein which, although thus far poorly 
characterised, has several putative functional domains (Figure 1.9). The N-terminal contains a 
32 amino acid signal peptide region, within which exists a leucine rich putative nuclear export 
signal (la Cour et al. 2004). Between residues 40 and 95 is a plexin-semaphorin-integrin (PSI) 
domain. Typically, PSI domains consist of 8 cysteine residues in an approximately 50 amino 
acid section, between which disulphide bonds exist (usually between cysteines 2-4, 3-8, 5-7, 
and occasionally 1-6) (Bork et al. 1999). PSI domains are usually extracellular and involved 
in protein-protein interaction and cellular signalling (Bork et al. 1999; Kozlov et al. 2004). 
There then follows a transmembrane domain (residues 95 to 122). 
Towards the C-terminal, there is a bipartate nuclear localisation signal and further 
sorting signal. This NLS plays a role in the translocation of PTTG into the nucleus; without 
this region PTTG is unable to regulate FGF-2 (Chien and Pei 2000). 





Figure 1.9 Putative structure of PBF. PBF contains an N terminal extracellular signal 
peptide with nuclear export signal (NES), alongside a cysteine rich region PSI domain, with 
di-sulphide bonds represented by red lines. The C-terminus contains a nuclear localisation 
signal and sorting signal and is necessary for the interaction with PTTG. A putative nucleolus 
signal (Nu.S) is also present in the intra-cellular region. 




1.4.1.2 Expression and regulation 
PBF is ubiquitously expressed in normal tissues (Yaspo et al. 1998; Chien and Pei 
2000). The mechanism of its regulation is not yet understood; PTTG over-expression results 
in an increase in PBF mRNA (Stratford et al. 2005), although neither EGFR or TGF-α  
affected expression in vitro despite causing an increase in PTTG levels (Vlotides et al. 2006). 
The PBF promoter contains a variable number of oestrogen response elements (ERE), with 
oestrogen  receptor  α  (ERα)  binding  to  the  promoter (Watkins et al. 2010). In MCF-7 breast 
cancer cells, treatment with both diethylstilbestrol  and  17β-estradiol induced PBF mRNA and 
protein expression (Watkins et al. 2010). The PBF promoter was also identified as a 
transcriptional target for Runx2 during a differential hybridisation screen (Stock et al. 2004). 
PBF was up-regulated in Runx2-expressing cells, and the PBF promoter bound Runx2, with 
transactivation in MC3T3-El cells. 
More recently, work on micro-RNAs in liver disease has shown that miR-122 may effect 
PBF expression (Li et al. 2013). Micro-RNAs are small segments of non-coding RNA which 
interact with complementary regions of a target mRNA, with subsequent repression of 
function (Krol et al. 2010); the group identified a predicted miR-122 complementary site in 
the  3’-untranslated region (UTR) of PBF, with repression of expression of GFP labelled PBF 
after treatment with miR-122 (Li et al. 2013).  
1.4.1.3 Function and subcellular localisation 
Despite the evidence for functional domains within the protein structure of PBF, the 
precise function of the protein is largely unknown beyond its interaction with PTTG. This 
interaction occurs at the C-terminus, allowing the nuclear translocation of PTTG (which does 
not contain an NLS) and facilitating the role of PTTG as a securin, and also a transcriptional 
activator of FGF-2. Both PTTG and PBF are required for the transactivation of FGF-2, with 




expression of each alone having no effect on the FGF-2 promoter (Chien and Pei 2000). In 
addition to this nuclear localisation of PBF, it has also been identified in intracellular vesicles, 
where it co-localised with the late endosomal marker CD63, while a C-terminal deletion 
mutant accumulates at the cell membrane (Smith et al. 2009). 
 
1.4.1.4 Post-translational modifications 
Although still relatively poorly characterised, there are a number of residues in the PBF 
amino acid sequence that are likely sites of post-translational modification (PTM).  
1.4.1.4.1 Glycosylation 
Asparagine residues located at position 45 and 54 both fulfil the criteria for potential N-
linked glycosylation sites. These are predicted when the local sequence reads Asp-Xaa-
Ser/Thr, where Xaa is any amino acid except proline (Rao and Bernd 2010). For PBF, the 
consensus sequences are N-K-T (N45) and N-V-S (N54). 
1.4.1.4.2 Phosphorylation 
Phosphorylation is a key process in the regulation of function of many cellular processes 
and is carried out by kinases that have varying specificities for phosphorylation motifs. 
Phosphorylation prediction software highlights several potential sites for serine, threonine or 
tyrosine phosphorylation. These were identified using the NetPhos 2.0 Server from the 
Technical University of Denmark (available at http://www.cbs.dtu.dk/services/NetPhos/). 
Putative phosphotyrosine sites were identified at Y174, while phosphoserine/threonine sites 
were identified at S85, S126, S132 and T10 (Figure 1.10). 





Figure 1.10 Predicted sites of serine, threonine and tyrosine phosphorylation within PBF. 
Scores are relative to 1, with a threshold set at 0.5 (from NetPhos 2.0, available at 
http://www.cbs.dtu.dk/services/NetPhos/). 
Software is also available to predict which kinases may phosphorylate a given residue (e.g. 
www.phosphonet.ca).  
1.4.1.4.3 SUMOylation 
The Small Ubiquitin-Like Modifier (SUMO) protein, similar to ubiquitin, is covalently 
bound to many proteins with effects on their cellular function. PBF has one predicted 
SUMOylation site, at lysine 169 (Ren et al. 2009). 
1.4.2 PBF in thyroid cancer 
1.4.2.1 PBF has a significant role in thyroid cancer 
The first description of the potential role of PBF in tumourigenesis identified increased 
levels of PBF mRNA in pituitary tumours compared to normal tissue, where a positive 
correlation was found between expression of PTTG and PBF in pituitary tumours (McCabe et 
al. 2003). A contemporaneous report described increased levels of PTTG and FGF-2 in 
follicular thyroid cancers compared to normal tissues, and suggested a potential role as 




prognostic markers for the disease (Boelaert et al. 2003). This prompted investigation into the 
role of PBF in thyroid disease. PBF mRNA expression was 3.3 times higher in a cohort of 
differentiated thyroid cancers compared to normal controls, and multiple regression analysis 
demonstrated an independent association between PBF mRNA expression and early tumour 
recurrence (Figure 1.11 A and B) (Stratford et al. 2005). These findings have recently been 
confirmed, with high PBF expression identified in 61.4 % of differentiated thyroid cancers, 
which directly correlated with a reduced disease specific survival (Hsueh et al. 2013). To 
support the theory that PBF has an effect independent of PTTG expression, PBF over-
expression in NIH3T3 cells (a standard fibroblast cell line (Todaro and Green 1963)) led to a 
12-fold increase in colony formation compared to controls; additionally, the transforming 
effect of PTTG was shown to be dependent on an intact domain for binding PBF. In vivo, 
mice injected with NIH3T3 cells stably over-expressing PBF developed aggressive high grade 
invasive carcinomas (Figure 1.11 C) (Stratford et al. 2005).  
These findings led to the further exploration of the role of PBF in the thyroid, in 
particular the mechanisms by which the above effects are mediated. 





Figure 1.11 A - PBF mRNA expression is significantly higher in thyroid cancer compared to 
normal thyroid tissue. B - Higher levels of PBF mRNA expression are associated with 
recurrent disease. C –Injection of NIH3T3 cells over-expressing PBF into nude mice induces 
tumour growth (black arrow) compared to controls (Stratford et al. 2005). *** = p < 0.001. 
 
1.4.2.2 Thyroidal effects of PBF in vivo 
To further explore the role of PBF in thyroid disease, a transgenic mouse model 
exhibiting thyroid specific over-expression was generated (PBF-Tg) (Read et al. 2011). These 
mice over-expressed hemagglutinin (HA)-tagged PBF (PBF-HA) specifically in the thyroid 
gland. The HA tag is derived from the glycoprotein human influenza hemagglutinin, and is 
commonly used in molecular biology to facilitate protein detection. Thyroidal specific over-
expression was achieved using the thyroglobulin promoter to drive PBF expression (Figure 




1.12), thus ensuring that not only would PBF over-expression be limited to the thyroid, but 
that it would only be found in thyroid follicular cells. 
 
Figure 1.12 Western blot demonstrating thyroid specific over-expression of PBF-HA in the 
PBF-Tg mouse (Read et al. 2011). 
 
The most characteristic phenotype of these mice was their significantly enlarged thyroid 
size. Compared to wild type littermates, the transgenic mice had thyroid glands 1.7 times 
heavier by week 7 and 3.2 times heavier by 52 weeks (Figure 1.13 A and B). In addition, the 
thyroids of the PBF-Tg mice were nodular and exhibited macro-follicles (Figure 1.13 C), 
suggesting that the over-expressed PBF may be altering the normal structural development of 
the thyroid. Another finding was that of both focal and nodular follicular hyperplasia. These 
lesions had large nuclei, and an increase in expression of phosphorylated AKT (a target of PI3 
kinase (PI3K)) and cyclin D1 (a downstream proliferation marker) (Read et al. 2011). The 
PI3K pathway is a signalling cascade involved in cellular proliferation which is frequently 
dysregulated in cancer. 





Figure 1.13 Thyroidal effects of PBF-HA over-expression. A - PBF-Tg mice developed 
significantly larger thyroid glands than their wild type (WT) litter mates. B- Representative 
image of thyroid glands from WT and PBF-Tg mice at 52 weeks (thyroid glands are outlined 
by dashed lines). C – H&E stained sections through mouse thyroid glands: Compared to WT 
(i), PBF-Tg mice developed macro-follicles (ii) and areas of hyperplasia (iii) (Read et al. 
2011). 
Given this phenotype, the potential impact of PBF on the thyroid hormone secretory 
pathway was investigated. PBF was found to sequester the thyroid hormone transporter 
MCT8 away from the plasma membrane and into the cell. Additionally, there was an increase 
in intra-thyroidal T3 and T4 levels (Smith et al. 2012). This did not, however, correspond to a 
difference in total serum T3 or T4, suggesting that although thyroidal MCT8 functional is 
repressed, there is compensation to maintain a steady state of thyroid hormone export. 
Subsequently, the hypothalamic-pituitary-thyroid negative feedback loop was not affected and 
there was no observed increase in serum TSH (Figure 1.14 A and B) (Read et al. 2011). There 
was, however, an increase in the expression of the TSH receptor (TSHR) (Figure 1.14 C) 
(Read et al. 2011) suggesting an increased responsiveness to TSH within the transgenic 




thyroids, although from that it was not possible to say whether this was as a direct or indirect 
response to excess PBF and repressed MCT8 function. Interestingly, this increase in TSHR 
did not seem to have a functional effect. When the mice were administered 50 mU of TSH, 
the increase in serum T4 found in wild type was absent in the transgenic mice (Figure 1.14 D) 
(Smith et al. 2012).  
 
Figure 1.14 Thyroid hormone profiles in the PBF-Tg mouse compared to WT. A - Intra-
thyroidal levels of unbound T3 (i) and T4 (ii), demonstrating an increase in the PBF-Tg 
mouse. B – Serum levels of TSH in WT and PBF-Tg mice, demonstrating no significant 
difference between the two. C – Western blot demonstrating increased levels of thyroidal 
TSHR in the PBF-Tg mouse. D – Change in serum T4 levels following administration of 50 
mU TSH in WT and PBF-Tg mice. No response to TSH was seen in the transgenic mouse 
((Read et al. 2011; Smith et al. 2012). WT = wild type, Non-Tg = non-thyroglobulin bound, 
TSH = Thyroid stimulating hormone. TSHR = TSH-receptor, NS = not significant, * = p < 
0.05, ** = P < 0.01. 




Taken together, these data imply that excess PBF is causing a sequestering of thyroid 
hormone within the thyroid gland, while preventing the hormones from being transported to 
the blood stream. To maintain a steady state level of serum T3 and T4, the amount of TSHR 
expressed by follicular cells is increased. However, this appears to be at a maximum capacity 
for responsiveness given that any further increase in TSH has no effect on serum thyroid 
hormone. 
No thyroid malignancies were observed in the transgenic mice, a fact which is 
potentially at odds with the finding that PBF is significantly over-expressed in human thyroid 
cancer. However, these data demonstrate a role for PBF in the proliferation of thyrocytes via 
the activation of AKT. In addition,  these  events  may  well  provide  the  first  “hit”  in  the  steps  
towards thyroid carcinogenesis. Therefore, while over-expression of PBF in isolation may not 
be sufficient to cause carcinogenesis, a second hit in combination could be.  
1.4.2.3 PBF and the sodium iodide symporter 
FGF2 had been shown to reduce iodide uptake in thyroid follicular cells (Cocks et al. 
2003), and both PBF and PTTG are required for the transcription of FGF2 (Chien and Pei 
2000). Given that PBF levels are higher in thyroid cancer compared to normal tissue, and that 
over-expression of PBF is associated with a poorer prognosis in thyroid cancer, experiments 
were performed to assess the effect that PBF (and PTTG) may have on the sodium iodide 
symporter, NIS. As described in Section 1.2.5.3, NIS is vital to the uptake of radioiodine into 
thyroid follicular cells, and it follows that any disruption to this function would lead to a 
poorer response to treatment.  
PTTG and PBF over-expression were shown to reduce NIS mRNA in primary 
thyrocytes (86 % and 95 % reduction respectively), with similar levels seen when co-
transfecting the two together, and also when transfecting a mutated PTTG which lacked the 




ability to transactivate FGF2 (Figure 1.15 A). This also had a functional effect, with PBF 
over-expression leading to a reduction in 125I uptake by 68 %, while PTTG over-expression 
resulted in a fall of 59 %. Here, co-transfection led to a greater reduction (83 %), while 
transfection of the mutant PTTG resulted in a fall of only 34 % (Figure 1.15 B). Together, 
these data indicated that while the suppression of NIS function by PTTG occurs mostly via 
FGF2, PBF mediates its effect via an independent mechanism. Promoter studies examined the 
effect of PBF and PTTG on the NIS promoter. Both proteins caused transcriptional repression 
via a PAX8/USF1 site within the human NIS upstream enhancer element, while PBF also 
repressed the basal NIS promoter, which harbours the transcriptional activation site (Boelaert 
et al. 2007). 





Figure 1.15 PBF and PTTG inhibit NIS expression and activity in primary thyroid cultures. A 
– NIS mRNA expression is reduced by PBF and PTTG transfection alone and in combination, 
and also with the SH3 deletion mutant of PTTG (SH3-). B – Iodide uptake in primary 
thyrocytes after transfection with PBF/PTTG/SH3- * = p < 0.05, ** = p < 0.01, *** = p < 
0.001 (Boelaert et al. 2007). 
The mechanism by which PBF repressed NIS function was examined in further studies. 
Interaction between PBF and NIS was confirmed by glutathione-S-transferase (GST) pull-
down and co-immunoprecipitation assays. PBF over-expression was shown to alter the sub-
cellular localisation of NIS, internalising it away from the plasma membrane and into 
intracellular vesicles (Figure 1.16), a process mediated via clathrin-dependant endocytosis due 
to strong co-localisation with CD63, a marker for late endosomes (Smith et al. 2009).  





Figure 1.16 Effect of PBF over-expression on NIS in COS-7 cells. A – Immunofluorescence in 
the presence of wild type (i) or over-expressed (ii) PBF, with NIS localising to intracellular 
vesicles with increased PBF. B – Corresponding cell surface biotinylation study 
demonstrating reduced cell surface NIS (i) but no change in total NIS (ii) with over-expressed 
PBF compared to WT levels (Smith et al. 2009). 
PBF-induced NIS repression was also observed in the PBF-Tg mouse model. In a similar 
effect to that apparent in the in vitro model, for age and sex-matched mice, NIS mRNA 
expression was reduced by approximately 50 % in the PBF-Tg mouse compared to wild type, 
and immunohistochemistry demonstrated a marked reduction in NIS staining in the transgenic 
thyroids (Figure 1.17 A and B) (Read et al. 2011). Primary cultures from these murine 
thyroids showed a 70 % repression of iodide uptake in the transgenic thyroids compared to 
wild type. Perhaps most importantly, this effect could be completely reversed by knocking 




down PBF using siRNA (Figure 1.17 C) (Read et al. 2011). This demonstrated that PBF is 
able to repress NIS, leading to a direct decrease in iodide uptake, both in vitro and in vivo, and 
that targeting this process may provide a potential therapy to increase iodide uptake in 
radioiodine refractory thyroid cancers. 
 
Figure 1.17 A - NIS mRNA expression in wild type (WT) and PBF transgenic (PBF-Tg) mice. 
B - NIS expression demonstrated by immunohistochemistry in WT and PBF-Tg mice. C – 
Iodide uptake in primary murine thyrocytes; PBF knockdown reversed the PBF-mediated 
repression of NIS function (Read et al. 2011).UT = untransfected, Src = scrambled siRNA. 
 
While the above studies have shown PBF to directly affect a number of key cellular 
processes, including NIS expression and function, the full range of functions that PBF has 
within the thyroid remain unknown. Additionally, there is still as yet no clear way to target 
PBF in the treatment of thyroid cancer. Further elucidation of the range of interactions PBF 
has within the cell may help determine potential therapeutic strategies, with the study of a 




protein’s   range   of   interactions   being   recognised   as   an   important   pre-requisite to the 
development of novel treatments for cancer. Mass spectrometry (MS) plays an ever increasing 
part in this process, and techniques to improve accuracy and combat technical difficulties are 
evolving. There is an increasing body of evidence demonstrating that MS has important and 
wide ranging applications to endocrine and thyroid cancer. As discussed above, thyroid 
cancers are often difficult to distinguish from benign tumours during initial investigation, and 
in some cases present late with a consequently worse prognosis. In addition, there is often a 
complex interplay between the on-going normal physiology of the thyrocyte, aberrant 
production of secreted hormones and disordered cellular function. Together, this results in 
thyroid cancer research being particularly amenable to mass spectromtery. 
1.5 Mass spectrometry and protein-protein interactions 
1.5.1 Role of protein-protein interactions in the cell 
Proteins do not exist in isolation in a cell, and each protein will have many other proteins 
with which it interacts  (its  “interactome”  (Sanchez et al. 1999)). These interactions are key to 
all cellular processes; understanding and mapping these is taking on an increasing importance 
in the field of translational molecular biology. The consequences of these include altered 
kinetic properties, substrate channelling, formation of new binding sites, inactivation of one 
or both proteins and a change in specificity for a given substrate (Phizicky and Fields 1995). 
In general, interactions can be classified as either stable or transient. Stable interactions 
are found in complex, multi-protein molecules such as haemoglobin. Transient interactions 
form the backbone of most cellular processes. The transient nature is brought about by the 
fact that a specific condition, for example a particular sub-cellular localisation or post-
translational modification, may be required for the interaction to occur and persist.  




Despite the variety of potential binding sites with a protein, which may change 
depending on cellular conditions, there are some domains which are associated with protein-
protein interaction. Examples of this include the leucine zipper (involved in stable 
interactions) and SH2/SH3 domains. The latter 2 are named for their homology to sections of 
the SRC oncogene in which they were first identified and are frequently involved in signal 
transduction and tyrosine kinase binding. 
As a translational approach, studying the expression and interactions of proteins in both 
normal and malignant tissues significantly enhances the understanding of the mechanisms of 
disease progression and pathogenesis. By mapping the human interactome, new therapeutic 
targets may be identified which can lead to the development of novel cancer treatments. 
1.5.2 General principles 
The principle behind protein identification by tandem mass spectrometry (MS/MS) lies 
in   the   fact   that   every  protein  has  a  predictable   fragmentation  pattern   (“peptide   fingerprint”)  
when cleaved by a digestive enzyme (Steen and Mann 2004). The most commonly used 
enzyme is trypsin, which cleaves peptide chains at the carboxyl side of lysine and arginine 
residues. An efficient, reproducible digestion is essential to generate worthwhile data and 
strategies include solubilising using 4 % SDS, which is removed by centrifuging the sample 
through a 35 kDa cut-off filter where the unfolded proteins are retained and the detergent 
removed in the filtrate. After concentration and purification, samples are digested using 
endoproteinase Lys C and / or trypsin and the peptides harvested for analysis (Wisniewski et 
al. 2009). Another common approach is the digestion of proteins in gel slices following 
separation of the proteins using SDS PAGE.  This process is also reliable as once again the 
protein substrates are denatured and unfolded.   
 




Tryptic digestion will often generate very complex peptide mixtures that are usually 
analysed by liquid chromatography (LC) MS/MS, where the peptides are separated using 
reverse phase HPLC prior to mass spectrometry. The peptides are eluted using a gradient of 
acetonitrile where the rate of the gradient is matched to the sample complexity. There has 
been considerable improvement in the design and performance of HPLC instrumentation and 
columns, allowing routine implementation of nano-bore (sub-μm / min flow rate) methods 
using columns with internal diameters of 50-100   μm.   Therefore,   peptides   elute   from   these  
columns in a very small volume, meaning that the actual concentration of peptides in the 
HPLC eluate is relatively high (Steen and Mann 2004). 
 
The mass spectrometric analysis of the HPLC-resolved peptides typically utilises two 
basic approaches; electrospray ionisation (ESI), or matrix assisted laser desorption/ionisation 
with a time of flight mass spectrometer (MALDI ToF/ToF). In the case of a MALDI 
instrument, a defined time period of HPLC column outflow is automatically spotted onto a 
MALDI target plate.  Typically, several hundred or more spots are generated for a complex 
sample. In electrospray ionisation the column eluate is sprayed into the mass spectrometer 
source via an emitter (a fine needle that can conduct an electrical current) which is spatially 
isolated from the actual mass spectrometer.  A high charge (1-5 kV) is applied to the emitter 
which ionises the peptides in the acidified HPLC solvent.  As this liquid exits the fine tip, 
small droplets are generated and manipulated by electric fields according to their mass to 
charge ratio (m/z). The ions reach a detector and a mass spectrum is generated. By examining 
the separation pattern of the peaks produced, the specific m/z of each ion can be calculated. 
Tandem mass spectrometry (MS/MS) refers to the further fragmentation of the most abundant 
precursor ions using an inert gas. These are then passed through the spectrometer again and 




the individual product ions assigned further peaks based on their m/z.  Each product ion is the 
result of the loss of one or more amino acid residues from the precursor ion; by examining the 
population of peaks and their m/z (the   peptide   “tandem   mass   spectrum”)   it   is   therefore  
possible to determine the amino acid sequence of the ion, and therefore the structure of the 
precursor ion. Once the mass spectrum has been matched to a peptide sequence, computer 
databases use the predictable cleavage sites of trypsin to match the peptide to a parent protein. 
1.5.3 Protein complexes 
The isolation of proteins using affinity purification of a target (bait) protein has allowed 
the detection of novel protein-protein interactions in many studies.  Antibodies to native or 
tagged proteins have been used extensively in this work and efforts to decrease the detection 
of non-specific binding partners have utilised tandem affinity tags (TAP-TAG) (Rigaut et al. 
1999).  However the protein complex is isolated, it is usual that the proteins are identified 
following resolution of the proteins using SDS-PAGE, band excision, and tryptic digestion.  It 
is important to perform suitable controls to detect non-specific interactions and it is 
particularly useful if some interactions with the target protein are already known as these can 
act as positive controls, as does the detection of the target. As well as individual protein-
protein interactions, the duration of these interactions and their relation to cellular function 
can also be determined, mapping out cell signalling pathways (Bisson et al. 2011). 
1.5.4 Protein quantitation 
Initially,   the   analysis   of   complex   samples   (often   termed   “shot-gun   proteomics”)  
focussed on identifying as many peptides/proteins as possible in complex samples such as 
blood serum and plasma, urine, CSF or tissue and cell lysates. However, it soon became clear 
that it is more relevant to determine either the absolute or relative abundance of proteins, 




particularly in biomarker discovery.  Several approaches have been developed and the actual 
protocol utilised is usually limited by the sample type, cost, mass spectrometer available and 
by the quality of data required.  All of the methods have advantages and disadvantages 
compared to the other protocols and the choice of approach can be affected by the experience 
and personal preferences of the group performing the analyses.   
 
Currently the most common approaches use stable isotope labelling strategies such that 2 
(or more) isotopically labelled versions of each peptide are produced (Elliott et al. 2009).  
These molecules are identical chemically and behave in exactly the same way during 
purification steps but vary by a known mass.  Therefore, since they are analysed under 
identical conditions, differences in the peak intensities of the isotopic versions represent an 
accurate estimation of the relative abundance of the isotopic species.  
 
The vast majority of quantitative proteomic methods attempt to determine the relative 
amount of large numbers of different peptides or proteins in complex samples without any 
prior knowledge of the proteins under investigation.  However, a focussed analysis of specific 
proteins can be performed if the protein of interest is known and if preliminary analysis can 
determine which unique tryptic peptides are consistently observed in LC MS/MS of digests of 
the target protein.  Then, an isotopically labelled version of the peptide is synthesised and a 
known amount spiked into samples.  When analysed by LC MS/MS, the natural and isotopic 
versions co-elute meaning that their relative MS spectra intensities can be used to calculate 
the concentration of endogenous peptide in the original sample (Gerber et al. 2003; Elliott et 
al. 2009). More recently the approach has been improved, to a large extent because of 
improvements   in   the   performance   of   “triple   quad”   mass   spectrometers, which generate a 




“cleaner”  spectrum by selecting for specific m/z values.    This facet can be used to not only 
quantify potential biomarkers, but also to identify the gene products of specific mutations that 
are known to be tumourigenic (Wang et al. 2011). These techniques are summarised in Figure 
1.18. 
 
Figure 1.18 The process of triple quadrupole mass spectrometry. Two quadrupole mass 
spectrometers are in series (Q1 and Q3), with a third non-mass filtering spectrometer in-
between (Q2). Q1 selects an ion of a specific mass, which is then fragmented in Q2 by 
collision with inert gases. In standard MS/MS, all fragments are analysed. In selected and 
multiple reaction monitoring only one, or a specific number, of the fragment ions is analysed, 
allowing for much quicker sample processing (Sharma et al. 2012). 




Stable Isotope Labelling by Amino acid in Culture (SILAC) is a method of isotopically 
labelling proteins metabolically, where 2 (or more) cell types, or the same cell type under 
different  conditions,  are  grown  in  either  “heavy”  or  “light”  media (Ong et al. 2002).  In the 
“heavy”  media  either  the  naturally  occurring  12C-arginine and/or the 12C-lysine is/are replaced 
by 13C versions.  When the cells grow and use the amino acids from the media to make new 
proteins,   the   cells   grown   in   the   “heavy”  media   isotopically   label   their   own   proteins   and   if  
sufficient rounds of cell division are allowed the labelling will approach equilibrium. An 
attempt to extend the SILAC approach for the quantitation of proteins in tissue samples has 
been reported (Geiger et al. 2010).  This  “super  SILAC”  approach   is   relatively  expensive as 
several cell lines have to be grown in 13C labelled amino acid containing media.   
1.5.5 Mass spectrometry and thyroid cancer 
In the field of thyroid cancer research, MS/MS has several distinct applications, 
including identifying biomarkers, facilitating personalised medicine and also in developing 
novel therapies. 
1.5.5.1 Identification of biomarkers 
One of the most significant areas of cancer biology in which MS/MS has had an impact 
is the identification of biomarkers. These are used in pre-diagnosis screening as well as 
prognostication of cancers and identification of recurrence. Standard molecular biology 
techniques such as immunohistochemistry and quantitative PCR remain in routine use to 
identify genes that may serve to stratify a tumour into a particular sub-group. However, using 
MS/MS, plasma and urine can be analysed as well as tumour tissue, enabling the detection of 
circulating  proteins  that  have  been  either  secreted  by  the  cancer  or  have  “leaked”  out (Manne 
et al. 2005; Ward et al. 2008; Turtoi et al. 2011). The application of this to the field of cancer 




research raises some exciting possibilities. The identification of a thyroid cancer biomarker 
that would allow the differentiation between a follicular adenoma and carcinoma may prevent 
a significant number of patients undergoing surgery. In addition, determining which tumours 
are more likely to de-differentiate or metastasise would clearly be invaluable when planning 
treatment. 
Despite thyroid cancer being the commonest endocrine malignancy, there remains a lack 
of reliable markers available that predict cancer within a thyroid nodule. The two most 
commonly used serum markers, thyroglobulin for differentiated thyroid cancer and calcitonin 
for medullary cancer, both have their disadvantages, and there is a continued need for further 
development. Genetic mutations such as RET/PTC, BRAF and RAS have all been identified in 
thyroid cancer specimens (Namba et al. 2003; Carta et al. 2006; Stanojevic et al. 2011), but 
these again require a tissue sample in order to identify them. While Fine Needle Aspiration 
Cytology (FNAC) can be useful for this, the amount of material obtained is often minimal 
and, even with ultrasound guidance, not necessarily fully representative of the tumour. As an 
alternative approach, a number of studies over the past decade have examined the proteome of 
thyroid samples. Initially, 2D electrophoresis was used to identify protein spots from normal, 
goitrous, hyperplastic, adenomatous and malignant thyroid specimens followed by sequencing 
from polyvinylidene difluoride (PVDF) membranes and MS/MS to determine which proteins 
were most abundant (Srisomsap et al. 2002). Cathepsin B was reportedly over-expressed in 
thyroid cancer and ATP synthase and prohibitin were specifically over-expressed in the 
papillary variant; proteins that had not been previously linked to thyroid cancer. Although this 
first study used both MS/MS and traditional methods, as MS/MS technology has advanced, 
the need to run synchronous techniques has diminished. Later, proteins over-expressed in 29 
thyroid tumour samples when compared with normal thyroid were identified using SELDI-




TOF MS/MS (Sofiadis et al. 2010). When the spectra produced from nuclear and cytosolic 
fractions of cell lysates were analysed, the Ca2+ binding ion S100A6 was over-expressed in 
PTC compared to FTC and normal thyroid, which was confirmed by Western blotting and 
immunohistochemistry (Sofiadis et al. 2010). Additionally, 2-hydroxyglutarate levels have 
been shown to be elevated in PTC compared to both normal thyroid and hyperplastic nodules 
(without the IDH1 and IDH2 mutations usually seen in gliomas and myeloid leukemias), 
although these results are yet to be validated (Rakheja et al. 2011). 
Characterisation of a thyroid tumour, then, may prove useful in further stratifying 
tumour tissue post-biopsy/surgery. However, it is the high-throughput analysis of serum and 
urine for secreted proteins that may serve as biomarkers which highlights the potential of 
MS/MS as a vital tool in cancer proteomics. Two recent studies have taken different 
approaches to the identification of the thyroid cancer secretome. The first utilised an in vitro 
model of TPC-1 (PTC) and CAL62 (ATC) cell lines (Kashat et al. 2010). After culturing cells 
in serum free conditions, media was collected, trypsinised and run through LC MS/MS. 
Proteins were classed as high-confidence if identified by 2 or more   peptides   with   ≥95%  
confidence. Forty six proteins were shortlisted; the mean number of peptides identified was 
4.82 with average sequence coverage of 12.5%. After further validation, 6 proteins were 
determined to be present in the thyroid cancer secretome; biotinidase, nucleolin, enolase1, 
PTMA, CYR61 and clusterin. The expression of these proteins in the serum of patients with 
thyroid cancer was then examined but unfortunately none of the proteins were proven to be 
over-expressed in this setting. This inability to translate results from an in vitro to an in vivo 
setting is a shortcoming observed in a number of MS/MS studies. However, identifying those 
proteins selectively secreted by thyroid tumours remains a fundamental imperative. Using 
human serum directly to identify secreted proteins has the advantage of being applicable to a 




large number of patients and also being representative of the in vivo setting. SELDI-TOF 
MS/MS was employed to study the serum protein profile of 224 patients, 108 with PTC and 
116 normal controls (Fan et al. 2009). Haptoglobin alpha-1 was found to be up-regulated in 
PTC while apolipoproteins CI and CII were down-regulated. Further, as the stage of tumour 
increased, there was a corresponding rise in haptoglobin alpha-1 and fall in the 
apolipoproteins. Further work is now needed to consolidate these observations and to 
determine if these proteins may be of use in the initial investigation of patients with suspected 
thyroid cancer. To differentiate PTCs from both nodular goitres and normal thyroids, a 
metabolomic approach comparing the three groups found that the greatest difference occurred 
in lipid metabolism, with 3-hydroxybutyric acid expression much higher in the PTC group 
compared to the others (Yao et al. 2011). The authors suggest that this may therefore be a 
potential marker to distinguish between PTC and benign nodular lesions. 
1.5.5.2 Personalised medicine 
The search for biomarkers for thyroid cancer does not seek to find a way of tailoring 
treatment, rather identifying novel proteins that can then be studied in a more translational 
context. When treating patients with cancer, future therapies are likely to evolve away from 
protocol driven management strategies to a more tailored, individual approach (Pirmohamed 
2010). In this respect, MS/MS can be used to identify proteomic differences between different 
groups of cancer patients and although not yet widespread in the field of thyroid cancer, has 
been used to study other malignancies. While most ovarian cancers will be initially 
susceptible to platinum based chemotherapy, many will eventually become resistant (Cho and 
Shih Ie 2009). Using ESI-MS/MS to examine the proteome of primary and post-
chemotherapy ovarian cancers, 11 proteins were identified that were expressed at higher 
levels in the recurrent group, all of which were confirmed by RT-PCR (Jinawath et al. 2010). 




By knocking down 2 of these (RELA (NF-κB   p65)   and   STAT5),   carboplatin-resistance in 
vitro was reversed. Most importantly, by treating the cells with either a NF-κB   or   STAT5  
inhibitor, their sensitivity to carboplatin was significantly enhanced. A similar study 
compared the proteome of paclitaxel-resistant and -sensitive cell lines, using both MALDI-
TOF and LC-MS/MS (Di Michele et al. 2009). A number of proteins that showed significant 
differential expression between the two were demonstrated and grouped into those related to 
stress response, metabolism, protein biosynthesis and apoptosis. Collectively, these studies 
provide a possible way of determining whether a patient will benefit from a particular 
chemotherapeutic agent prior to its delivery, potentially avoiding both unnecessary side 
effects and cost. 
Previous techniques have performed proteomic analyses on either serum or fresh tissue, 
but in some cases the specimen may have already been paraffin embedded and examined by a 
pathologist. Several methods exist for carrying out HPLC-MS/MS on formalin fixed and 
paraffin embedded (FFPE) tissue, which is much more applicable to a hospital setting 
(Gustafsson et al. 2010; Paulo et al. 2011). In this way, previously archived samples could be 
revisited in certain cases or as new discoveries regarding treatment are made, allowing a 
patient’s   treatment   to   remain   contemporary,   regardless   of   when   the   original   diagnosis   was  
made or surgery performed. As mentioned above, statistical analysis is often hampered by 
insufficient sample numbers for what are often rare or unusual malignancies and by the short 
follow up time that the patients recruited to current studies have available. By using FFPE 
tissue, which has been archived and for which long term patient outcomes are known, studies 
will be able to compare larger numbers of samples and correlate different proteomic measures 
to specific patient factors, such as recurrence and response to treatment. 




1.5.5.3 Interaction proteomics 
MS has enabled the large scale identification of protein-protein interactions (Downard 
2006; Volkel et al. 2010), and from these large interaction networks have been generated. 
Tyrosine kinase inhibitors (TKIs) are promising agents in the treatment of many cancers 
(Raymond et al. 2011; Verbeek et al. 2011), and proteomic analysis of interactions can 
identify more accurately specific kinases to target (Gorla et al. 2009). Directly related to this, 
MS/MS allows the identification of post-translational protein modifications (Chung et al. 
2011), including phosphorylation, which can lead to further therapeutic insight. However, if 
high molecular weight proteins are examined, the presence of post-translational modifications 
may obscure the data; analyses must therefore be tailored to specific events, such as 
phosphorylation or glycosylation. It has been demonstrated that resistance to the TKI 
lapatinib in breast cancer cell lines is linked to increased phosphorylation of Src family 
kinases (Rexer et al. 2011). Further, by treating these cells with Src inhibitors the sensitivity 
to lapatinib is restored. Similarly, LC-MS/MS has been utilised to explore the 
phosphorylation of the epidermal growth factor receptor (EGFR) (Zhang et al. 2011). Thirty 
phosphorylation sites were documented and were related to activating mutations in cancer cell 
lines as well as sensitivity to the EGFR inhibitor erlotinib. These strategies thus highlight the 
potential to target treatment for specific cancers based on the proteomic profile of the tumour 
tissue, and to monitor and address disease progression in the light of the on-going treatment 
regimen. 
1.6 Hypothesis and aims 
Over recent years, PBF has been shown to have transforming effects in vitro, and 
tumourigenic effects in vitro. Specifically in relation to thyroid disease, PBF over-expression 




leads to a macro-follicular goitre with areas of hyperplasia. High levels of PBF are found in 
thyroid cancer when compared to normal tissue, and the amount of PBF present within 
thyroid tissue has a positive correlation with thyroid cancer recurrence. At a cellular level, 
PBF binds to both NIS and MCT8, internalising them away from the cell membrane, with a 
direct functional response in terms of iodide uptake and thyroid hormone transport. This has 
important consequences for the treatment of thyroid cancer and implications on prognosis. 
 
The hypothesis of this thesis is that in addition to those described, PBF has a range of 
interactions with the thyroid cell, and that increased levels of PBF, as observed in thyroid 
cancer, lead to a disruption of cellular processes key to normal thyrocyte function and, by 
extension, to the treatment of thyroid cancer. 
 
From this, the aims of this thesis were: 
1. Identification of potential novel binding partners of PBF. Tandem mass 
spectrometry was used to identify potential binding partners of PBF. From the 
large list of potential proteins, scoring systems and validation strategies were 
employed to generate a shortlist of most likely interactors, and from this 3 were 
chosen to be further validated based on predicted function. 
2. Validation of binding partners. GST-tagged pull down assays and co-
immunoprecipitation were used to validate the potential binding partners 
identified by MS/MS. 
3. Functional assessment of the significance of interactions. Functional studies, 
including iodide uptake and secretion assays, were used to investigate the 




functional significance of the interactions, and the potential to utilise them as 
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Unless otherwise stated, all reagents described were obtained from Sigma-Aldrich 
(Poole, UK). 
2.1 Cell lines 
K1 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). 
The K1 line is a moderately-well differentiated human papillary thyroid carcinoma cell line 
displaying the V600E BRAF mutation (Meireles et al. 2007), but expressing wild-type p53. 
The TPC-1 cell line is a moderately differentiated human PTC line expressing wild type p53 
and BRAF, but with the RET/PTC1 re-arrangement on chromosome 10 (Ribeiro et al. 2008). 
They were kindly provided by Dr Rebecca Schweppe (Division of Endocrinology, 
Metabolism, & Diabetes, University of Colorado Denver, Aurora, Colorado). Both cell lines 
were cultured from passage 7 (P7) as a monolayer in 75 cm2 flasks in RPMI with L-
Glutamine (Life Technologies, Grand Island, NY, USA), 105 U/L penicillin, 100 mg/L 
streptomycin (Invitrogen, Paisley, UK) and 10 % fetal bovine serum (FBS) (Invitrogen). Cells 
were passaged twice weekly, using a 10 % (K1) and 5 % (TPC1) division and kept in a 37 °C 
incubator with 5 % CO2, with fresh P7 cells re-cultured every 6 to 8 weeks. 
The FRTL-5 cell line is a rat thyroid cell line derived from normal rat thyroid tissue, and 
displays normal thyroid cellular functions, including iodide uptake and thyroglobulin 
synthesis (Ambesi-Impiombato 1986). Cells were cultured from P10 in  1  x  Coon’s  modified  
Hamm’s   F-12 medium (Biochrom AG, Berlin, Germany) with 30 mM sodium bicarbonate 
made up to 1 litre with H₂O then sterilised through a 0.22 µm pore 54.5 cm  polyethersulfone 
membrane (Corning Ltd, Ewloe, UK), with 105 U/L penicillin, 100 mg/L streptomycin, 300 
U/L thyroid stimulating hormone and 300 µg/L insulin) with 5 % FBS. 
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HeLa cells, a malignant epithelial cell line derived from a cervical epidermoid 
carcinoma (Scherer et al. 1953), were used as a non-thyroid cell line due to their ease of 
transfection and well characterised phenotype. Cells were cultured from P5  in Dulbecco 
Modified   Eagle’s Media (DMEM) (PAA, Pasching, Austria), supplemented with 4.5 g/dL 
glucose, 105 U/L penicillin, 100 mg/L streptomycin and 10 % FBS. Cells were passaged twice 
weekly and split at 20 %. 
2.2 Transfection 
2.2.1 Plasmid purification 
2.2.1.1 Vectors 
Over-expression of protein was achieved through transfection with mammalian 
expression vectors containing the complete coding sequence for the gene of interest. Plasmids 
used were pCI-Neo (Promega, Madison, WI, USA), pcDNA3.1+ (Invitrogen), pCMV6-XL 
(Origene, Rockville, M, USA). All contained the cytomegalovirus promoter and sites for 
antibiotic resistance. 
2.2.1.2 Restriction digest and ligation 
The Invitrogen Restriction Digest kit was used to digest a cDNA sequence from a vector 
according to the   manufacturer’s   instructions.   Unique restriction enzymes were chosen as 
described in relevant chapters. 4 µg of insert and vector DNA were combined with the 
restriction enzymes (each at 10% of digest mixture), 10 % 1 x BSA, 10 % Buffer H and 
incubated at 37 °C for 2 hours. The digest solution was combined with DNA loading dye 
(0.042 % bromophenol blue, 0.042 % Xylene cyanol FF, 2.5 % Ficoll) and run through a 1 % 
agarose gel in 1 x TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA) at 100 V for 1 
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hour. Using ultraviolet light, the DNA bands corresponding to the insert and the linearised 
vector were excised with a clean scalpel. 
DNA was extracted using the QIAquick Gel Extraction Kit (QiaGen) according to the 
manufacturer’s   instructions,  with  all  centrifugation  steps  carried  out  at  17,900  x  g  in  a  table  
top microcentrifuge. Briefly, Buffer QG was added to the gel slice in a ratio of 3:1 (v:w) in a 
microcentrifuge tube and then incubated at 50 °C for 10 minutes with regular vortexing. Once 
completely dissolved, 10 µL of 3 M sodium acetate pH 5.0 were added before adding 1:1 
isopropanol and mixing. The sample was then centrifuged in a spin column for 1 minute to 
bind the DNA and the flow through discarded. After adding 0.5 ml Buffer QG the sample was 
spun again for a further minute and flow through again discarded. The DNA was washed with 
0.75 ml Buffer PE for 1 minute and the spun again for a further minute to remove any residual 
wash solution. The DNA was eluted with Buffer EB by spinning for 1 minute, collecting the 
supernatant in a clean microcentrifuge tube. DNA purity was assessed using the NanoDrop© 
ND-1000 Spectrophotometer (NanoDrop), with a pure sample having a 260/280 ratio between 
1.8 and 2 : 1. Where indicated, samples were purified using the Macherey Nagel PCR Clean 
Up Kit (Macherey Nagel), according to  manufacturer’s   instructions.  All   steps  were  at room 
temperature with all centrifugation at 11,000 x g for 30 seconds unless otherwise stated. One 
part DNA was combined with 2 parts Buffer NTI and transferred to a Clean-up Column. After 
centrifugation to bind the DNA, the sample was washed twice with 700 µL Buffer NT3. The 
membrane was then dried by centrifuging for 2 minutes and the DNA eluted in 35 µL of 
Buffer NE for 1 minute, then re-assessed using the NanoDrop as above. 
Ligation of the 2 digest products was performed using DNA ligase (Invitrogen). Equal 
molar quantities of linearised vector and insert were incubated with 10 % DNA Ligase and 10 
% 10 x Buffer for 16 hours at 6 °C. The samples were then incubated at 22 °C for 3 minutes 
Chapter 2  Material and Methods 
 
 64 
then 70 °C for 10 minutes to heat inactivate the DNA Ligase. The DNA samples were then 
used to transform bacteria as described below. 
2.2.1.3 Bacterial transformation 
Transformation  was   carried  out  using  Subcloning  Efficiency™  DH5α™  Competent  E.  
Coli Cells (Invitrogen) according  to  the  manufacturer’s   instructions.  10  ng  of  plasmid  DNA  
were added  to  50  µL  of  DH5α™  cells  in  a  1.5  ml  microcentrifuge  tube.  After  incubation  on  
ice for 30 minutes to increase the permeability of the cell membrane, cells were heat shocked 
at 42 °C for 20 seconds and then incubated on ice for a further 2 minutes. 950 µL of 
Lysogeny Broth (LB) were added and the samples incubated at 37 °C for 1 hour with shaking. 
Bacterial cells were pelleted by centrifugation on at 13,000 rpm on a bench top centrifuge and 
the supernatant discarded. The cells were then re-suspended in the remaining LB 
(approximately 100 µL). This suspension was plated on warmed LB-Agar (1 % Agar) 
containing antibiotics. Plates were incubated at 37 °C for 16 hours. 
2.2.1.4 DNA purification and sequencing 
Purification was performed using the Wizard® Plus SV Miniprep DNA Purification 
System   (Promega)   according   to  manufacturer’s   instructions.   Following   incubation, a single 
colony was selected from the plate and incubated in 5 ml LB with antibiotics at 37 °C for 16 
hours with shaking. All subsequent steps were carried out at room temperature. The bacterial 
suspension was centrifuged at 10,000 x g for 5 minutes and the supernatant discarded. Cells 
were re-suspended in 250 µL of Cell Resuspension Solution by vortexing and transferred to a 
1.5 ml microcentrifuge tube. A cleared lysate was then prepared by the addition of 250 µL of 
Cell Lysis Solution and incubating the suspension until it had cleared. 10 µL of alkaline 
protease were added to inactivate any endocucleases released during cell lysis and the lysate 
incubated for 5 minutes. Finally, 350 µL of neutralisation solution were added to terminate 
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the lysis and the tube inverted 4 times before centrifuging for 10 minutes at 14,000 x g. 
Subsequent centrifugation was carried out at 14,000 x g for 1 minute. After transferring to a 
spin column, the cleared lysate was centrifuged and the eluate discarded. Plasmid DNA was 
washed twice by centrifugation with Column Wash Solution (750 µL wash 1, 250 µL wash 2) 
by centrifugation. Finally, the DNA was eluted with 100 µL of nuclease free water (NF-H₂O). 
DNA quantification was carried out using the NanoDrop© ND-1000 Spectrophotometer 
(NanoDrop) and accompanying ND-1000 v3.3 software on the DNA-50 setting.  
To sequence the plasmid DNA, 250 ng of DNA were combined with 3.2 pmol of 
forward or reverse primer and made up to 10 µL with NF-H₂O. Primers for pcDNA3.1+ were 
T7 forward (TAATACGACTCACTATAGGG) and BGH reverse 
(TAGAAGGCACAGTCGAGG). 
Samples containing bacteria that had incorporated the plasmid DNA were used to 
prepare a glycerol stock, which was then used to re-amplify the DNA as needed. 0.5 ml of 30 
% filter-sterilised glycerol were mixed with 0.5 ml of the bacterial culture. After incubation 
on ice for 30 minutes, the stock was stored at -80 °C. 
2.2.1.5 DNA Amplification 
Once the sequence of the plasmid DNA had been verified as correct, amplification of 
plasmid   DNA   was   performed   using   the   GenElute™   HP   Plasmid   Maxiprep   Kit   (Sigma)  
according to the manufacturer’s instructions. 5 ml of LB with antibiotics were inoculated with 
a pipette dipped in the appropriate glycerol stock for 8 hours at 37 °C with shaking. This was 
then transferred to 150 ml of LB with antibiotics and cultured overnight at 37 °C on an orbital 
shaker. All subsequent steps took place at room temperature unless otherwise stated. After 
transferring to 50 ml centrifuge tubes, the culture was then centrifuged at 5000 x g for 10 
minutes and the supernatant discarded. The bacterial pellet was re-suspended thoroughly with 
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a total of 12 ml chilled resuspension solution, following which 12 ml of lysis buffer were 
added, the tube inverted 6 times and left to stand for 5 minutes. The solution was then 
neutralised by adding 12 ml neutralisation solution and inverting 4 times. DNA was bound 
using 9 ml binding solution and after inverting twice the mixture was transferred to the barrel 
of a filter syringe and incubated for 5 minutes. During this period, a spin column was 
prepared by centrifuging 12 ml of Column Preparation Solution at 3000 x g for 2 minutes. 
The DNA solution was then filtered through the syringe into the spin column and centrifuged 
for 2 minutes at 3000 x g. The DNA was then washed by centrifuging first with 12 ml 
Column Wash Solution 1 for 2 minutes at 3000 x g then 12 ml of Column Wash Solution 2 
for 5 minutes, again at 3000 x g. Finally, DNA was eluted using 3 ml Elution Buffer and 
centrifuging for 5 minutes at 1000 x g. Sequencing was performed as above to verify the 
plasmid as well as additional purification steps, if necessary, as described. 
2.2.2 Transfection of bacterial plasmids 
Cells were seeded into 6 well plates 10 x 104 cells per well. After 24 hours incubation at 
37 °C, transfection was carried out using Fugene6 (Roche, Indianapolis, USA), or 
polyethylenimine (PEI). All quantities refer to transfection per well of a 6 well dish. Fugene6 
transfection  was   carried   out   according   to   the  manufacturer’s   instruction using an optimised 
ratio of 6 µL Fugene6 : 2 µg plasmid DNA. 
PEI facilitates high transfection efficiencies with low toxicity in cells that had previously 
been difficult to transfect (Neu et al. 2005). PEI was used at 3 mM in 20 mM HEPES buffer 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), with 150 mM NaCl, allowing for 20 
µL per well. As for Fugene6 transfection, plasmid DNA was used at 2 µg per well, made up 
to the same volume as PEI with 20 mM HEPES buffer and 150 mM NaCl. After 5 minutes 
incubation at room temperature, PEI and DNA were combined and incubated for a further 20 
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minutes. Immediately prior to transfection, the well medium was changed for 1 ml of SFM. 
Forty microliters of transfection mix per well were then added and the plates returned to the 
incubator for 4 hours. After this time, the medium was replaced with 2 ml of fresh media 
supplemented with 105 U/L penicillin, 100 mg/L streptomycin and 10 % FBS. 
2.2.3 siRNA transfection 
Short interfering RNA (siRNA) was used to activate the RNA interference pathway, 
thereby reducing specific gene expression. siRNA transfection was facilitated by 
Lipofectamine 2000 (Invitrogen). Scrambled siRNA was used as a control transfection. Cells 
were cultured as described in Section 2.2.2 and incubated for 24 hours. Gene specific siRNA 
(see relevant chapters) or scrambled siRNA was transfected to deliver a concentration of 100 
nM in serum free Opti-MEM (Invitrogen). Thirty minutes prior to transfection, media was 
changed to 1 ml of serum free (SF) Opti-MEM. Six microliters of Lipofectamine and siRNA 
were prepared in separate aliquots of 100 µL SF Opti-MEM and incubated for 5 minutes at 
room temperature. The two solutions were then combined and incubated for a further 15 
minutes, before drop-wise addition into the culture wells.  
2.3 Western blotting 
2.3.1 Protein Extraction and quantification 
Twenty-four hours following transfection (72 hours for siRNA transfection), cells were 
washed in phosphate buffered saline (PBS) then lysed in Radioimmunoprecipitation Assay 
(RIPA) buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 % v/v Igepal CA-630, 6 mM sodium 
deoxycholate, 1mM ethylenediaminetetraacetic acid (EDTA)), with 60 µL/ml Protease 
Inhibitor Cocktail (containing 104 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), 
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80 µM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM Leupeptin, 1.5 mM Pepstatin A, in 
dimethyl sulfoxide (DMSO)) (Sigma), which specifically inhibits serine, cysteine and aspartic 
proteases, and amidopeptidases. Lysis was completed by a 20 minute freeze-thaw cycle 
followed by 30 seconds vortex mixing. 
Protein concentration was measured using the bicinchoninic acid (BCA) colorimetric 
assay kit (Pierce), with cell lysates compared to bovine serum albumin (BSA) standards of 0, 
0.125, 0.25, 0.5, 0.75, 1 and 2 mg/ml in RIPA buffer. Both lysates and standards were 
measured in duplicate, with 78.4 µL Reagent A and 1.6 µL Reagent B added to each sample. 
After incubation for 30 minutes at 37 °C, absorbance was measured at 560 nM using the 
Victor3 1420 Multilabel Counter (PerkinElmer). The standard curve produced from the BSA 
concentrations was then used to determine the sample concentration. 
2.3.2 Western blotting 
Western blotting was performed as previously described (Smith et al. 2009; Watkins et 
al. 2010; Read et al. 2011). 15-30 µg of protein was incubated for 5 minutes at 95 °C with 40 
% v/v loading buffer (Laemmli buffer (Biorad) with 0.105 g/ml dithiothreitol (DTT, Sigma)). 
The samples were then pulse centrifuged at 13,000 rpm on a bench-top centrifuge. Resolving 
gel (375 mM Tris (from 1.5 M, pH 8.8 stock), 12 % acrylamide (from 30 % (w/v) acrylamide 
: 0.8 % (w/v) bis-acrylamide stock (Geneflow)), 3.5 mM sodium dodecyl sulphate (SDS), 0.1 
% (v/v) tetramethylethylenediamine (TEMED, Sigma), 4.4 mM ammonium persulphate 
(APS)) and stacking gel (375 mM Tris (from 1.5 M, pH 6.8 stock), 5 % acrylamide, 7 mM 
SDS, 0.2 % TEMED,  8.8 mM APS) were made and wells rinsed using running buffer (24.8 
mM Tris, 192 mM glycine, 3.47 mM SDS). Protein samples were then separated by SDS-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) in running buffer as above, with 5 µL 
Precision Plus Protein Standard (Biorad) used as a molecular weight marker.  
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Following separation, proteins were transferred onto previously activated (immersion in 
100 % methanol for 30 seconds ) PVDF membrane in transfer buffer (25.0 mM Tris, 192 mM 
glycine, in 20 % methanol) at 360 mA for 1 hour. PVDF membranes were then blocked in 5 
% w/v non-fat milk (Marvel) in Tris-buffered saline with Tween (TBS-T) (20 mM Tris (from 
1 M, pH 7.6 stock), 137 mM NaCl, 0.00025 % v/v Tween 80) for a minimum of 1 hour at 
room temperature. Primary antibodies were prepared in either 5 % w/v milk or 5 % w/v 
Bovine Serum Albumin (BSA) in TBS-T. Primary antibodies were used at (v/v ratios): 
polyclonal rabbit anti-human PBF 1:300, anti-Cortactin 1:1000, anti-HA (mouse) 1:2000, 
anti-HA (rabbit) 1:1000, anti-Src 1:1000, suppliers are listed in individual chapters. The 
membranes were incubated with 5 ml of the primary antibody on a rocker overnight at 4 °C. 
Excess antibody was eliminated by washing membranes 4 times for 15 minutes in TBS-T at 
room temperature before incubating with secondary antibody (horse radish peroxidase (HRP)-
conjugated polyclonal goat anti-rabbit immunoglobulin or HRP-conjugated polyclonal rabbit 
anti-mouse immunoglobulin (both at 650 ng/ml) made in 5 % w/v milk in TBS-T) on a rocker 
for 1 hour at room temperature. Following 6 ten minute washes with TBS-T, antigen-antibody 
complexes were detected using ECL (Pierce) according  to  the  manufacturer’s  instructions. 
2.4 Co-immunoprecipitation 
Cells were cultured in T25 flasks and treated as required by the specific experiment. 
Cells were harvested using 500 µL RIPA / 30 µL PI cocktail as above.  After end-over-end 
rotation at 4 °C for 10 minutes, cells were sonicated for 30 seconds (medium setting, 
Bioruptor Standard, Diagenode, Liège, Belgium) before undergoing end-over-end rotation for 
a further 10 minutes at 4 °C. The samples were then centrifuged at 12,000 g for 10 minutes at 
4 °C and the cell lysate transferred to a clean micro-centrifuge tube. Thirty micrograms of 
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protein (as determined by BCA assay, above) were retained and the samples incubated with 
primary antibody overnight at 4 °C with end-over-end rotation. Protein G sepharose beads 
(GE Lifesciences, Little Chalfont, Buckinghamshire, UK) were pulse washed with RIPA 
buffer before a 1:1 (v:v) bead slurry was prepared with RIPA. Fifty microliters of slurry were 
added to the samples and incubated for 2 hours at 4 °C with end-over-end rotation. Pulse 
centrifugation precipitated the beads and the supernatant was discarded. The beads were 
washed in 500 µL RIPA by pulse centrifugation 4 times. Bound proteins were then eluted 
with  loading  buffer  (1:20  β-mercaptoethanol and 1 % SDS in Laemlli buffer and incubated at 
37 °C for 30 minutes).  Loading buffer was added to the retained cell lysates and both these 
and the samples were analysed by Western blotting as described above. 
2.5 GST-tagged pull down assays 
2.5.1 Expression of GST-tagged PBF 
The pGEX plasmid (Amersham, Biosciences, Little Chalfont, Buckinghamshire, UK) 
was used to express PBF as a fusion protein with a GST tag as previously described (Turnell 
et al. 2000; Smith et al. 2009). This was expressed from overnight cultures of E. Coli; After 
induction with isopropyl  β-D-1-thiogalactopyranoside for 3 hours, the culture was centrifuged 
at 5000 rpm for 5 minutes. The pellet was re-suspended in 14 ml lysis buffer (8 M urea, 15 
mM Tris–HCl, pH 7.4, 15 mM  beta-mercaptoethanol), with the remainder of the process 
carried out on ice. After sonicating 4 times for 1 minute, the solution was centrifuged twice at 
18,000 rpm for 20 and 5 minutes, preserving the supernatant. The supernatant was again 
preserved and combined with 1 ml of packed agarose beads, before being incubated on a 
rotating mixer at 4 °C overnight. The beads and bound protein were isolated by centrifugation 
at 3000 rpm for 5 minutes, and subsequently washed 4 times by centrifugation in 50 ml GST 
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lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.05 % NP-40) and in 50 ml then 15 ml 
EDTA buffer (50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 5 % sucrose (w/v), 1 mM EDTA and 1 
% NP-40). GST-PBF was eluted from the beads with 3 ml elution buffer (40  μl  of  25  mM  
glutathione in 50 mM Tris-HCl, pH 8,) for 3 hours at 4 °C. The protein was finally purified by 
dialysis tubing in EDTA buffer with a cut off of 12-14 kDa.   
2.5.2 Translation of L-α-[35S]-methionine labelled protein 
The TNT Couples Reticulocyte Lysate System (Promega) was used to translate and 
[35S]-methionine label each protein of interest from the relevant plasmid, according to the 
manufacturer’s  instructions.  The  reaction  consisted  of:  25  µL  rabbit  Reticulocyte  lysate,  2  µL  
TNT buffer, 1 µL amino acid mixture (minus methionine), 0.5 µL RNAsin Ribonuclease 
Inhibitor, 2 µg plasmid DNA, 2 µL [35S]-methionine, 1 µL TNT RNA polymerase and 17 µL 
nuclease free water. This was then incubated for 2 hours at 30 °C. 
2.5.3 Binding assay 
Twenty micrograms of GST-PBF (and separately 20 µg GST only control) were 
combined with 10 µL [35S]-methionine labelled protein and incubated on ice for 30 minutes. 
After the addition of 500 µL low salt buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 % NP-40), 
50 µL packed glutathione agarose beads were added to each sample and incubated at 4 °C for 
2 hours with end over end rotation. The beads were then pulsed and the supernatant discarded 
before washing 4 times with low salt buffer. GST-PBF was then eluted with 40 µL of 25 mM 
glutathione in 50 mM Tris pH 8 for 1 hour at 4 °C. Subsequently, 40 µL of loading buffer 
(Laemmli   sample  buffer  with  5%   (v/v)  β-mercaptoethanol) were added to each sample and 
analysed by SDS-PAGE. 1 µL [35S]-methionine  labelled protein was combined with 20 µL 
Chapter 2  Material and Methods 
 
 72 
loading buffer and run as a 10 % input control. Following electrophoresis, the gel was dried 
and exposed to radiographic film for between 1 and 24 hours at –20 °C. 
2.6 Fluorescence immunocytochemistry 
Glass cover slips were washed in 100 % ethanol, rinsed in PBS and placed in 34.8 mm 
diameter cell culture plates. Cells were seeded into the wells at a varied concentration 
depending on cell type: K1 – 75,000 / well, TPC1 and HeLa – 50,000 / well. 
After 24 hours growth, transfection was carried out as described previously. After a 
further 72 hours, medium was removed and the wells rinsed with 1 ml PBS. The following 
steps took place at room temperature unless otherwise stated. The coverslips were fixed for 20 
minutes in 800 µL fixing solution (0.1 M phosphate buffer (from 0.2 M Na2HPO4 pH 
corrected to 7.4 using 0.2 M NaH2PO4), 0.2 % paraformaldehyde, 0.2 % glucose, 0.02 % 
sodium azide). After rinsing twice with PBS, cells were permeabilised with 800 µL of chilled 
100 % methanol for 20 minutes. Cells were rinsed again twice with PBS and then blocked 
with 800 µL 10% newborn calf serum (NCS) in PBS. After blocking, the coverslips were 
placed face down onto 80 µL of 1 % BSA in PBS with primary antibody, on parafilm and 
incubated in the dark for 1 hour. Specific antibody concentrations are detailed in the relevant 
chapters. Subsequently, the coverslips were rinsed 3 times with PBS, then placed face down 
onto 80 µL of 1 % BSA in PBS with 1 % NCS, 1:250 Alexa Fluor® 488 Goat Anti-Mouse 
IgG (H+L) (Invitrogen), 1:250 Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) (Invitrogen) 
and 1:1000 Hoechst stain 33258 (Sigma) and incubated for 1 hour in the dark. The coverslips 
were again rinsed 3 times in PBS and after removing any excess liquid were mounted on to 
slides using Fluorescent Mounting Medium (Dako) and air dried in the dark. Coverslips were 
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then fixed to the slides using nail varnish (Monsoon Accessorize, London, UK) and slides 
stored at 4 °C. 
2.7 Human primary thyroid cultures 
Fresh thyroid tissue was obtained from patients undergoing thyroidectomy 
(hemi/total/completion) with the approval of the Local Research Ethics Committee. All 
patients gave written informed consent for their tissue to be collected. Collected thyroid tissue 
was surplus to histological requirements, and was taken from an area of macroscopically 
normal tissue in the contra-lateral lobe to the site of disease. Thyroid tissue was collected 
from patients with diagnoses of multinodular goitre, suspicious thyroid nodules and thyroid 
cancer. 
Thyroid specimens were prepared as described previously (Eggo et al. 1996). Thyroid 
tissue was extensively macerated under sterile conditions until a smooth consistency was 
obtained. The tissue was then digested in 0.2 % collagenase Type 2 (Worthington 
Biochemicals, NJ, USA) in Hanks’ Balanced Salt Solution (HBSS) (Sigma) (filter sterilised 
through a 0.22µm pore 54.5 cm  polyethersulfone membrane (Corning)) for 16 hours at room 
temperature or 3 hours at 37 °C. The resulting tissue was further filtered through a 1 ml sieve 
and the pellet washed in HBSS. The pellet was re-suspended in primary thyroid media as 
described previously (Ambesi-Impiombato 1986; Eggo et al. 1996): 1   x   Coon’s   modified  
Hamm’s  F-12 modified medium (Biochrom AG) with 30 mM sodium bicarbonate made up to 
1 litre with H₂O then sterilised as above, supplemented with 105 U/L penicillin, 100 mg/L 
streptomycin, 300 U/L thyroid stimulating hormone, 300 µg/L insulin and 5 % fetal bovine 
serum, and, after plating, incubated at 37 °C. After 72 hours, serum was omitted. Cells were 
considered ready for experimentation between days 9 and 11.  
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2.8 Statistical analysis 
Data were analysed using IBM SPSS Statistics Version 19 (IBM, UK). Normal 
distribution  of  data  was  determined  and  parametric  data  groups  were  analysed  by  student’s  t-
test. Significance was taken as p < 0.05. ImageJ (public domain software, available at 
http://rsb.info.nih.gov/ij/) was used to calculate scanning densitometry results. 
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Despite being first described over 10 years ago (Chien and Pei 2000), relatively little is 
understood regarding the precise role of PBF within the cell, certainly compared to its named 
binding partner PTTG. The majority of the work concerning PBF has focussed on its 
involvement with thyroid disease, and specifically thyroid cancer (see section 1.4.2). PBF 
over-expression has a diverse range of effects within the cell, interacting with NIS and 
internalising it from the cell membrane (Boelaert et al. 2007; Smith et al. 2009), with a similar 
effect observed in relation to the thyroid hormone transporter MCT8 (Smith et al. 2012). PBF 
is transforming in vitro, tumourigenic in vivo, and over-expression is found in thyroid cancers 
and is associated with early cancer recurrence (Stratford et al. 2005). It has recently been 
shown to be additionally related to the presence of metastases, advanced stage, multicentricity 
and increased mortality; acting as an independent prognostic indicator (Hsueh et al. 2013). 
PBF also increases the invasiveness of breast cancer cells in vitro (Watkins et al. 2010), an 
observation which may underlie the increased recurrence observed in thyroid cancer. 
To help explain this diversity of effect it is important to understand the breadth of PBF 
relationships within the cellular interactome. Currently described interactors with PBF are 
PTTG (Chien and Pei 2000), NIS (Smith et al. 2009), MCT8 (Smith et al. 2012) and p53 
(unpublished data) but these are insufficient to fully explain the range of effects PBF is 
involved in. Key areas of interest include proteins involved in the movement of PBF around 
the cell, allowing it to reach the cell membrane and internalise the membrane transporters. 
Given the association with early cancer recurrence, another is any role of PBF in pathways 
associated with invasion or metastasis. A final area of specific interest is the identification of 
the serine/threonine or tyrosine kinases which may be responsible for phosphorylating PBF. 
Chapter 3  Optimisation of tandem mass spectrometry 
 
 77 
MS/MS is a tool that is developing momentum as the optimum method of identifying 
protein-protein interactions. Although several variations exist, one of the most straightforward 
is the analysis of samples that have been immunoprecipitated with the protein of interest. 
With the powerful detection that is inherent in MS/MS also come limitations. The first of 
these is the contamination of test samples by material exogenous to the experimental process 
(i.e. dust, skin etc.). Where small amounts of target protein are present, these additions can 
significantly hamper results. The second is the software used to analyse the mass spectra. 
Each protein has a unique fingerprint, based on the position of trypsin digestion sites and the 
subsequent chains of amino acids generated. When a peptide chain is analysed, the resulting 
mass spectrum, caused by the ionisation and fragmentation of the peptide, is assigned by the 
software to a protein. If the spectrum contains all possible fragments of the peptide (therefore 
scoring highly), and the protein is identified by several such peptide spectra, it can be 
assumed that it is genuinely present in the sample. Unfortunately, where the spectrum is 
ambiguous, containing some identified and some unidentified peaks, it may be assigned 
incorrectly to a protein. In these cases it is likely that only 1 peptide will be assigned to this 
protein, and it can therefore be discarded from further analysis. A difficulty arises where a 
protein that is present, but in low quantities, is only identified by 1 peptide and is therefore 
wrongly excluded. A way to account for this is to either examine the spectra for these proteins 
manually to determine if it is accurate, or to match those proteins identified by 1 peptide 
across several experiments, lending credibility to what may otherwise have been a discarded 
result. 
The aim of this chapter, therefore, was to establish the optimal conditions for MS/MS, 
from cell culture, transfection and immunoprecipitation to gel digest, MS/MS and data 
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analysis. Key contaminants and non-specific interactions would be identified and spreadsheet 
templates to facilitate the fast analysis of the large amounts of data would be produced. 
3.2 Methods 
3.2.1 Cell culture 
K1 and TPC1 cells were maintained in RPMI as described in Section 2.1. For analysis 
by Western blotting, cells were seeded onto 6 well plates; for immunoprecipitation, T25 and 
T75 flasks were used. 
3.2.2 Bacterial plasmids 
PBF-HA in pci-Neo was sublcloned into pcDNA3.1+ using the restriction enzymes 
EcoR1 and Xba1 as described in Section 2.2.1. Transfection was carried out using Fugene6 or 
PEI as described in Section 2.2.2. 
3.2.3 Fluorescence-activated cell sorting (FACS) 
K1 and TPC1 cells were transfected with the pMax-GFP plasmid (Amaxa, Cologne, 
Germany). After 24 hours, cells were processed as described in Section 2.3.1, with 1 % 
paraformaldehyde instead of RIPA / PI. After transferring to a test tube, samples were 
analysed using the FACSCalibur 4-colour flow cytometer (BD Biosciences, Oxford, UK). 
GFP was detected in the FL1 channel with settings calibrated using mock-transfected cells as 
a negative control. FL1 was set to log 400 with an amplification gain of 400. Forward and 
side scatter were set to linear. The M1gate was set at approximately 2.5 x 101. 
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3.2.4 Western blotting 
Western blotting was performed as described in Section 2.3. Primary antibodies were 
anti-HA (mouse monoclonal, HA.11 Clone 16B12, Covance, UK) 1:2000 and monoclonal 
anti-β-actin (clone AC-15, Sigma-Aldrich), 1:10000. 
3.2.5 Tandem mass spectrometry (MS/MS) 
3.2.5.1 Immunoprecipitation 
K1 and TPC1 cells were cultured in T75 flasks and transfected with PBF-HA or blank 
vector using PEI, as described in Section 2.4. Cells were washed 4 times with 10 ml cold PBS 
then scraped into a 50 ml centrifuge tube, combining samples from several T75 flasks in each 
tube.  The samples were spun for 5 minutes at 1200 rpm and the supernatant discarded.  The 
cells were re-suspended in 1ml of high salt lysis buffer (50 mM Tris pH 7.4, 1% v/v Igepal 
CA-630, 400 mM NaCl) / PI cocktail (ratio 1 ml lysis buffer:60 µl PI) and the resultant 
suspension transferred to a micro-centrifuge tube.  Subsequent steps were as described in 
Section 2.4, using anti-HA (above) as primary antibody and high salt lysis buffer instead of 
RIPA. 
Proteins were separated using the NuPage Bis-Tris electrophoresis system (Invitrogen) 
as  per  manufacturer’s  instructions,  using  1x  running  buffer  with 500 µl NuPage antioxidant.  
Under positive pressure in dust-free conditions, the gels were removed from the casing and 
incubated in Colloidal Coomassie Blue stain (0.08 % Coomassie Brilliant Blue G250 (Sigma), 
1.6 % Orthophosphoric Acid, 8 % Ammonium Sulphate, 20 % Methanol) with gentle 
agitation overnight at room temperature.  Gels were de-stained with 4 to 5 washes in 1 % 
acetic acid and stored in 1 % acetic acid at 4 °C until digest. 
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3.2.5.2 Gel digest 
All steps were undertaken in a positive pressure hood to minimize keratin contamination 
and all washes and incubations carried out at room temperature with gentle agitation unless 
otherwise stated.  Gels were scanned and processed to allow identification of visible bands. 
The gels were then placed onto a clean glass slide and each lane excised and divided into 
sections approximately 2 mm in height. Gel pieces were washed twice with 500 µl 50 % 
acetonitrile / 50 mM ammonium bicarbonate for 45 minutes.   They were then incubated for 
one hour at 56 °C with 50 µl of 50 mM DTT in 10 % acetonitrile/50 mM ammonium 
bicarbonate and the supernatant discarded.  After adding 50 µl of 100 mM iodoacetamide in 
10 % acetonitrile with 50 mM ammonium bicarbonate, samples were incubated in the dark for 
30 minutes and the supernatant removed.  A further three washes with 500 µl 10 % 
acetonitrile in 40 mM ammonium bicarbonate for 15 minutes were undertaken and the bands 
subsequently dried down using a vacuum centrifuge for 60 minutes.  200 µg / ml trypsin 
solution were prepared using Sequencing Grade Modified Trypsin (Promega) according to the 
manufacturer’s   instructions   and   diluted   to   12   µg / ml with 10 % acetonitrile with 40 mM 
ammonium bicarbonate.  30 µl of this were added to the dried gel pieces and the samples 
incubated for 60 minutes.  40 µl of 10 % acetonitrile with 40 mM ammonium bicarbonate 
were added and the samples incubated at 37 °C overnight.  The supernatant was collected and 
the samples incubated in 60 µl of 3 % formic acid for 60 minutes.  After collecting the 
supernatant, a further 60 µl of formic acid were added to the gel pieces and incubated for 60 
minutes.  The supernatant was again retained and combined with the previous sample 
collected. 
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3.2.5.3 Sample processing 
100 µl of sample were loaded into clean sample tubes.  These were then loaded into the 
Ultimate 3000 High Performance Liquid Chromatography (HPLC) unit (Dionex, California, 
USA) as per manufacturer’s   instructions.   An   acetonitrile   gradient   was   used   as   advised.    
Following HPLC, the samples were run in continuity through the AmaZon ETD ion trap and 
tandem mass spectrometer (Bruker Daltronics, Coventry, UK). 
3.2.5.4 Data analysis 
Mass spectrographs were analysed using a pan-mammalian database via the Mascot 
search engine (v2.2.06, Matrix Science Ltd, London, UK), with results generated by 
ProteinScape (v3.0.0.446, Bruker, Coventry, UK). 
3.3 Results 
3.3.1 Optimisation of transfection efficiencies for K1 and TPC1 cells 
3.3.1.1 Subcloning PBF-HA into pcDNA3.1 
 Full length PBF-HA, already in use within our group in the mammalian expression 
vector pCI-Neo, was subcloned into pcDNA3.1+, using the restriction enzymes EcoR1 and 
Xba1, as described in section 2.2.1.2. Correct insertion was confirmed by sequencing using 
the T7 and BGHrev primers. Transfection was confirmed by Western blotting (Figure 3.1). 




Figure 3.1 Western blot demonstrating PBF-HA transfection in K1 cells, compared to 
untransfected   (UT)   and   vector   only   (VO)   transfected   cells.   β   actin   is shown as a loading 
control. 
3.3.1.2 Polyethylenimine results in the greatest transfection efficiencies 
In order to obtain the greatest transfection efficiency (TE) for the thyroid cancer cell 
lines, Fugene6 – the transfection reagent used for transfection of K1 and TPC1 cells within 
our group, was compared with polyethylenimine (PEI, Sigma). Cells were transfected with a 
Green Fluorescent Protein (GFP) -tagged vector (pMax-GFP (Amaxa, Cologne, Germany)) 
and, after trypsinisation, were analysed by Fluorescence-Activated Cell Sorting (FACS). K1 
and TPC1 cells were transfected under a number of conditions, with varying amounts of 
transfection reagent, plasmid DNA and agitation. Untransfected cells were used as a negative 
control – as they demonstrated only base line fluorescence, a cut off could be set above which 
the  cells  were  classed  as  “transfected”  (the  “M1  gate”,  Figure 3.2A). When transfected cells 
were analysed under the same conditions, the percentage of cells that fell within the M1 gate, 
and could thus be classed as transfected, was determined (Figure 3.2B). 




Figure 3.2 Representative FACS output from cells untransfected (A) and transfected (B) with 
pMax-GFP. The FL1 axis indicated the degree of fluorescence, with the y axis representing 
the number of cells. The percentage of M1 gated cells was substantially higher for the 
transfected sample compared to the untransfected cells. 
Each set of transfections was carried out in triplicate and repeated on 3 occasions with a 
different passage of cells. For PEI transfection, using NaCl supplemented serum-free media 
improved transfection (data not shown).  Centrifuging the plates after transfection had a 
negative effect on transfection of K1 cells (many cells became detached) but in the TPC1 cell 
line, although a negative trend was seen, variability was such that no significance could be 
attributed to this.   The optimum ratio of PEI to DNA was 10:1, using 2 µg DNA for K1s and 
4 µg DNA for TPC1s (for a 6 well plate transfection).  The maximum TE was 81.4 ± 1.6 % 
for K1s and 55.5 ± 4.8 % for TPC1s (Figure 3.3).   




For Fugene transfection, 65.6 ± 10.4 % TE was reached in the K1s using 2 µg DNA with 
a Fugene to DNA ratio of 3:1. In the TPC1 cell line, the maximum reached was 23.4 ± 7.4%, 
with 4 µg DNA in a ratio of 3:1.  In this cell line, centrifuging the plates after transfection had 
a positive effect; at the lower concentration of DNA, TE was significantly increased to 37.5 ± 
3.1 % (p = 0.02), whereas at 4 µg DNA, there was no significant change in TE  (25.4 ± 7.4 %, 
p = 0.9) (Figure 3.3). A summary of the optimum conditions for transfection in the cell lines 
is given in Table 3.1. 
 
Figure 3.3 Transfection efficiencies (TEs) of K1 and TPC1 cells for differing transfection 
reagents. TEs are given as percentage of gated cells relative to untransfected cells (n = 3).ns 
= not significant, ** = p < 0.01, *** = p < 0.001 
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 Fugene 6 Polyethylenimine 
K1 
DNA (µg) 2 2 
Reagent:DNA ratio 3:1 10:1 
Spun/Unspun NSD Unspun 
TPC1 
DNA (µg) 2 4 
Reagent:DNA ratio 3:1 10:1 
Spun/Unspun Spun Unspun 
Table 3.1 Optimum transfection conditions for K1 and TPC1 cells. NSD = No significant 
difference. 
3.3.2 Optimisation of MS/MS 
3.3.2.1 Volume of culture and negative control 
In order to determine the optimum amount of cell lysate to use in the MS/MS process, 
K1 cells were cultured in T25 plates and transfected with PBF-HA, using PEI, as described 
above. The cell lysate was harvested and immunoprecipitated using an anti-HA antibody (as 
above). A different negative control was used in each experiment; in the first an additional 
flask was cultured and transfected as before but no antibody was used to precipitate the lysate 
(this ensured that any peptides identified in the negative control were the result of non-
specific binding between proteins and the protein G coated sepharose beads), while in the 
second the cells were transfected with blank vector and immunoprecipitated with antibody, 
thus revealing the extent of non-specific binding to the antibody as opposed to PBF-HA. The 
immunoprecipitant was run through SDS-PAGE using pre-cast gels to reduce the risk of 
contamination, and following this the gels were stained with colloidal Coomassie blue in a 
negative pressure fume hood. This demonstrated the predominant protein bands present in the 
sample while again reducing the risk of contamination.  
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Using the protein ladder as a guide for molecular mass, both the test and control lanes 
were divided into a number of small gel pieces, again under negative pressure. A 
representative gel image with markers to demonstrate cut locations is shown in Figure 3.4. 
 
Figure 3.4 Representative scan of polyacrylamide gel stained with colloidal Coomassie blue 
after SDS-PAGE. Dominant protein bands stained blue. La - Ladder used to determine 
molecular mass of gel segments. PBF-HA - Cells transfected with PBF-HA. V/O - Cells 
transfected with blank vector. 
Bovine serum albumin was used to calibrate both the HPLC and tandem mass 
spectrometer, and following this the samples were then passed through MS/MS; the resulting 
peptides were identified using a pan-mammalian database. The predominant proteins 
identified for the test and control samples were different types of keratin and porcine trypsin. 
While the latter was to be expected given that this was used to digest the proteins during the 
Chapter 3  Optimisation of tandem mass spectrometry 
 
 87 
extraction process, the former were all due to contamination of the samples at one, or several 
points, of the process from gel staining to entry into HPLC. There were several other proteins 
identified in all samples across both experiments, again most likely resulting from 






Junction plakoglobin Keratin 
Kinesin Laminin 
Myosin Vimentin 
Table 3.2 Proteins identified as contaminants in both experiments and in multiple samples. 
Once these contaminants had been discounted, the control samples were examined to 
identify those proteins present due to non-specific binding, either to the anti-HA antibody or 
to the sepharose beads. This was determined to be any protein identified by greater than 2 
peptides in either of the control samples, which was not in the contaminant list above. In 
general, the number of peptides by which these were identified ranged from 3 to 8, while the 
contaminants were identified by > 30 peptides. The other group of proteins were those that 
had been carried over to MS/MS during the preceding steps. These included trypsin, as 
mentioned above, immunoglobulins and proteins likely remaining from the culture process 
(e.g. bovine albumin). A list was thus developed of proteins whose presence in a test sample 
was unlikely to be attributable to interaction with PBF, and could therefore be discounted, the 
highest ranking of which are listed in Table 3.3. 









E3 ubiquitin-protein ligase 
UBR1 Immunoglobulins 
Histone-lysine N-
methyltransferase  Alpha-S1/2-casein 
DNPK1 Beta-lactoglobulin 
Kinase suppressor of Ras 2  
Table 3.3 Table detailing the highest ranking non-specific interactions identified by MS/MS, 
and those proteins carried over as a result of experimental process. 
This list would be updated with each experiment and included subunits of proteins 
where applicable, as these could be identified separately by the database. The process by 
which the original list of proteins was reduced to a final shortlist is summarised in Figure 3.5. 
Run 2 had a greater number of proteins in the original list (before contaminants, non-specific 
interactions and experimental carry-over results were removed). The final step in the process, 
removing any proteins identified in the control samples by 2 peptides (not already covered in 
one of the previous steps) and then any identified by 1 peptide only in the test sample, yielded 
a final shortlist that contained similar numbers of proteins.  




Figure 3.5 Flowcharts demonstrating the process by which the original list of proteins 
identified by MS/MS was reduced to give a final shortlist of potential interacting proteins. A - 
Experiment 1 (no antibody used as negative control). B - Experiment 2 (blank vector 
transfection used as negative control). 
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From these first two experiments, therefore, a number of limitations were identified 
which had to be addressed prior to proceeding with further MS/MS and determination of 
potential binding partners. 
Contamination 
Contamination by large amounts of keratin was significantly impeding the results. Of all 
peptides identified, 53.9 % were assigned to contaminants (Table 3.4). The mass spectrometer 
is only capable of analysing one compound of a particular m/z at a time; therefore if a large 
number of contaminant peptides were passing through the analyser this would be at the 
expense of other proteins. This was demonstrated by the poor yield of PBF in the test results. 
In the first experiment, PBF was only identified by 1 peptide (sequence coverage (SC) 6.7 %), 
and although 3 peptides were identified in the second experiment (SC 23.3 %) this was still 
fewer than expected. 
Sample n = 1 n = 2 Total 
Test Control Test Control 
Total peptides 4267 3910 6085 7044 21306 
Contaminants 
peptides 2176 1990 3393 3916 11475 
Percent 
contamination 51.0 % 50.9 % 55.8 % 55.6 % 53.9 % 
Table 3.4 Number of peptides attributed to contaminants in both test and control samples, 
across both experiments. 
Non-specific interactions 
A significant number of peptides resulted from presumed non-specific interactions. 
While the purpose of the control samples was to identify these, large numbers would have a 
similar effect to the contaminants in swamping the true values and therefore where possible 
should be reduced. 
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Low peptide yield 
As well as reducing swamping, increasing the amount of lysate present would improve 
the average peptide yield per protein, helping to identify the true binding partners. 
 
To manage these limitations, the following conditions were changed: 
x Cell culture was carried out in T75 flasks, increasing the seeding area and cell count at 
confluency by 3 fold. 
x High salt lysis buffer reduces non-specific interactions when immunoprecipitating for 
mass spectrometry (Shimwell et al. 2009) and this was therefore used in place of RIPA 
buffer. Additional wash steps were performed prior to cell lysis to remove as many 
residual proteins as possible. 
x All steps of the procedure were undertaken in negative pressure conditions, using 
unopened, sealed microcentrifuge tubes for each experiment to reduce the risk of external 
contamination. 
For the third experiment, again using K1s, the negative control used was blank vector 
transfected cells, with an additional list of control proteins transferred from the first 2 
experiments. The process by which the shortlist of proteins was generated is described in 
Figure 3.6.  




Figure 3.6 Flowchart demonstrating the process by which the shortlist of potential binding 
partners was generated. 
There was less contamination, with 25.9 % of peptides belonging to contaminants (as 
opposed to 50.9 % and 55.7 % in the first 2 experiments) (Table 3.5).  
Sample n = 1 n = 2 n = 3 
Test Control 
Total peptides 8177 13129 6522 9452 
Contaminants 
peptides 4166 7309 1307 2998 
Percent 
contamination 50.9 % 55.7 % 20.0 % 31.7 % 
Table 3.5 Comparison of the number of peptides attributed to contamination. Experiment 1 
(no antibody negative control) and Experiment 2 (blank vector negative control) show totals 
for both test and control results. 
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The number of proteins identified that could be attributed to either non-specific 
interaction or experimental carry-over was slightly reduced (13 and 96 respectively, compared 
to 30 and 97 on average from the first 2 experiments), although the reduction in the number of 
peptides attributed to these showed a greater reduction (7.5 % vs. 11.8 % and 14.6 %). 
Importantly, significantly more peptides were identified as belonging to PBF under the new 
conditions. In total, 45.6 % of the PBF sequence was covered by identified peptides (Figure 
3.7), compared with 6.7 % and 23.3 % as described above. 
 
Figure 3.7 Amino acid sequence for PBF. Amino acids identified by MS/MS are highlighted in 
yellow. Trypsin digest sites are printed in red. 
 
3.3.3 Optimum conditions for MS/MS 
Based on the above results, a number of conditions were deemed to be necessary in 
order for MS/MS to identify potential binding partners with the greatest degree of accuracy, 
with minimal contamination and false positive results, and these are listed in Table 3.6. 
 




Culture K1 cells in a T75 flask 
Transfect 15 µg DNA 
Transfect using PEI at 10:1 
Lyse and wash using high salt lysis buffer 
Use sterile, new microcentrifuge tubes for each step 
Gel staining and digest Work in negative pressure hood for all steps 
Analysis of output 
Discard all contaminants 
Discard proteins identified as non-specific interactors 
Produce a shortlist based on proteins not found in a 
control  sample  and  identified  by  ≥  2  peptides 
Table 3.6 Summary of the optimum conditions needed for MS/MS. 
 
3.4 Discussion 
MS/MS provides a valuable method of identifying small amounts of protein from within 
a complex sample, although it is prone to misleading results due to contamination and non-
specific interactions in the case of immunoprecipitated proteins. The aim of this chapter was 
to define the optimum conditions for co-immunoprecipitation and MS/MS, in order to 
develop a protocol that would allow for the accurate identification of potential binding 
partners of PBF. 
Once the PBF-HA cDNA had been successfully sub-cloned into the vector pcDNA3.1+, 
optimum transfection conditions were determined using FACS. It was essential that a high 
level of transfection was achieved; the immunoprecipitation step relied on the transfected HA 
tag, therefore low levels of transfection would result in a smaller amount of PBF-HA 
immunoprecipitating and with that a smaller number of interacting proteins. By using K1 and 
TPC1 cells transfected with pMax-GFP, FACS identified those cells that had undergone 
transfection by their degree of fluorescence. Altering the amount of plasmid DNA as well as 
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transfection reagent allowed for multiple conditions to be assessed, with TEs of 81.4 % for 
K1 and 55.5 % for TPC1 cells achieved. 
Once the optimal conditions for transfection had been established, the cells were lysed 
and passed through MS/MS. In the two initial experiments, 2 different negative controls were 
implemented. The first, using cells that had been transfected with PBF-HA as for the test 
samples but immunoprecipitated without the anti-HA antibody, identified those proteins 
present in the output data as a result of binding to the protein G sepharose beads and any that 
had been carried across as a result of the experimental process. In the second, the negative 
control was treated in exactly the same way as the test sample, but the cells were transfected 
with blank vector only. This had the advantage of identifying the same group of proteins as 
the first control, but with the addition of any proteins that had been carried through as a result 
of non-specific binding to the anti-HA antibody. Together, these 2 controls were able to 
provide a list of contaminants, non-specific interactors and carry-through proteins that could 
be discarded from future results.  
The above measures removed many proteins from the output data, but there were still 
1707 in the first and 2085 in the second to be analysed. The next step of the process removed 
any proteins that had been identified by 2 peptides in either of the control samples. The 
principle behind this step were that there would be many peptides/proteins that were identified 
that were not the result of true interaction between themselves and PBF-HA, and not 
identified by enough peptides to be placed on the previous list of exclusions. Using 
spreadsheet analyses, these lists could be compared easily and any peptide that met the criteria 
removed. Finally, only proteins that had been identified by more than one peptide were 
included in the shortlist of potential binding partners. 
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This method of shortlisting did have shortcomings. It is possible that some interacting 
proteins were discarded due to a chance/false finding in the control sample. Similarly, one 
may have been overlooked as it was only identified by one peptide, either due to a small 
amount of protein present or as a result of swamping by a more abundant peptide. 
Another limitation of the process was that PBF was only identified by one peptide in the 
first and 3 peptides in the second experiment. It was not possible to determine whether this 
was a result of swamping by other peptides or a lack of protein brought forward to MS/MS. 
To improve on these results, a number of conditions were changed to address the 
potential and definite problems. Firstly, cells were cultured in larger quantities, which 
increased by three-fold the amount of lysate used for immunoprecipitation. More wash steps 
were undertaken, using a high salt lysis buffer, with the aim of both reducing the number of 
non-specific interactions and reducing the amount of protein brought through from cell 
culture. Finally, all steps were undertaken in a negative pressure fume hood with a clean filter, 
to reduce the amount of dust contamination. 
The following results were much improved, contamination by keratin and similar 
proteins was reduced by 50 – 60 %, and although the number of proteins from the non-
specific and carry-over lists remained similar, the proportion of peptides attributed to them 
was reduced by almost a half. Additionally, PBF was strongly identified in this experiment, 
adding credibility to other strongly identified proteins. 
Concluding remarks 
This chapter has described the process by which the optimal conditions for identification 
of potential binding partners of PBF have been determined. The process involved keeping 
contamination by keratin and other dust based contaminants to a minimum, while also 
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reducing the amount of non-specific interactions using high salt lysis buffer and stringent 
wash steps. 
Although the final shortlist from the first two experiments would not be used in further 
analysis, they provided important information as to the proteins that could be discarded from 
analysis. 
 




Chapter 4 Novel binding partners of PBF 
identified by MS/MS 
  




Chapter 3 discussed the optimisation of the MS/MS process to achieve the greatest 
possible sensitivity for the detection of potential binding partners of PBF. This was an 
important step as although MS/MS is an exceptionally sensitive tool, it is also 
undiscriminating   and  will   therefore   “identify”   a   very   large   number   of   proteins, which will 
include the true interactors as well as contaminants, non-specific interactors and those 
proteins inherent to the experimental process. A number of experimental conditions and 
analysis parameters were therefore set which limited the results to those proteins most likely 
to represent true interacting partners. Although there may be some valid results that would be 
discounted as a result of this, as well as many false positives that would be carried forward, 
these would be minimised.  
The aim of this chapter, therefore, was to generate a shortlist of likely binding partners 
and, from these, select three to take forward to validation experiments and functional studies. 
In addition, a secondary aim was to determine a larger list of potential binding partners that 
could be used in further studies of PBF function. 
4.2 Methods 
4.2.1 MS/MS protocol 
Mass spectrometry was carried out as described in Section 3.2.5. K1 and TPC1 cells 
were used for transfection, co-immunoprecipitation and generation of gel fragments for use in 
HPLC and MS/MS. Anti-HA was used to immunoprecipitate lysates from cells transfected 
with PBF-HA, while our polyclonal rabbit anti-human PBF (Eurogentec, Seraing, Belgium, 
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(Smith et al. 2009)) was used for cells transfected with untagged PBF or untransfected cells. 
Analysis was as described in Section 3.2.5.4. 
4.2.2 Statistical methods 
Full lists of protein hits from both test and control samples were exported to MS Excel. 
Contaminants, non-specific interactions, carry over proteins and duplicates were deleted (see 
section 3.3.2). Any protein identified in the control samples by 3 peptides once, or 1 or 2 
peptides more than once, was also removed. The resulting long-list was used to compare 
results across the different runs, with protein hits assessed on the number of peptides 
identified, the number of runs the protein was found in, and the score for each protein. 
4.3 Results 
4.3.1 Immunoprecipitation with anti-HA 
Using the protocol optimised in Chapter 3, potential binding partners of PBF were 
identified using K1 cells. Despite variation in the total number of proteins identified in each 
run, the final shortlist number was similar, with most variation occurring in the number of 
proteins identified by one peptide only or with duplicated proteins assigned to different 
species (Table 4.1). The amount of contamination varied across experiments, despite strict 
adherence to dust free protocol; the major contributor to this was keratin (Table 4.2). 
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 R3 R4 R5 
Test sample proteins 3166 2677 3784 
Contaminants 226 352 273 
Non-contaminants 2890 2325 3511 
Non-specific 
interactions 13 14 22 
Experimental carry 
through 96 123 135 
Potential results 2781 2188 3374 
Present in control 377 617 683 
1 peptide/duplicates 2246 1432 2502 
Shortlist 158 139 189 
Table 4.1 Table demonstrating elimination process for proteins identified by MS/MS runs R3 
to R5. 
 R3 R4 R5 
Total peptides 6522 6180 6070 
Contaminants  1307 3428 1886 
Percent 
contamination 20.0 % 55.5 % 31.1 % 
Table 4.2 Contamination of MS/MS samples in runs R3 to R5. 
4.3.2 Binding partners identified in TPC1 cells 
To provide another cell line representative of thyroid cancer with which to validate and 
compare potential binding partners, TPC1 cells were used. This was another model of 
moderately differentiated thyroid cancer, but one displaying the RET/PTC re-arrangement as 
opposed to BRAF mutation. The protocol was identical to that used for K1 cells. The number 
of proteins identified was comparable to the K1 cells (Figure 4.1), while contamination was 
27.9 %.  




Figure 4.1 Flowchart demonstrating protein elimination process for TPC1 cells. 
 
4.3.3 Immunoprecipitation using an anti-PBF antibody 
The above experiments sought to identify potential binding partners of PBF using a 
tagged protein; the final experiment involved immunoprecipitating using an anti-PBF 
antibody, with K1 cells either transfected with PBF, or left untransfected. As a percentage of 
total peptides, contamination was higher in both of these experiments. The number of 
shortlisted proteins was again comparable to previous runs (Figure 4.2). However, one 
limitation of these experiments was that PBF was not identified in the untransfected run. This 
may have been due to the excess contamination; however it is possible that the anti-PBF 
antibody was not strong enough to ensure sufficient pull back of protein-protein complexes to 
allow detection of these lower levels of PBF, especially in the presence of other swamping 
proteins. 
 





Figure 4.2 Flowcharts detailing analyses of a PBF transfected run (A) and an untransfected 
run (B). 
4.3.4 Shortlisting of potential binding partners 
To draw up a final list of potential binding partners, the shortlist from each experiment 
was compared, with those proteins scoring highest across several runs being included. 
Following this, the full list of proteins (i.e. including those identified by 1 peptide only) was 
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compared across each experiment, to identify any proteins that may have been excluded based 
on a lower score that were actually present in multiple runs, thus representing potential true 
positives. This list is documented in Appendix 1. Finally, a search was carried out for any 
proteins that had been predicted as potential binding partners based on analysis of PBF 
structure.  Ranking of this final shortlist was carried out by assessing the total score assigned 
to the protein across all experiments by the Mascot search engine, and factoring in the total 
number of peptides identified. The final list of 9 proteins is shown in Table 4.3. After 
assessing the scores and potential relevance to PBF physiology as well as practicality of 
future experiments, three proteins were chosen for validation: thyroglobulin, cortactin and src 
/ src-family kinases. 
 




Table 4.3 Table listing the proteins identified by MS/MS as most likely to interact with PBF. 
Score was assigned by Proteinscape for each experiment. Ranking was based on average 
score per peptide across the experiments (n=6). Peps = Number of peptides, Sc = Score, 
Untrans  =  Untransfected,  “-“  =  no  peptides  found. 




In chapter 3, the optimum conditions for MS/MS were described, and in this chapter 
these were used to generate a list of proteins that may interact with PBF. Initially, 3 
experiments were performed utilising HA-tagged PBF and immunoprecipitating with an anti-
HA antibody. Each provided a similar number of proteins for consideration. A further 3 
experiments were then carried out with varied conditions; in the first, the K1 cell line was 
substituted for the TPC cell line. Although both represent papillary thyroid carcinoma, the 
genotype of the two varies and there may have been proteins identified in the TPC1 line that 
were missed in the K1 cells. Similarly, should a protein be found in both cell lines, this would 
lend credibility to the potential interaction. Finally, K1 cells were again used but 
immunoprecipitation was carried out using an anti-PBF antibody, with both over-expressed 
and endogenous levels of PBF. In the former, this would hopefully identify any proteins  in 
which an interaction with PBF was disrupted by the HA tag, and the latter would provide 
strong evidence for an interaction as only those proteins present in abundance in the 
immunoprecipitant would be picked up by MS/MS. 
To develop a final shortlist, the results from all experiments were compared on an Excel 
spreadsheet. It was not practical to validate all potential interactions, or even all those that 
appeared most likely, and therefore a number of strategies, both objective and subjective, 
were employed to generate a list of proteins for validation. Firstly, the elimination protocol 
described in Chapter 3 was used on each list of proteins, although in this case those identified 
by 1 peptide only were retained. Filters were then used to remove all proteins identified by 
only 1 peptide in 1 run, and proteins identified by a total of 2 peptides were manually 
searched and eliminated if their scores were low. In the next stage, the number of peptides 
each protein was identified by in each run was combined, as was the score assigned by 
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Mascot. This  then  allowed  a  “score  per  peptide” to be generated, and the remaining proteins 
ranked by this result. The list was again manually searched, and a shortlist of 9 proteins was 
generated, based on both final score and also potential relevance. Each of these proteins 
would benefit from further study, but due to restraints on time and resources, 3 were chosen 
for further validation and, if proven as true interacting partners, functional studies. 
 
Cortactin: Average score per peptide (ASP) – 40.0 
Cortactin was first described in the early 1990s as a Src substrate that bound to 
filamentous actin and was present in lamellipodia; cytoskeletal actin projections from the 
mobile edge of a cell which aid movement (Wu and Parsons 1993). The CTTN gene is located 
at 11q13, which is a region amplified in a number of cancers, including breast and head and 
neck (Schuuring et al. 1993). Cortactin has seen been implicated in a number of processes key 
to cancer progression: invadopodia formation (protrusions from the cell membrane associated 
with invasion), cell migration, stabilising of branched actin networks and membrane 
trafficking (Weaver 2008; Kirkbride et al. 2011). Cortactin had the highest score of all the 
shortlisted proteins, and was identified in both K1 and TPC1 cells. Given that PBF is a protein 
that is shuttled to and from the cell membrane, and that over-expression leads to an increase in 
cell invasion, an interaction with cortactin may serve to further explain these effects. This, 
combined with its high score, led to cortactin being chosen for validation. 
 
Thyroglobulin: ASP 33.5 
Thyroglobulin is the essential pre-cursor to thyroid hormone and is present in abundance 
in the thyroid follicle. Although at first it was thought possible that its presence may have 
been due to the high quantity present and therefore a non-specific binding/carry over, none 
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was identified in any of the control samples and therefore it could not be discounted. 
Additionally, when the data generated from the first 2 experiments (carried out in T25 flasks) 
was searched, thyroglobulin was identified by 2 peptides in each, lending further credence to 
the result. Given that the PBF-Tg mice displayed macro-follicular, hyperplastic goitres with 
deranged thyroid hormone content, this potential interaction may provide clues as to the 
mechanism by which this occurs. 
 
Src family kinases: ASP 29.1 
A number of Src family kinases (SFKs) were identified, including Lyn, Src and Yes; the 
former of which had the highest score. The SFKs have significant homology and it is possible 
that peptides assigned to one member actually belonged to another. These proteins were of 
particular interest, as kinase prediction software had identified Src as a potential kinase for 
PBF. Given this fact, and that there are a number of cancer therapies currently being trialled 
using Src as a target, it was felt appropriate to shortlist the SFKs as potential binding partners. 
The parent member of the group - and the kinase with the highest predicted score on 
phosphorylation prediction software - was Src, and these factors led to its inclusion in the 
validatory group. 
 
The remaining proteins were from a variety of functional classes, and future research 
will focus on defining these in more detail. 
 
Heat shock protein 90 – beta: ASP 38.6 
Hsp90 is a 90 kDa protein which is ubiquitoiusly expressed and plays a key role in 
protein homeostasis. It is a chaperone protein involved in protein folding as well as 
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intracellular trafficking (Pearl and Prodromou 2006). Expression of Hsp90 is abundant, and 
this rises 2 to 3 fold in tumours compared to normal tissue (Moulick et al. 2011). Inhibition of 
Hsp90 has been the subject of clinical trials for some time (Barrott and Haystead 2013), 
although none are in regular oncological use. The protein scored highly in MS/MS, and it will 
certainly warrant further investigation. 
 
Leucine-rich repeat flightless-interacting protein 1 / 2: ASP 27.5 
LRRK1 is a large, 225 kDa protein which is thought to function as a GDP/GTP-binding 
protein (Korr et al. 2006). Although   its   paralogue,   LRRK2,   is   associated  with   Parkinson’s  
disease (Lu and Tan 2008), very little is known regarding the function of LRRK1. Mutations 
have been described in both LRRK1 and 2; a barrier to clear functional work on either protein 
is the lack full length recombinant proteins, with either truncated or tagged proteins being 
used (Civiero and Bubacco 2012). LRRK1 scored highly, however despite this the lack of 
commercially available materials with which to perform validatory experiments meant that it 
would not have been feasible to pursue it at this stage and LRRK1 and 2 were therefore 
discarded. 
 
Focal Adhesion kinase 1: ASP 24.3 
FAK is a non-receptor tyrosine kinase with important roles in normal human 
development, as well as cell migration (via the actin cytoskeleton) and proliferation  (Schaller 
2010). Perhaps most importantly in relation to this thesis, FAK phosphorylates Src, and in 
doing so increases its kinase activity (Aleshin and Finn 2010). It is possible that FAK was 
identified through indirect interaction with PBF, with a complex forming between activated 
Src, FAK and PBF at the cell periphery. Another possibility is that FAK is the kinase 
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responsible for phosphorylating PBF. Given the limited time available for this PhD, and the 
strength of data suggesting Src as the principle kinase for PBF (both with phosphorylation 
prediction software and MS/MS), only Src was taken further for validation.  
 
Uveal autoantigen with coiled-coil domains and ankyrin repeats: ASP 21.2 
UACA is an autoantigen initially identified in thyroid tissue and shown to be 
upregulated by TSH (Wilkin et al. 1996). Most studied in relation to its role in panuveitis 
(Ohkura et al. 2004), it has recently been shown to be upregulated in a lung and prostate 
cancer, with the proposed mechanism being inhibition of apoptosis (Burikhanov et al. 2013). 
How this would correlate with the effects of PBF is unclear, and while a potential interaction 
with UACA is interesting and will warrant further study in the future, the paucity of evidence 
regarding its structure and function at the current time led to its exclusion from further study. 
 
Adenomatous polyposis coli protein: ASP 21.1 
The APC gene encodes a protein that down-regulates the Wnt signalling pathway 
through  interaction   with   β-catenin, and thereby inhibits tumourigenesis (Yokoyama et al. 
2011). Mutations in APC result in Familial Adenomatous Polyposis (FAP), a hereditary 
disorder of multiple colonic polyps with a 100 % progression to malignancy. There is a 1-6 % 
lifetime risk of thyroid cancer with FAP, usually papillary (Steinhagen et al. 2012). In 
addition, β-catenin mutations are observed in anaplastic thyroid carcinomas (Yokoyama et al. 
2011), further indicating that aberrant activation of this pathway is important in thyroid 
cancer. However, its contribution outside of FAP / specific ATC studies is as yet unknown. 
An interaction between APC and PBF could, therefore, provide an explanation for the 
tumourigenic effects of PBF, and will be an exciting avenue for further research.  
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Citron Rho-interacting kinase: ASP 19.2 
Citron kinase is a serine/threonine kinase first identified as a binding partner of Rho (a 
small GTP-ase from the same family as the proto-oncogene Ras) (Zhao and Manser 2005).  
Having been mainly studied in the context of neuronal growth, it has a role in the contractile 
process of cytokinesis (Madaule et al. 2000). Mice deficient in the CRIK gene display 
abnormal cytokinesis and apoptosis of neuronal precursors (Di Cunto et al. 2000). The 
relevance of citron kinase to PBF physiology is not readily apparent. While it is known to 
phosphorylate MLC (Yamashiro et al. 2003), further studies have not been carried out to 
identify other substrates, and whether it was identified due to direct or indirect interaction 
with PBF will prove interesting for further research in the future. 
 
Concluding remarks 
This chapter has described the generation of a shortlist of potential binding partners of 
PBF, and also provided a longer list (Appendix 1), both of which will serve as a resource for 
further research beyond the scope of this thesis. Three proteins have been highlighted for 
validation and functional experiments: Thyroglobulin, cortactin and src, all of which have the 
potential to provide further insight into the mechanisms by which PBF has its effects of the 
cell. 
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Chapter 5 PBF and thyroglobulin interact in 
thyroid cells 
  




The first of the 3 proteins chosen for validation, thyroglobulin is a large, 660 kDa 
dimeric molecule that is a vital component of the thyroid follicle. It is synthesised within the 
thyroid follicular cell via a complex series of steps, increasing in size until the final product is 
fully assembling immediately prior to secretion into the colloid (Malthiery and Lissitzky 
1987). Thyroglobulin (Tg) was identified in 3 of the main experiments and also in the initial, 
standard setting experiments and was therefore one of the stronger results produced. This was 
especially interesting as the thyroid glands of the PBF-Tg mice displayed macro-follicular 
goitres with higher intra-thyroidal levels of T3 and T4 (Read et al. 2011; Smith et al. 2012); it 
is conceivable, therefore, that an interaction between PBF and Tg might contribute to this 
phenotype. The aim of this chapter was thus to validate the interaction between PBF and Tg, 
and if proved, to assess its functional significance. 
5.2 Methods 
5.2.1 Cell culture and transfection 
K1 and TPC1 cells were maintained in RPMI as described in section 2.1. PBF-HA was 
transfected into K1, TPC1 and primary thyrocytes as described in Section 2.2.2. 
5.2.2 GST pull-down assay 
GST-tagged PBF was translated as described in 2.5.1. [35S]-methionine labelled 
thyroglobulin was prepared using the TNT® T7/SP6 Coupled Reticulocyte Lysate System 
(Promega, as described in Section 2.5) from the full length Tg cDNA in the vector pCR-XL-
TOPO (IMAGE clone 9056745, Source Biosciences). The assay was performed as described 
in Section 2.5.  
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5.2.3 Co-immunoprecipitation and Western Blot 
Protein was extracted from cell lysates as described in section 2.3.1. Co-
immunoprecipitation was performed as per Section 2.4, with anti-Tg (Dako UK Ltd, Ely, UK) 
used at concentrations of 1:10, 1:7.5 and 1:5 to immunoprecipitate thyroglobulin. For Western 
blotting, anti-Tg was used at 1:500, anti-HA at 1:2000 and anti-PBF at 1:500. Anti-β  actin  
was used as a loading control as described above. 
5.2.4 Primary thyroid culture 
Human thyroid tissue was obtained and cultured as described in Section 2.7 with the 
approval of the Local Ethics and Research Committee. 
5.2.5 Homogenisation of thyroid tissue 
Human thyroid tissue was obtained from macroscopically normal thyroid tissue after 
thyroidectomy with approval of the Local Ethics Research Committee. Tissue was snap 
frozen in liquid nitrogen and stored at -80 °C. Thyroid tissue was homogenised in 300 µL 
RIPA / PI (described in Section 2.3.1). Prior to analysis, the homogenate was diluted with 
RIPA in to final concentrations of 12.5 %, 33.3 %, 50 % and 100 % homogenate. 
5.2.6 Fluorescence immunocytochemistry 
Samples were prepared as described in Section 2.6. Primary antibodies were anti-Tg 
(EPR3614, Abcam, Cambridge, UK) (1:100) and anti-HA (1:200). 
5.2.7 Statistical analysis 
Statistical analysis was performed as described in 2.8. 
 




5.3.1 Translation of [35S]-methionine labelled thyroglobulin and GST pull-down 
assay 
Despite scoring highly in MS/MS, the interaction between PBF and Tg needed to be 
validated by at least one other independent technique. The first to be implemented was the 
GST pull-down assay. In this experiment, GST-tagged PBF and [35S]-methionine labelled Tg 
were translated and analysed in a cell free setting. GST-tagged PBF was first generated and 
found to run at the predicted size of 42 kDa when probed with our anti-PBF antibody (Figure 
5.1A). Tg was translated but when run on SDS-PAGE, no band was seen at the predicted 
mass of 330 kDa (for the monomeric molecule). Instead, a number of bands were observed at 
lower masses, as indicated in Figure 5.1B by asterisks. It was thought possible that these may 
represent sub-units of Tg, and therefore the pull-down assay was run to test if any of these 
fragments bound to GST-PBF. No evidence of an interaction was evident for any of these 
bands (Figure 5.1C, n = 3), and given the difficultly in translating such a large molecule in 
vitro, further attempts at pull-down were not attempted. 




Figure 5.1 GST tagged pull-down assay to investigate an interaction between PBF and 
thyroglobulin. A: GST-tagged PBF ran at the expected size of 42 kDa. B: [35S]-methionine Tg 
translation produced a number of bands of differing molecular weight (indicated by 
asterisks). C: No evidence of an interaction between GST-PBF and Tg was observed (n = 3). 
 
5.3.2 Co-immunoprecipitation 
Due to the large size of the Tg molecule and the difficulties encountered during the pull-
down assay with translation of the protein from cDNA, an assessment of binding of 
endogenous Tg to PBF was made, the first step of which involved determining the expression 
of Tg within the thyroid cell lines used in this thesis. 
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5.3.2.1 Thyroglobulin expression in transformed cell lines 
In the first instance, untransfected K1 and TPC1 cells were assessed by Western blotting 
for their endogenous Tg content. In both of these cell lines, there was a predominant band at 
approximately 140 kDa, with some fainter bands evident at lower masses (Figure 5.2A). No 
bands were observed above 140 kDa that could be attributed to the full length monomeric or 
dimeric molecule. A similar picture was observed when 6 % acrylamide gels were used as 
opposed to 12 %, although the gels were more difficult to work with and as no additional 
information was gained they were not used further (data not shown). These bands may have 
represented denatured sub-units (see Discussion, Section 5.4), as peptide chains were 
identified by MS/MS at these levels (approximately 150, 50 and 30 kDa) and some binding to 
PBF should therefore be evident.  
Given the altered thyroid hormone content of the PBF-transgenic mouse thyroids, the 
effect of over-expressing PBF-HA on Tg content was assessed prior to co-
immunoprecipitation to identify if there was a potential alteration in expression which would 
hinder interpretation of results. There was no significant difference in Tg levels between cells 
transfected with PBF-HA and those transfected with vector only (105.7 ± 33.6 % of control, p 
= ns, n = 3) (Figure 5.2). 




Figure 5.2 Thyroglobulin expression in K1 and TPC1 cells. A: In TPC1 and K1 cells, Tg was 
identified predominantly as a band at 140 kDa. B: Representative Western blot demonstrating  
no change in Tg with PBF-Ha transfection (i), and scanning densitometry showing relative 
value with VO vs. PBF-HA  transfection  (n  =  3).  β  actin  is  shown  as  a  loading  control. 
 
5.3.2.2 Co-immunoprecipitation in cell lines 
Having established that thyroglobulin levels were not altered by the over-expression of 
PBF-HA, K1 cells were transfected with PBF-HA and the lysates immunoprecipitated with an 
anti-HA antibody. The subsequent solution was run through SDS-PAGE and probed for Tg. 
There was no evidence of interaction between the two proteins in this assay (Figure 5.3, n = 
3). The reverse co-immunoprecipitation, in which lysates were immunoprecipitated with anti-
Tg and probed for PBF-HA, did not demonstrate an interaction (data not shown). 




Figure 5.3 Attempted co-immunoprecipitation of PBF and Tg in K1 cells. K1 cells were 
transfected with PBF-HA and immunoprecipitated with an anti-HA antibody. No evidence of 
interaction was demonstrated in this assay. T/F = transfection,  IP = immunoprecipitate,  WB 
= Western blot 
 
5.3.2.3 Thyroglobulin expression in human primary thyrocytes 
This lack of evidence of an interaction in the cell free setting and in transformed cell 
lines led us to assess whether Tg would be more appropriately assessed in primary thyroid 
cultures, in which the processes for generation of the final molecule would be potentially 
more intact. Human primary thyroid cultures from macroscopically normal thyroid tissue 
were assessed by Western blot and compared to the 2 cell lines. In all cases, there were many 
more bands of varying sizes present in the samples from primary culture; the dominant bands 
were around 140 kDa and above, which were more likely to represent the monomeric 
molecule, although lower bands were also observed, including a band at approximately 25 -  
30 kDa (Figure 5.4, indicated by red asterisks). 




Figure 5.4 Western blot of human primary thyrocytes, TPC1 and K1 cells to demonstrate the 
expression of Tg.  In  addition  to  the  bands  ≥  140  kDa,  a  smaller  band  at  25 kDa was observed 
in the primary cells (red asterisk). β actin is included as a loading control. 
 
5.3.2.4 Co-immunoprecipitation using human primary thyrocytes and thyroid 
tissue 
Due to the large number of bands observed when probing for Tg, the decision was made 
to immunoprecipitate with the anti-Tg antibody and probe for PBF in an attempt to detect an 
interaction. There was however still concern that the full length Tg molecule was not present 
in thyroid cultures, and that this would only be fully formed within the thyroid gland itself. 
Therefore, alongside co-immunoprecipitation using primary thyroid cultures, macroscopically 
normal thyroid tissue was homogenised and immunoprecipitated with anti-Tg.  
In the former experiment, un-transfected cells were used to ensure as little disruption to 
the culture as possible. Immunoprecipitation of the lysates was carried out with differing 
concentrations of anti-Tg antibody. PBF was successfully co-immunoprecipitated with all 
concentrations, compared to no detectable PBF in the no-antibody control sample. The 
highest yield of PBF was with an antibody to lysate ratio of 1:5 (Figure 5.5). 
 




Figure 5.5 Co-immunoprecipitation of PBF and Tg in human primary thyroid cells. A: 
Untransfected cell lysates were immunoprecipitated with differing concentrations of anti-Tg 
and probed for PBF, with evidence of interaction compared to the no-antibody control ("No 
ab"). B: Scanning densitometry analysis of PBF Co-IP relative to PBF lysate. 
Using this antibody ratio, co-immunoprecipitation was performed on homogenised human 
thyroid tissue. In this experiment, the homogenate was diluted with decreasing quantities of 
RIPA buffer prior to immunoprecipitation, and as expected this led to an increase in the 
amount of PBF detected, although this was not significant (Figure 5.6) (R2 = 0.44, p = 0.36), 
providing further evidence to support the interaction between PBF and Tg. 




Figure 5.6 Co-immunoprecipitation of PBF and Tg in homogenised human thyroid tissue. A: 
Homogenised tissue was diluted with differing amounts of RIPA buffer and 
immunoprecipitated with anti-Tg then probed for PBF. B: Scanning densitometry analysis of 
the amount of co-immunoprecipitated PBF (n = 3). 
5.3.3 Fluorescence immunocytochemistry 
5.3.3.1 Thyroglobulin and PBF co-localise in intra-cellular vesicles  
Having validated the MS/MS findings, fluorescence immunocytochemistry was 
undertaken to assess in what areas of the cell PBF and Tg interact. Initially, this was 
performed in K1 and TPC1 cells, and a small degree of co-localisation was observed within 
intra-cellular vesicles in the peri-nuclear region, with some co-localisation also apparent  at 
the cell membrane (Figure 5.7). 




Figure 5.7 Fluorescence immunocytochemistry of K1 and TPC1 cells. PBF-HA is shown as 
green, Tg in red, with areas of co-localisation in yellow. Nuclear staining (DAPI) is blue. 
PBF and Tg appear to co-localise in intra-cellular vesicles as well as in the peri-nuclear 
region (white arrows). Bars, 20 µm. 
 
Given the differences in band size detected by Western blotting between the transformed 
cell lines and primary thyrocytes, further immunofluorescence studies were performed on the 
human primary thyroid cultures. These cells were more confluent as a result of their culture 
conditions, and in places congregated into 2D follicle-like structures (Figure 5.8). 
 
Figure 5.8 Immunofluorescence of untransfected primary human thyroid culture. Tg was 
stained red. A 2D follicle-like structure is evident in the bottom right of the image. Bars, 20 
µm. 
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When these cells were transfected with PBF-HA and stained for both HA and Tg, some 
co-localisation was again seen in vesicles, but this was not a consistent finding, and there 
were examples of cells where there was no evidence of co-localisation (Figure 5.9). Due to 
the high density and overlap of cells, it was not possible to determine the precise intracellular 
nature of any co-localisation within the follicle-like structures. 
 
Figure 5.9 Immunofluorescence of primary human thyroid cells transfected with PBF-HA. 
PBF-HA was shown as green, Tg in red with areas of co-localisation in yellow. Nuclear 
staining (DAPI) is blue. As for the cell lines, possible co-localisation of PBF and Tg is 
observed in intra-cellular vesicles (white arrows). Bars, 20 µm. 
 
5.4 Discussion 
Thyroglobulin, in its most stable form, exists as a 660 KDa dimeric protein made up of 2 
identical peptide chains of 2748 amino acid each (Dunn and Dunn 1999). It is the most 
abundant protein within the thyroid gland and essential for the synthesis of thyroid hormone. 
It is in this respect that Tg is most studied, as the clinical effects of deranged thyroid hormone 
synthesis can be profound. There is, however, significantly less evidence regarding the 
synthetic pathway of the protein itself, and how aberrations in this pathway may arise. 
 
Chapter 5  Thyroglobulin 
 
 125 
Initial studies focussed on attempting to validate the MS/MS findings using GST pull-
down assays. In these, no interaction was observed between PBF and Tg; the [35S]-methionine 
labelled Tg also produced bands of differing sizes and none at the expected masses of 330 
kDa or 660 kDa. When Tg expression was determined in TPC1 and K1 thyroid cancer cell 
lines, again no large size band was detected, but rather a strong band at 140 kDa, as well as 
other, fainter, lower mass bands.  The potential explanation for these findings lies in the 
synthesis of Tg and also its sub-unit structure. 
 
Tg polypeptide chains undergo glycosylation in the rough endoplasmic reticulum, and 
the process of dimerization begins here. Chaperone proteins prevent the progression of Tg 
synthesis unless all aspects of post-translational modification are met, and therefore the final 
molecule (as exported into the colloid) will only be present in the cell should the pre-existing 
conditions be favourable (den Hartog et al. 1995; Miot et al. 2012). Clearly, in a cell free 
setting this is not possible and it is likely, therefore, that precursor peptides were detected.  
The GST pull-down assay, therefore, would not appear to be the best method with which to 
test an interaction with Tg. 
 
The banding pattern demonstrated on Western blotting is most likely due to the 
breakdown of protein structure during denaturing prior to SDS-PAGE. The weight of Tg sub-
units has been described (Spiro 1973) (Table 5.1), and several of the bands observed, 
including the major band at 140 kDa, are documented. The authors of this study used a variety 
of gels of differing concentration to fully assess the sub-units; however, in these experiments 
the lower percentage gels did not yield additional data, and given their difficult handling and 
lack of reliable results, 12 % acrylamide was used. This also correlated with the MS/MS 
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findings: Tg peptides were identified in gel bands corresponding to several different 
molecular weights, and it is likely that these were the result of breakdown during the 
denaturing process. Unfortunately, there is no description as to the composition or source of 
the   bands   identified   by   Spiro’s   group;;   therefore   it   is   not   possible   to   correlate   the   peptide  
chains determined by MS/MS to any particular subunit. 











Table 5.1 Molecular weights of known sub-units of Tg following denaturing (Spiro 1973). 
 
Accepting for the purposes of these experiments that the Tg subunits would be analysed 
as a surrogate marker for total Tg, TPC1 and K1 cells were transfected with PBF-HA to 
determine if this altered the quantity of Tg within the lysate. No difference was observed, 
suggesting that the mechanism by which PBF alters both the size and thyroid hormone 
content of the thyroid gland (Read et al. 2011) is not via a change in cellular Tg. Co-
immunoprecipitation of Tg and PBF was attempted in the cell lines, but no reliable Tg band 
could be identified, either at 140 kDa or elsewhere on the gel. This may have been due to the 
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smaller quantities of Tg sub-units present after Co-IP which, while identified by MS/MS, 
were not detectable on Western blotting. 
 
To over-come the difficulties observed with studying Tg in cell lines, human primary 
thyroid cultures were used. TG gene expression is controlled by a number of thyroid specific 
transcription factors, of which TTF-1, TTF-2 and Pax-8 are the most important (Fayadat et al. 
1998). Cultures from macroscopically normal human thyroid tissue contain a more 
differentiated phenotype than transformed cell lines. Although the Tg content of TPC1 and 
K1 cells has not been investigated, studies have shown that transfecting PAX-8 into K1 cells 
increased the expression of Tg (Mu et al. 2012). Primary thyrocytes subjected to the same 
protein  extraction conditions as K1 and TPC1 cells demonstrated a similar band pattern, 
although there was an increase in high molecular weight bands compared to the cell lines. 
These bands correlated more closely with the bands described in Table 5.1. 
Immunoprecipitation was performed with the anti-Tg antibody, therefore ensuring that any 
intact Tg would be precipitated. To determine if there was an optimum concentration of 
antibody to use, 3 conditions were used, as well as a no-antibody control. While the latter lane 
remained empty, co-immunoprecipitated PBF was identified in each of the other samples, 
supporting the interaction first identified by MS/MS. For the higher concentration of anti-Tg, 
there was an increase in the amount of PBF detected relative to the quantity in the cell lysate 
which would again support that PBF was detected as a specific binding partner to Tg.  
 
The final step in the binding analysis was to use homogenised thyroid tissue. The vast 
majority of Tg in the thyroid gland is situated within the colloid. These structures are not 
present in two dimensional cell cultures and therefore cells grown in vitro (either cell lines or 
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primary culture) lack the final element of Tg synthesis and transport: the movement across the 
apical membrane into the colloid. The human thyroid gland specimens were homogenised and 
further diluted with RIPA to differing concentrations. Immunoprecipitating with anti-Tg and 
probing for PBF again identified the two as interacting, although a direct comparison between 
this and primary culture was not appropriate due to the very different conditions. However, 
work carried out within our group by Dr V Smith on the transgenic mouse thyroid gland has 
demonstrated that PBF is present not only within the thyroid epithelial cell, but also at the 
apical membrane and within the colloid itself (Figure 5.10). Combining this with the data 
obtained from the above experiments suggests that PBF may interact with Tg both within the 
cell and in the colloid, and this interaction could perhaps explain the phenotype seen in our 
transgenic mouse model. 
 
Figure 5.10 Confocal microscopy of a cross section through a PBF-transgenic mouse thyroid. 
PBF-HA is shown in green and localised within the colloid as well as at the apical 
membrane. Thyroid epithelial cells are shown via MCT8 staining in red. Courtesy of Dr V 
Smith, University of Birmingham. 
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Preliminary experiments into the co-localisation of Tg and PBF identified intra-cellular 
vesicles as well as the peri-nuclear region as potential sites of interaction, both in cell lines 
and human primary thyrocytes. The significance of this remains to be determined; whether 
PBF is transported with Tg to the cell membrane, or if the interaction is only transient within 
the cell will be the focus of further study. In addition, techniques such as 3D cell culture, 
which allow the formation of functional colloid units within primary thyroid cultures in vivo, 
will be essential to assess the functional significance of the interaction. 
 
Concluding remarks 
This chapter has investigated the potential interaction between PBF and thyroglobulin. 
Due to its large size and the requirement for a number of physiological conditions to be met in 
order for the full length protein to be assembled, studies using the transformed cell lines did 
not generate conclusive data. However, co-immunoprecipitation of PBF with Tg was 
demonstrated in primary thyroid cultures and homogenised thyroid tissue. In addition, 
fluorescence immunocytochemistry identified potential co-localisation sites within 
intracellular vesicles and the peri-nuclear region of the cell. These preliminary observations, 
therefore, provide a basis on which to further investigate the interaction and assess its 
functional significance, particularly in light of the transgenic mouse phenotype.
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Chapter 6 Investigating the interaction between 
cortactin and PBF 
  




In Chapter 4, cortactin was identified by MS/MS as a protein highly likely to interact 
with PBF. Cortactin interacts with filamentous actin and thus regulates the actin cytoskeleton, 
in particular the stabilisation of the branched actin assembly (Weaver et al. 2001). It is also 
found in the leading edge of migrating cells, with over-expression of cortactin leading to 
increased cell mobility and knockdown reducing it (Bryce et al. 2005).While this is part of the 
normal physiological process of the cell, cortactin has also been shown to play a role in 
cancer, including in the formation of invadopodia and podosomes (Artym et al. 2006), and in 
the membrane trafficking of proteins to and from the cell surface (Cao et al. 2003). Cortactin 
also has a role in the secretion of certain proteins, and this is important in the Extra Cellular 
Matrix (ECM)-degrading properties of invadopodia (Clark and Weaver 2008). To date, 
cortactin over-expression has been found in head and neck squamous cell carcinoma, as well 
as cancers of the breast, ovary, stomach, liver, colon and oesophagus (Kirkbride et al. 2011).  
Thus, the finding of cortactin as a possible binding partner of PBF had the potential to 
explain some of the effects previously observed with PBF over-expression. PBF is a protein 
present within the cytoplasm of the cell as well as at the cell membrane (Smith et al. 2009), 
and it is possible that cortactin may be key to this membrane trafficking. In addition, work 
within our group has shown that PBF is a secreted protein (Watkins et al. 2010), a process 
cortactin might influence. Finally, the link between PBF over-expression and increased cell 
invasiveness could potentially be mediated by cortactin. 
The initial aim of this chapter, therefore, was to attempt to validate the interaction 
between PBF and cortactin. If confirmed, the effect of changes in cortactin expression on PBF 
physiology would be assessed. Specifically, these experiments would address PBF 
localisation, secretion and membrane transport. 




6.2.1 Cell lines and transfection 
K1, TPC1 and HeLa cells were maintained as described in Section 2.1 and transfected 
with PBF-HA, pCDNA3.1+, or Myc- and FLAG-tagged cortactin (Cambridge Bioscience, 
Cambridge, UK). Cortactin knock-down was achieved with siRNA transfection, carried out as 
described (Section 2.2.3) using ON-TARGETplus Human CTTN siRNA (Thermo Scientific). 
6.2.2 GST pull down assays 
GST-tagged PBF was translated as described in 2.5.1. [35S]-methionine  cortactin was 
prepared using the TNT® T7/SP6 Coupled Reticulocyte Lysate System (Promega; as 
described in Section 2.5) from the full length CTTN cDNA (in the bacterial vector POTB7 
(IMAGE clone 3637586, Source Biosciences). The assay was performed as described in 
Section 2.5.  
6.2.3 Western blotting and co-immunoprecipitation 
These were carried out as described in Section 2.3. Antibodies used were anti-cortactin, 
1:1000 for Western blotting, 1:10 for immunoprecipitation (clone 4F11, Millipore, UK), anti-
HA (see Section 2.3.1), anti-Myc Tag, 1:2000 for Western blotting, 1:50 for 
immunoprecipitation (clone 9B11, Cell Signalling), anti-FLAG (Agilent Technologies, 
Wokingham, UK ), 1:2000 for Western blotting, 1:50 for immunoprecipitation. 
6.2.4 Fluorescence immunocytochemistry 
This was performed as described in Section 2.6, using K1, TPC1 and HeLa cells. 
Chapter 6  Cortactin 
 
 133 
6.2.5 Secretion assay 
6.2.5.1 Cell seeding and transfection 
Cells were seeded into 6 well plates and transfected as described in section 2.2.2. For 
cells undergoing knockdown and over-expression, siRNA transfection took place at 24 hours 
after seeding, and plasmid transfection a further 24 hours later. Medium was changed to 1 ml 
RPMI as above with 5% FBS at either 24 or 48 hours after initial transfection. At 72 hours, 
media and cells were harvested for analysis. 
6.2.5.2 Confirmation of transfection 
Cells were harvested in RIPA/protease inhibitor as described previously and protein 
concentration determined by Bradford assay. Thirty micrograms of protein were assessed by 
Western blotting to determine over-expression/knock down prior to further analysis. 
6.2.5.3 Assessment of secretion by Western blotting 
The medium was transferred to a 1.5 ml microcentrifuge tube and spun at 12,000 rpm on 
a benchtop centrifuge for 5 minutes to separate cell debris. The supernatant was then 
transferred to a 15 ml centrifuge tube, and protein precipitated by the addition of 2 ml 100 % 
ethanol and centrifuging for 15 minutes at 1000 rpm. The pellet was then re-suspended in 
RIPA with protease inhibitor. Protein concentration was quantified using the Bradford assay; 
30 µg of protein was then separated by SDS-PAGE and Western blotting performed as per 
section 2.3. 
6.2.5.1 Enzyme-Linked Immunosorbent Assay (ELISA)  
Secretion of PBF was determined using the PTTG1IP ELISA kit (USCN Life Science 
Inc.,  China),  as  per  manufacturer’s  instructions:  Standards  were  prepared  from  serial  dilution  
of the provided stock standard, to dilutions ranging from 0.156 to 50 ng / mL. 100 µL of 
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standards and samples (n = 2) were loaded in duplicate onto the plate. The plate sealer was 
applied and the plate incubated for 2 hours at 37 °C, allowing any PBF present to be bound to 
the anti-PBF antibody adherent to the well. The supernatant was discarded before adding 100 
µL of Detection Reagent A (biotin conjugated anti-PBF) to each well and incubating for a 
further 1 hour at 37 °C. The supernatant was again discarded and the wells washed 3 times 
with 350 µL Wash Solution. One hundred microliters of Detection Reagent B (avidin 
conjugated to Horseradish Peroxidase (HRP)) were then added and the plate incubated for 30 
minutes at 37 °C to allow binding of avidin to biotin. A further 5 washes were carried out 
with 350 µL of Wash Solution. After the addition of 90 µL of TMB Substrate Solution, the 
plate was incubated in the dark for 20 minutes at 37 °C, causing a colour change in those 
wells containing PBF, biotin-conjugated antibody and HRP-conjugated Avidin. The reaction 
was stopped with 50 µL of sulphuric acid Stop Solution and absorbance at 450 nm measured 
using the Victor3 1420 Multilabel Counter. Concentration was calculated from a standard 
curve generated by the standards.  
6.3 Results 
6.3.1 Validation of the interaction between cortactin and PBF 
6.3.1.1 GST pull-down assay 
As discussed in Section 5.3.1, before commencing any functional experiments it was 
necessary to validate the MS/MS interaction using glutathione-S-transferase (GST) pull-down 
assays and co-immunoprecipitation. GST-tagged PBF was translated as described in 5.2. The 
resulting band ran at the expected size of approximately 42 kDa (Figure 6.1A). [35S]-
methionine labelled cortactin was translated using a cell free system and detected at 
approximately 80 kDa (Figure 6.1B). However, the pull down assay failed to show a 
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difference in detection of cortactin between samples incubated with GST-PBF and GST alone 
(n = 3) (Figure 6.1C). Therefore this technique was unable to validate an interaction between 
the two.  
 
Figure 6.1 GST pull down assay investigating an interaction between PBF and cortactin. A: 
GST-tagged PBF ran at the expected size of 42 kDa. B: [35S]-methionine labelled cortactin 
was translated and ran at 80 kDa. C: No evidence of an interaction was observed when 
comparing GST-PBF to GST alone (n = 3). 
6.3.1.2 Co-immunoprecipitation 
Given that GST pull-down assays had failed to demonstrate an interaction between 
cortactin and PBF, co-immunoprecipitation was used to assess whether a more physiological 
setting was necessary for the two to bind. The endogenous expression of cortactin in K1, 
TPC1 and HeLa cells was examined and shown to be similar (data not shown). Following 
this, K1 and TPC1 cells were transfected with PBF-HA and immunoprecipitated with an anti-
cortactin antibody before being run through SDS-PAGE. Due to a strong light chain band 
from the anti-cortactin antibody at 25 kDa, it was not possible to reliably identify PBF on 
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immunoblotting. When the reverse experiment was performed, i.e. immunoprecipitating with 
an anti-HA antibody, any cortactin band was hidden again by immunoglobulin bands.  
It was decided, therefore, to transfect cortactin into the cells. Given that cortactin was 
potentially hidden during Western blotting by non-specific antibody bands, a tagged vector 
was used for transfection, containing full length cortactin cDNA as well as an N-terminal Myc 
and FLAG tag (“Cort-Myc-FLAG”). This would allow a highly specific antibody to be used 
to immunoprecipitate cortactin and might therefore permit more efficient PBF detection by 
Western blotting. The tag would also help detect cortactin in the reciprocal experiment. In 
order to ensure the validity of the tagged protein, Western blotting was performed on the 
lysate of cells transfected with Cort-Myc-FLAG. The same samples were run in triplicate, and 
transfected cortactin was detected using an anti-cortactin antibody as well as ones directed to 
Myc and FLAG epitopes (Figure 6.2), demonstrating that this over-expressed protein could be 
detected by any of the three antibodies. Cortactin exists in predominantly two isoform within 
the cell, p80/85 (Buday and Downward 2007); over-expression resulted in an increase in both 
forms, although only the larger isoform was detected by the anti-Myc antibody.  




Figure 6.2 Western blot of HeLa cells demonstrating transfection with Cort-Myc-FLAG, with 
detection by 3 different antibodies. β actin is included as a loading control. 
Using this plasmid, HeLa cells were transfected with both cortactin and PBF-HA and the 
resulting cell lysate immunoprecipitated using the anti-Myc antibody. After running these 
through SDS-PAGE, immunoblotting showed a clear interaction between PBF-HA and 
Cortactin-Myc, when compared to cells transfected with PBF-HA only, or in the no-antibody 
control (Figure 6.3). The reverse experiment, in which lysates were immunoprecipitated using 
anti-HA, and immunoblotted for anti-Myc, could not be interpreted again due to interference 
from non-specific / immunoglobulin bands at 75 kDa (data not shown). 




Figure 6.3 Cortactin-Myc-FLAG interacts with PBF-HA as demonstrated by co-
immunoprecipitation. Western blot showing co-immunoprecipitation of PBF-HA after 
immunoprecipitating with an anti-Myc antibody. T/F = transfection, IgG control = 
immunoglobulin only control, IP = immunoprecipitation, WB = Western blot. 
 
6.3.2 Cortactin has no effect on PBF expression 
Before proceeding to functional studies, HeLa cells were again used to establish if over-
expression of one protein had an effect on the amount of the other within the cell. When PBF-
HA was over-expressed, there was no significant difference in the amount of cortactin 
compared to vector only controls (76.2 ± 7.1 %  of control, p = ns, n = 3) (Figure 6.4A). 
Similarly, over-expression of Cort-Myc-FLAG had no effect on PBF-HA levels (123.4 ± 17.3 
% of vector only controls, p = ns, n = 3) (Figure 6.4B) 




Figure 6.4 PBF and cortactin do not affect expression of each other. A: i - Western blot of 
HeLa cells transfected with either vector only (VO) or Cort-Myc-Flag. ii – Scanning 
densitometry did not show a significant difference in PBF-HA levels between the 2 conditions. 
B: i - Western blot of HeLa cells transfected with either vector only (VO) or PBF-HA. ii – 
Scanning densitometry demonstrated no difference in cortactin with either VO or PBF-HA 
transfection. Cortactin was detected using an anti-cortactin antibody. β actin is shown as a 
loading control. 
6.3.3 Cortactin and PBF may co-localise in intra-cellular vesicles 
The localisation of cortactin and PBF was examined in both K1 and TPC1 cells as well 
as HeLas. In some cells,  PBF-HA appeared to co-localise with cortactin in intracellular 
vesicles (Figure 6.5). 




Figure 6.5 Fluorescence immunocytochemistry demonstrating possible co-localisation of 
PBF-HA and cortactin in K1, TPC1 and HeLa cells. PBF-HA was identified in red using an 
anti-HA antibody, Cortactin was identified in green and nuclear staining (DAPI) was shown 
in blue. Areas of potential co-localisation between PBF-HA and cortactin were shown in 
yellow, and occurred predominantly within intra-cellular vesicles (white arrows). Bars, 20 
µm. 
 
6.3.4 PBF is present in membrane projections 
Given the role of cortactin in invadopodia formation, and the increase in invasiveness of 
cells over-expressing PBF (Watkins et al. 2010), immunofluorescence was undertaken to 
determine if PBF was present in membrane projection or invadopodia-like structures. No 
membrane projections were apparent in cells stained for both cortactin and PBF-HA; 
however, when a more effective anti-HA antibody was used (and cortactin not stained for) 
membranous projections were observed, albeit faintly (Figure 6.6). This suggests a possible 
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role for PBF in invadopodia, although further experiments will be required to elucidate any 
potential mechanism. 
 
Figure 6.6 Fluorescence immunocytochemistry of three different HeLa cells. PBF-HA is 
stained green and over-exposed to demonstrate membrane projections (white arrows).  Bars, 
20 µm. 
 
6.3.5 Investigations into the effect of cortactin on PBF secretion 
PBF is a secreted protein (Watkins et al. 2010), although the mechanism for this has not 
yet been established. Given the known role of cortactin in protein export, its effect on PBF 
secretion was assessed using 2 assays: Western blotting and ELISA. Cortactin was over-
expressed as described above. In order to determine if a lack of cortactin had a detrimental 
effect on the secretion of PBF, siRNA targeting cortactin was transfected into HeLa cells. 
This led to a substantial knock down of cortactin expression when compared to transfection of 
scrambled siRNA. A representative Western blot demonstrating cortactin over-expression and 
knockdown is shown in Figure 6.7. 




Figure 6.7 Representative Western blot demonstrating knock down and over-expression of 
cortactin in HeLa cells. Scrambled siRNA (Scr siRNA) was used as a negative control and β 
actin as a loading control. 
 
6.3.5.1 Endogenous PBF secretion is not detectable by Western blotting  
HeLa cells were transfected with Myc-tagged cortactin or blank vector to test the effect 
of over-expression, and with cortactin siRNA or scrambled siRNA to test the effect of 
knockdown. Cells and media were harvested at 24 and 48 hours. The cell lysates were 
subjected to Western blotting to demonstrate that the transfection had been successful, 
following which the media was assessed for PBF content by Western blotting. Previous work 
performed by our group using this technique has shown that over-expressed PBF-HA is 
secreted, and that glycosylation and/or the N terminal signal peptide was essential for this 
(Watkins 2010). However, when media were analysed by Western blotting, no PBF was 
detected at its expected size (Figure 6.8). Therefore using this technique, it was not possible to 
establish whether PBF secretion was dependent on cortactin expression within the cell. 
 




Figure 6.8 Assessment of the effect of cortactin on PBF secretion by Western blotting. Media 
were analysed at 24 (A) and 48 (B) hours post-transfection. Efficacy of transfection and 
knockdown were demonstrated by Western blot of the cell lysate. PBF was not detected in the 
media at either timepoint. 
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6.3.5.2 Cortactin does not affect PBF secretion as demonstrated by ELISA 
Due to the failure to detect secreted PBF by Western blotting, a separate, independent 
experiment to assess PBF secretion was performed using Enzyme-Linked Immunosorbent 
Assay (ELISA). Transfection of HeLa cells was performed as described in Section 2.2.2; at 
both 24 hour and 48 hour timepoints, media and cells were harvested, and cell lysates 
analysed to ensure adequate transfection and knockdown of cortactin. As demonstrated 
previously, the cell lysates exhibited a marked increase in cortactin with over-expression, and 
no detectable cortactin when siRNA was used. At the 24 hour timepoint when cortactin was 
over-expressed, there was no significant difference in the amount of secreted PBF (99.5 ± 
38.9 % of control, p = ns); a similar effect was observed at the 48 hour timepoint (92.2 ± 29.9 
% of control, p = ns). For cortactin knockdown, a greater drop was observed for both 
timepoints (79.9 ± 37.1 % at 24 hours, 80.5 ± 32.6 % at 48 hours) although neither of these 
differences were significant (Figure 6.9). Of note, there was a wide variability in the amount 
of secreted PBF detected, and this contributed to the large inter-experimental error. 




Figure 6.9 Assessment of the effect of cortactin on PBF secretion by ELISA. A: Relative 
concentrations of PBF detected in media at 24 and 48 hours post transfection with either 
cortactin or siRNA targeting cortactin. Standard error of the mean is plotted as error bars. B 
– Western blots demonstrating over-expression and knockdown of cortactin at 24 (i) and 48 
(ii)  hours  post  transfection.  β  actin  is  shown  as  a  loading  control. VO = Vector Only, O/E = 
over-expression, ns – not significant. 
 
6.4 Discussion 
Cortactin was identified as a potential binding partner of PBF in Chapter 4, scoring the 
highest of all the shortlisted proteins. Cortactin has been studied for its role in normal cellular 
physiology, where it is involved in cell structural maintenance via the actin cytoskeleton, 
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membrane trafficking of proteins and cell mobility via lamellipodia. In addition to this, 
cortactin has a clear role in the development of malignancy. It is over-expressed in a number 
of cancers, and in vitro studies have demonstrated that cortactin is involved in the formation 
of invadopodia; membranous protrusions that promote invasion by secreting enzymes which 
can break down the extra-cellular matrix (Kirkbride et al. 2011). 
To determine whether the interaction identified by MS/MS was valid, GST pull-down 
studies were first undertaken to assess binding in a cell-free setting. Although [35S]-
methionine labelled cortactin was successfully translated at the predicted molecular mass, no 
binding was identified in the assay. While this did not support the MS/MS findings, it was 
possible that binding could only occur within the cell once a particular post-translational 
modification had taken place, to either cortactin or PBF, or required the presence of a binding 
partner to facilitate the interaction.  
Co-immunoprecipitation was therefore performed, immunoprecipitating lysates from 
cells transfected with PBF-HA with either an anti-HA or anti-cortactin antibody. 
Unfortunately, both of these experiments were hindered by non-specific immunoglobulin 
bands obscuring the target areas on the Western blot (25 kDa for PBF-HA and 75 kDa for 
cortactin). To counter this, cells were transfected with cortactin which had been tagged with 
Myc and FLAG epitopes. Both these tags were small, and had well established antibodies 
suitable for co-immunoprecipitation. By also increasing the amount of cortactin within the 
cell, this allowed the amount of antibody used in the immunoprecipitation step to be reduced, 
and also reduced the exposure time needed for Western blot detection of protein. This plasmid 
was successfully validated, showing a significant increase in the amount of cortactin 
following transfection. Importantly, when anti-Myc and anti-FLAG antibodies were used, 
there was no non-specific interaction identified. Interestingly, expression of the p85 isoform 
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of cortactin was greater than the p80. The significance of the ratio of the 2 isoforms has not 
been established, although it has been suggested that the p85 is associated with tumour 
invasiveness (Zhang et al. 2006).   Using this plasmid for over-expression, PBF-HA was 
successfully co-immunoprecipitated with Myc-tagged cortactin; no non-specific binding was 
identified and due to the lower amount of antibody used and short exposure time, there was 
no contamination by light chain immunoglobulin. While this provided good evidence for an 
interaction between the 2 proteins, the reverse experiment remained problematic, due to the 
large immunoglobulin band at 75 kDa. Methods exist to counter this problem, such as using 
magnetic beads, and are currently being used within our group to further investigate this 
angle. 
PBF is known to have a direct effect on the expression of NIS via the NIS promoter 
(Boelaert et al. 2007). Therefore, before any functional studies were performed, experiments 
were undertaken to ascertain whether the over-expression of either PBF or cortactin had any 
effect on expression of the other. When analysed by Western blotting, there was no difference 
in the amount of either protein detected when the other was over-expressed.  
Having established that the 2 proteins interact, fluorescence immunocytochemistry was 
performed to identify areas of co-localisation within the cell. The resulting data were 
inconclusive, however in both the thyroid cell lines (K1 and TPC1) and also in the HeLa cells, 
cortactin demonstrated potential co-localisation with PBF-HA in intra-cellular vesicles, 
although further experiments would be needed to explore this observation. PBF has been 
shown to internalise the membrane proteins NIS (Smith et al. 2009) and MCT8 (Smith et al. 
2012), although the exact mechanism of this remains unclear. PBF co-localises with the late 
endosome marker CD63, suggesting that this may be mediated by clathrin-dependant 
endocytosis (Smith et al. 2009). Cortactin regulates both clathrin-dependent and –independent 
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endocytosis (Cao et al. 2003; Sauvonnet et al. 2005), and this may therefore be key in 
understanding and potentially preventing the reduction and subsequent repression of these 
membrane bound transporters by PBF. 
As cortactin plays a role in invadopodia formation and function, a feature which is 
directly related to tumour invasiveness, and PBF increases invasiveness (Watkins et al. 2010), 
as an additional preliminary study the potential role  PBF in invadopodia was then assessed. 
No co-localisation between PBF and cortactin was observed in cell membrane projections, 
although when cells stained only for PBF-HA were over-exposed, membrane protrusions 
staining for PBF-HA were apparent. These invadopodia-like structures were visible in a 
number of cells types with PBF-HA transfection. These preliminary data are currently the 
focus of study within our group to further define the potential role of PBF in invadopodia 
function, using specific invadopodia assays. 
The invasive potential of PBF is reliant on its secretion (Watkins 2010); the above 
studies have suggested a role for cortactin in the transport of PBF to and from the cell 
membrane, and also a link between PBF and invadopodia. The final area assessed was to 
determine whether cortactin had a role in the secretion of PBF. As well as stabilising 
invadopodia, cortactin regulates the secretion of matrix metalloproteases (MMPs) which 
degrade the ECM (Clark and Weaver 2008), and therefore may also provide the mechanism 
for PBF secretion. Two separate assays were performed to investigate a link between PBF 
secretion and cortactin. For both, secretion was assessed with over-expression of cortactin 
(using blank vector transfection as a control) and cortactin knockdown.  Loss of cortactin 
results in a reduction in invadopodia number as well as reduced ECM degradation (the latter 
through reduced secretion of MMPs) (Clark et al. 2007). The first method used - assessment 
by Western blotting - had been successfully implemented to demonstrate that PBF was a 
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secreted protein previously by our group (Watkins 2010). However, in this experiment, no 
PBF was detected in the media at 24 and 48 hours, although the cells themselves had 
transfected successfully as indicated by Western blotting of the cell lysates. Given that 
endogenous as opposed to over-expressed PBF was used, the concentration of any PBF within 
the media would have been significantly lower than identified in previous studies (Watkins et 
al. 2010), potentially below the detection limit of Western blotting. 
This led to the second method, Enzyme-Linked Immunosorbent Assay (ELISA), which 
utilised an antibody to immobilise PBF to a plate, with subsequent detection being potentially 
more sensitive than Western blotting. There was significant variability in the output generated 
from the ELISA, which led to high standard errors and the results not reaching significance. 
There was a trend towards reduced secretion of PBF with cortactin knockdown, however.  
These 2 experiments, therefore, should be seen as preliminary studies on which to base 
future research. Questions that will need to be addressed include the validity of co-
transfecting PBF alongside either cortactin or siRNA, and also (perhaps most importantly) the 
timing at which analysis should be performed. In addition, cell surface biotinylation assays 
will allow the quantitative assessment of the effect of cortactin on PBF membrane trafficking. 
These experiments are on-going within our group. 
 
Concluding remarks 
This chapter has validated the interaction between PBF and cortactin, and suggested that 
they may co-localise in intra-cellular vesicles, which may explain the membrane trafficking of 
PBF as well as its secretion. PBF is found in protrusions from the cell membrane when over-
expressed; preliminary studies have identified potential ways of studying the effects of 
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cortactin knockdown and over-expression on PBF secretion, and will provide a starting point 
for future work researching this interaction and its functional significance. 
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Chapter 7 Validation of the interaction between 
SRC and PBF  




The SRC tyrosine kinase family are non-receptor tyrosine kinases, members of which 
are SRC, LYN, YES, FYN, FGR, LCK, HCK, BLK and FRK. Two members of this group, 
LYN and SRC, were identified by MS/MS. The two proteins share 78 % homology (BLAST 
analysis, available at http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins), which includes 
the sections of the peptide chains identified by MS/MS. As phosphorylation prediction 
software had identified SRC as a potential kinase for PBF, and as the most well studied 
member of the group, SRC was chosen for validation studies and potential functional work. 
 
c-SRC is regarded as the first identified oncogene, and is the cellular homologue of v-
SRC, the oncogenic component of the Rous sarcoma virus, which causes tumours in chicken. 
c-SRC, henceforth referred to as SRC, contains four SRC homology   (“SH”)   domains,   of  
which SH2 and SH3 are key to its regulatory mechanism (Figure 7.1A) (Bjorge et al. 2000).  
Inactivation of SRC is brought about by phosphorylation at Y530; this then interacts with the 
SH2 domain to bring the protein into a closed configuration, thereby inactivating it. In 
addition, the SH3 domain interacts with a proline rich segment within the kinase domain 
causing further de-activation. When de-phosphorylated at Y530, the molecule opens to allow 
auto-phosphorylation at Y419 and subsequent activation (Figure 7.1) (Anbalagan et al. 2012). 
Activated SRC is involved in cellular proliferation, survival, migration and angiogenesis, and 
it follows that an aberrant increase in SRC expression is associated with many human 
malignancies. 
The aim of this chapter was to independently validate the binding between SRC and 
PBF, an essential process prior to functional studies exploring the interaction. 




Figure 7.1 Diagrammatic representation of SRC. A: The protein consists of four SH domains, 
with SH1 responsible for kinase activity. Negative regulation is through phosphorylation at 
Y53 (yellow). Loss of this C terminal region leads to mutant activation, as seen in v-SRC. B: 
Inactivation and activation of SRC. i. Phosphorylation at Y530 allows coupling to the SH2 
domain. ii. This allows interaction between SH3 and the kinase domain to bring the molecule 
into a closed, inactive position. iii. De-phosphorylation at Y530 and auto-phosphorylation at 
Y419 open the molecule resulting in activation. 
 
7.2 Methods 
7.2.1 Cell culture and transfection 
K1, TPC1 and HeLa cells were maintained as described in Section 2.1. Transfection was 
carried out with PBF-HA and SRC in pcDNA3.1+ using Fugene6 as previously detailed.  
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7.2.2 GST pull-down assay 
GST-tagged PBF was translated and [35S]-methionine labelled SRC was translated from 
full length SRC cDNA (kindly provided by Dr Yotis Senis, University of Birmingham, in the 
bacterial expression vector pOTB7) as described in Section 2.5.   
7.2.3 Subcloning of SRC cDNA into pcDNA3.1+ 
In order to allow transfection of cell lines, SRC was subcloned into pcDNA3.1+, using 
the restriction enzymes EcoR1 and Xba1, as described in Section 2.2.1.2. Correct insertion 
was confirmed by sequencing using the T7 and BGHrev primers. 
7.2.4 Western blotting and co-immunoprecipitation 
Western blotting and co-immunoprecipitation was performed as previously described in 
2.4. Monocloclonal rabbit anti-human SRC (Cell Signalling, Danvers, MA) was used at 
1:1000 for Western blot and 1:10 for immunoprecipitation. Anti-HA and anti-β   actin  were  
used as previously described.  
7.2.5 Fluorescence immunocytochemistry 
This was carried out as described in Section 2.6. Anti-Src was used at 1:100. Other 
antibodies were used as previously described. 
7.3 Results 
7.3.1 Validation of the interaction between SRC and PBF 
7.3.1.1 GST pull down assay 
Before examining the functional significance of a potential interaction between SRC and 
PBF, the putative interaction was investigated using glutathione-S-transferase (GST) pull 
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down assays and co-immunoprecipitation. In a cell-free setting, GST-tagged PBF was 
translated and its size determined by SDS-PAGE with the resulting band running at the 
expected (Figure 7.2A). [35S]-methionine labelled SRC was translated using a cell free system 
and detected at 60 kDa (Figure 7.2B). To test for an interaction, GST-tagged PBF was 
incubated with [35S]-methionine labelled SRC, using GST alone as a negative control. After 
eluting, the samples were run through SDS-PAGE with 10% [35S]-methionine labelled SRC 
as a positive control. When compared to GST alone, GST-PBF appeared to bind SRC in this 
cell free setting (Figure 7.2C), although a small degree of binding was apparent in the GST-
only control lane. 
 
Figure 7.2 GST pull down assay. A: Western blot of translated GST-PBF. B: [35S]-methionine 
labelled SRC detectable at approximately 60 kDa. C: GST pull-down assay demonstrating 
binding between SRC and GST-PBF when compared to GST alone. 
7.3.1.2 Co-immunoprecipitation  
As well as examining the interaction in a cell free system, co-immunoprecipitation was 
performed to establish if the interaction occurred in a more physiological setting. As the 
endogenous expression of SRC in TPC and K1 cells is low, over-expressed SRC was used. 
The full length human cDNA for SRC was sub-cloned into the mammalian expression vector 
pcDNA3.1+ from the bacterial vector pOTB7. The resulting plasmid was sequenced and 
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shown to contain the full length SRC cDNA. When transfected into TPC1, K1 and HeLa cells, 
SRC was over-expressed as expected (Figure 7.3).  
 
Figure 7.3 Over-expression of SRC in K1, TPC1 and HeLa cell lines demonstrated by 
Western blot. 
Due to the high transfection efficiency of HeLa cells, they were used for co-
immunoprecipitation, and were transfected with both PBF-HA and SRC. Western blot analysis 
was performed and demonstrated that PBF-HA expression was not affected by SRC over-
expression (n = 3, Figure 7.4).  
 
Figure 7.4 Over-expression of SRC does not affect PBF-HA expression. A: i.) Western blot 
analysis of HeLa cells transfected with either VO or SRC. There was no significant difference 
between the two conditions in terms of PBF-HA expression as demonstrated by scanning 
densitometry (ii.) (28.6 ± 16.4% of control, n = 3, p = ns). 
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Subsequently, after immunoprecipitating PBF-HA with an anti-HA antibody, SRC was 
detected, whereas in control lanes no SRC was identified (Figure 7.5A). In the reciprocal 
experiment, PBF-HA was co-immunoprecipitated with SRC using a SRC antibody (Figure 
7.5B). Together with the GST-pull down and MS/MS data, this demonstrated an interaction 
between the two.  
 
Figure 7.5 PBF-HA binds to SRC in HeLa cells in forward and reverse co-
immunoprecipitation assays. A: Western blot showing co-immunoprecipitation of SRC after 
immunoprecipitating with an anti-HA antibody. B: Western blot showing co-
immunoprecipitation of PBF-HA after immunoprecipitating with an anti-SRC antibody. 
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7.3.2 PBF and SRC co-localise 
Having confirmed the interaction between SRC and PBF, their cellular localisation was 
then examined using fluorescence immunocytochemistry in K1, TPC1 and HeLa cells 
transfected with PBF-HA and SRC. In all 3 cell lines, the distribution of both PBF-HA and 
SRC was similar; both were found in the cytoplasm and at the cell membrane (Figure 7.6).  
 
Figure 7.6 Fluorescence immunocytochemistry demonstrating co-localisation of PBF-HA and 
SRC in K1, TPC1 and HeLa cells. PBF-HA was identified in green using an anti-HA 
antibody, SRC was identified in red, nuclear staining was shown in blue. Areas of co-
localisation between PBF-HA and SRC were shown in yellow, and occur within intra-cellular 
vesicles (white arrows) and at the cell membrane (blue arrow). Bars, 20 µm. 
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7.3.3 SRC does not alter the sub-cellular localisation of PBF-HA 
The final analysis performed was to assess the effect of Src over-expression on PBF sub-
cellular localisation. An increase in SRC expression did not have an effect on PBF sub-
cellular localisation, as apparent in Figure 7.7, where 2 adjacent cells are displayed. The lower 
right cell is co-transfected with PBF-HA and SRC, while the upper cell is transfected with 
PBF-HA only. It is readily apparent that PBF-HA has a similar distribution in both cells.  
 
Figure 7.7 Fluorescence immunocytochemistry demonstrating that SRC does not affect PBF 
sub-cellular localisation. HeLa cells were transfected with SRC (red) and PBF-HA (green), 
areas of co-localisation are shown in yellow and nuclear staining in blue. In the 2 cells, only 
the lower cell has been transfected with SRC; however PBF-HA distribution is similar in 
both. Bars, 20 µm. 
 
  




The SFKs were identified by MS/MS as potential interacting partners of PBF, and SRC 
had been identified as a potential kinase for PBF. These factors led to the decision to include 
SRC in the final shortlist of proteins to take on for further experiments. As in previous 
chapters, the first step in this process was to independently validate the interaction between 
PBF and SRC, using GST-tagged pull down assays and also co-immunoprecipitation. The 
GST pull-down assay demonstrated an interaction in a cell-free setting, but initial attempts at 
co-immunoprecipitation were unsuccessful (data not shown) as the expression of SRC was 
not sufficient for detection by Western blotting. MS/MS is significantly more sensitive than 
co-immunoprecipitation, with the capability of detecting femtomolar concentrations of 
peptides, hence the identification of SRC in those assays when compared to co-
immunoprecipitation. The c-DNA for SRC was subcloned into a mammalian expression 
vector, which facilitated its transfection into the cell lines used in previous chapters. The over-
expression was confirmed in all cell lines on Western blotting. Using this model, SRC was 
over-expressed in HeLa cells and an interaction was confirmed by forward and reverse co-
immunoprecipitation. Taken together, these data validated the interaction between PBF and 
SRC first identified by MS/MS. 
 
Finally, fluorescence immunocytochemistry was performed to investigate any co-
localisation of the two proteins. Western blot analysis demonstrated no change in PBF-HA 
expression when SRC was over-expressed. Immunofluorescence indicated co-localisation at 
both the cell membrane and within intra-cellular vesicles in HeLa cells. The location of SRC 
within the cell is important to understanding any potential kinase role it may have regarding 
PBF. Usually, cytoplasmic SRC is in the pY530 inactive state; de-phosphorylation here leads 
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to translocation to the cell membrane where full activation is achieved through 
phosphorylation at Y419 (Anbalagan et al. 2012). The findings above indicate co-localisation 
at the cell membrane, where active SRC may be able to phosphorylate PBF, and also within 
intra-cellular vesicles, the consequences and reasons for which are as yet unknown and are the 
focus of on-going study. 
 
Concluding remarks 
This chapter has validated the interaction between PBF and the tyrosine kinase SRC 
using two independent binding assays. Co-localisation was observed within intra-cellular 
vesicles and also at the cell membrane, and it is at this location that SRC is active as a protein 
kinase. These data, taken together with phosphorylation prediction, suggest that SRC may be 
the kinase responsible for phosphorylating PBF. The following chapter further explores this 
interaction, and the functional implications of targeting it. 
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Chapter 8 The role of SRC and its inhibition on 
PBF-induced NIS repression 
  




The previous chapter validated the interaction between SRC and PBF using GST pull-
down assay and co-immunoprecipitation. Additionally, co-localisation was observed in intra-
cellular vesicles and at the cell membrane. These data were important preliminary steps prior 
to any investigation into the kinase role of SRC within PBF physiology, and what effect SRC 
may have on PBF function and thyroid cancer development. 
SRC lies downstream of a number of cell membrane receptor tyrosine kinases, and thus 
plays a vital part in many of the key cellular process they govern (Figure 8.1). In human 
malignancies such as breast, gastrointestinal, lung, ovary and lymphomas, SRC is 
overexpressed, with its effects on adhesion, cell growth and angiogenesis contributing to 
metastasis formation (Alvarez et al. 2006). However, over-expression of SRC alone is 
insufficient to act as a transforming event in these cells, rather depending on the mutation of 
the c-terminal part of the protein, as seen in v-SRC, which constitutionally activates the 
kinase (Shalloway et al. 1984). A truncated version of the protein lacking the c-terminal 
regulatory mechanism was found in 12% of advanced colorectal carcinomas, demonstrating a 
direct role in disease progression (Irby et al. 1999).  




Figure 8.1 SRC lies downstream of several receptor tyrosine kinases. Activation of SRC leads 
to activation of other pathways which in turn control key cellular events. Increased activation 
of these physiological processes can lead to increased invasiveness and metastasis of cancer. 
EGFR – epidermal growth factor receptor, PDGFR – platelet derived growth factor receptor, 
FGFR – fibroblast growth factor receptor, MET – hepatocyte growth factor receptor. 
Adapted from (Irby and Yeatman 2000). 
Despite a potential link between SRC activity and medullary thyroid cancer being put 
forward in 2004 (Liu et al. 2004), the relationship between SRC and differentiated thyroid 
cancer was not described until 2009 where a SRC inhibitor was shown to reduce growth and 
invasion in a number of thyroid cancer cell lines,  although this was thought to be due to 
inhibition of SRC phosphorylating Focal Adhesion Kinase (FAK) (Schweppe et al. 2009). 
Since then, SRC has been identified as up-regulated in invasive thyroid cancers (Cho et al. 
2012), with inhibition of SRC reducing metastases and tumour growth (Chan et al. 2012). 
Total SRC is not increased in thyroid cancers, therefore it is the phosphorylation, and 
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consequently the activation, of SRC that promotes this aggressive tumour behaviour, although 
the exact pathway by which this effect is mediated remains unknown.  
Tyrosine phosphorylation is a post-translational modification that is often key to 
controlling  a  protein’s  activity  within  a  cell.  Unpublished data within the McCabe group have 
recently shown PBF to be phosphorylated at Y174, although the kinase responsible was 
unknown. Phospho-site prediction software identified SRC as a potential kinase for this 
residue. The aims of this chapter were therefore to determine whether SRC, which was 
confirmed to bind PBF in Chapter 7, was responsible for phosphorylating PBF. This 
interaction could then be targeted with a variety of inhibitors, with the aim of reducing 
phosphorylation and potentially increasing iodide uptake in radioiodine refractory, PBF over-
expressing, thyroid cells. 
8.2 Methods 
8.2.1 Cell culture and transfection 
K1, TPC1, HeLa and FRTL-5 cells were maintained as described in 2.1. Human primary 
thyroid tissues were cultured with approval of the Local Ethics and Research Committee as 
described in Section 2.7.  
8.2.2 Western Blotting 
Western Blotting was performed as described in Section 2.3.2. In addition to antibodies 
previously described, a PBF phospho-specific   antibody   to   residue   Y174   (“anti-Y174”)  
(CovalAb, Villeurbanne, France) was kindly provided by Dr V Smith, University of 
Birmingham, and was used at 1:500. 
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8.2.3  Fluorescence immunocytochemistry 
Immunofluorescence was carried out as described in Section 2.6. In addition to 
previously described antibodies, anti-Y174 was used at 1:100. 
8.2.4 Assessment of phosphorylation status 
8.2.4.1 Treatment with a phosphatase inhibitor 
In order to preserve the phosphorylation status of proteins, cells were harvested using the 
irreversible tyrosine phosphatase inhibitor sodium orthovanadate (Na₃VO₄). Prior to 
harvesting, cells were treated for 15 minutes with 100 µM pervanadate (from a 30 mM stock 
solution: 951.1 µL PBS, 6 µL hydrogen peroxide, 42.9 µL Na₃VO₄, incubated in the dark at 
room temperature for 15 minutes). The medium was then removed and the cells washed with 
1 ml cold PBS before adding 100 µL modified RIPA (50 mM Tris, 150 mM NaCl, 1 % 
Igepal, 6 mM sodium deoxycholate, 1 mM ethylene glycol tetraacetic acid (EGTA), buffered 
to pH 7.4) with 1 mM Na₃VO₄ and 6 % protease inhibitor cocktail. Cells were scraped into a 
microcentrifuge tube, sonicated for 30 seconds and spun on a benchtop centrifuge at 12,000 
rpm for 20 minutes. The supernatant was then stored at -20 °C. 
 
8.2.4.2 Treatment with tyrosine kinase inhibitors (TKIs) 
In an attempt to alter the phosphorylation of PBF, cells were treated with a panel of 
TKIs. The different TKIs used, with their known targets and dose, are shown in Table 8.1. 
Thirty minutes prior to harvesting, appropriate TKIs were added to the media and plates 
returned to the incubator. Protein was then harvested as described above. 
 




TKI Dose (nM) Target(s) 
Gefitinib 10 Epidermal growth factor receptor (Ciardiello 2000) 
Imatinib 10 Abl, c-kit  α,  platelet  derived  growth  factor  receptor (Buchdunger et al. 1996) 
PD173074 10 Fibroblast growth factor receptor, Vascular endothelial growth factor receptor (Mohammadi et al. 1998) 
SU11274 10 c-MET (Sattler et al. 2003) 
PF573228 10 Focal adhesion kinase (Slack-Davis et al. 2007) 
PP1 2 – 10 Src (Hanke et al. 1996) 
PP3 2 - 10 Src family negative control (Liu et al. 1999) 
Table 8.1 Dose and target(s) of tyrosine kinase inhibitors (TKIs) used. 
 
8.2.5 Iodide uptake assays 
8.2.5.1 TSH responsiveness 
Prior to uptake analysis, functionality of primary thyrocyte cultures were assessed. 
Primary human thyrocytes are able to remain functional for several weeks when cultured as 
described in Section 2.7, although this decreases with time (Eggo et al. 1996). In addition, 
cultures from some patients may not exhibit functions associated with differentiated thyroid 
follicular cells. This may be due to the specimen originating from macroscopically normal, 
but histologically abnormal, thyroid tissue. The response to TSH by primary thyrocytes is a 
reliable marker of thyroid cell function, with increasing concentrations of TSH resulting in an 
increase in iodide concentration by the cell. However, at super-physiologic doses of TSH, 
iodide uptake falls (Eggo et al. 1996). For each prep, half of a 24 well plate was kept in TSH 
and serum free medium from day 4 (the other half being maintained in serum-free medium 
only). On day 7, the cells were treated (in duplicate) with 0.01, 0.1, 0.3, 1 and 10 U of TSH. 
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On day 9 the ability of the cells to take up 125I was measured as described below; any 
preparations that did not show the anticipated TSH response were discarded. 
8.2.5.2 Iodide uptake 
Primary thyroid cells were treated with sodium iodide (NaI) containing 100,000 cpm 125I 
(Hartmann Analytic, Braunschweig, Germany) to give a final concentration of 10-7 NaI. This 
concentration of iodide ions had been optimised to ensure maximal uptake by thyrocytes 
(Eggo et al. 1996). The cells were returned to the incubator for 3 hours to allow the uptake of 
125I by the thyrocytes. Subsequently, the cells were washed rapidly twice with HBSS to 
remove any residual 125I and lysed in 200 µL 2 % SDS. After transferring to a test tube, 125I 
uptake was assessed by analysing the gamma emissions as measured on a LKB Wallac 1260 
Multi gamma II gamma counter for 1 minute. To standardise the results between wells, the 
amount of protein present was quantified using the BCA assay as described in Section 2.3.1, 
with BSA standards made in 2 % SDS. In addition, transfection was determined by running 
25 µL of the lysate through SDS-PAGE and immunoblotting with antibodies targeting the 
transfected protein. 
Iodide uptake was also measured in HeLa, TPC1 and K1 cells. Cells were seeded in 9.5 
cm2 tissue culture wells and transfected as previously described. After 48 hours further 








8.3.1 SRC over-expression leads to phosphorylation of PBF 
As work within our group has shown that PBF is a phospho-protein, the above model of 
SRC over-expression was used to determine the effect of SRC on the phosphorylation status 
of PBF. An antibody specific to Y174- phosphorylated PBF (pY174) was kindly provided by 
Dr Vicki Smith. Having been previously validated by Dr Smith to demonstrate specificity in 
Western blotting, fluorescence immunocytochemistry also validated its use in identifying 
PBF-HA phosphorylated at Y174 (Figure 8.2).  
 
Figure 8.2 Detection of pY174 by fluorescence immunocytochemistry. HeLa cells were 
transfected with PBF-HA and stained for HA (green) and pY174 (red). Yellow staining 
indicated both HA and Y174, demonstrating that exogenous PBF was phosphorylated and 
detectable by IF. Bars, 20 µm. 
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HeLa cells were transfected to transiently over-express PBF-HA, and co-transfected 
with either SRC or blank vector. As phosphorylation is a post-translational modification that 
can easily be disrupted by the process of harvesting and lysing cells, the phosphatase inhibitor 
pervanadate was added 30 minutes prior to harvesting in order to preserve the phosphorylated 
state of PBF, with vehicle-only treatment as a control. With vector only transfection, pY174 
was apparent at low to undetectable levels; however, SRC was shown to significantly increase 
the amount of pY174 (n = 3) (Figure 8.3). Cells transfected with the Y174A mutant of PBF 
(which cannot be phosphorylated at residue 174) were used as a negative control and did not 
demonstrate detectable phosphorylation. In addition, using pervanadate increased the yield of 
pY174 as would be expected. 
 
Figure 8.3 SRC over-expression leads to increased phosphorylation of PBF at Y174 (pY174). 
Western blot analysis of HeLa cells co-transfected with PBF-HA and either SRC or VO. 
Treatment was either with (PV+) or without (PV-) pervanadate. Y174A was a mutant of PBF 
which could not be phosphorylated at   Y174.   β actin shown for loading control and HA to 
demonstrate transfection. 
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8.3.2 TKIs affect pY174 in a time and dose dependent manner 
Phosphorylation is a key post-translational modification that frequently governs a 
protein’s   function  within   a   cell,   and   having   demonstrated   that   PBF   is   a   phosphorylated   at  
Y174, the effect of a small panel of tyrosine kinase inhibitors (TKIs) on pY174 was assessed. 
HeLa cells transfected to over-express PBF-HA were treated with pervanadate as described 
above, following which 10 nM aliquots of gefitinib, imatinib, SU11274 and PD173074 were 
added. SU11274 led to an 89 ± 2.6% reduction in pY174 (p < 0.05, n = 3) (Figure 8.4). 
 
Figure 8.4 Western blot analysis of the effect of various TKIs on pY174 expression. A: 
Representative Western blot of HeLa cells treated with either vehicle (DMSO) or TKI 
demonstrated some degree of reduction in pY174 with all TKIs, although imatinib and 
PD1736 did not have a significant effect. Y174A indicates non-phosphorylatable PBF mutant. 
PV+ indicates treatment with pervanadate. B: Scanning densitometry revealed a significant 
reduction for gefitinib (34 ± 1.6%, p < 0.05, n = 3) and SU11274 (89 ± 2.6%, p < 0.05, n = 
3). 
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Given that SU11274 led to the greatest response of the panel of TKIs, this was used to 
determine the optimum dose that could be applied in order to demonstrate an effect. Using 
concentrations varying from 0 to 10 µM, SU11274 was applied to HeLa cells over-expressing 
PBF-HA. A reduction in pY174 was observed with the lowest dose, 0.5 µM (79.5 ± 2.1% of 
control, p < 0.05, n = 3) (Figure 8.5). There was a significant difference between the reduction 
observed with 0.5 µM and concentrations of 2 µM (95.2 ± 1.5%), 5 µM (95.5 ± 1.2%) and 10 
µM (96.4 ± 1.4%) (all p < 0.01, n = 3). The optimum dose was therefore taken to be 2 µM. 
 




Figure 8.5 SU11274 reduces pY174 expression in a dose dependent manner. Representative 
Western blot showing a reduction in pY174 with increasing concentrations of SU11274. 
Below, scanning densitometry demonstrated a significant reduction compared to control with 
all concentrations used (p < 0.05, n = 3). 
Once the optimum dose of TKI had been determined, the optimum treatment time was 
assessed. HeLa cells were again transfected with PBF-HA, and all treated with 2 µM 
SU11274. In these experiments, treatment time ranged from 0 minutes to 24 hours. All cells 
were treated with pervanadate as above to preserve phosphorylation after cell harvest. In 
Western blot, a decrease in pY174 expression was observed at all timepoints when compared 
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to the 0 minutes negative control (Figure 8.6A). However, the change across the range was 
small and therefore it was decided to use the 30 minute timepoint for subsequent experiments, 
given the potential cytotoxicity of the inhibitor.  
Fluorescence immunocytochemistry across the same timepoints was also performed. 
Interestingly, for all timepoints there appeared to be a fall in the amount of pY174 associated 
with the cell membrane, with more being located in intracellular vesicles. However, this was 
not quantified directly (Figure 8.6B). 




Figure 8.6 Time course treatment of HeLa cells with SU11274. A: Representative Western 
blot demonstrating a time-dependent reduction in pY174 with SU11274 treatment (2 µM). B: 
Fluorescence immunocytochemistry of HeLa cells treated for differing time periods with 
SU11274, with pY174 staining in red. With increasing treatment time, there was less 
membrane localisation observed. Bars, 20 µm. 
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8.3.3 Inhibition of SRC by PP1 leads to reduced pY174 expression 
Given that the panel of TKIs was shown to differentially affect PBF phosphorylation, 
and that SRC is involved in the process, a specific SRC inhibitor was used to determine 
whether SRC was an essential or contributory kinase in the process. The SRC specific 
inhibitor PP1 (a cell-permeable pyrazolopyrimidine compound) was used. PP3, which is a 
non-functioning analogue of PP1, was used as a negative control. PP1 was able to reduce 
pY174 levels significantly compared to both DMSO and PP3 (which exhibited similar levels) 
in HeLa cells co-transfected with PBF-HA and SRC (Figure 8.7). This response was a partial 
reversal of the increase apparent with over-expressed SRC.  
 
Figure 8.7 Western blot analysis of HeLa cells transfected with PBF-HA, demonstrating an 
increase in pY174 with SRC over-expression and also a reduction in pY174 when treated with 
the SRC inhibitor PP1 when compared with DMSO alone. There was no change in pY174 
when the inactive version of the inhibitor, PP3, was used. VO = vector only. 
This demonstrated that PP1 was able to reduce the effect that over-expressed SRC had 
on PBF phosphorylation, but as yet the effect of inhibitors on pY174 in the presence of 
endogenous SRC was undetermined.  Following on from this, the effect of PP1 when 
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compared to the other TKIs was assessed in cells with endogenous levels of SRC and PBF. 
K1, TPC1 and HeLa cells were again treated with the panel of inhibitors, but were 
untransfected. Understandably, in these circumstances pY174 was significantly harder to 
detect. K1 and TPC1 cells both showed a reduction in pY174 with PP1 treatment, and in K1 
and HeLa cells gefitinib also had an inhibitory effect on phosphorylation. These data 
demonstrated that pY174 could not only be detected in the presence of endogenous levels of 
SRC, but also that PP1 still had an effect on the amount of phosphorylation. 
 
Figure 8.8 Western blot analysis of K1, TPC1 and HeLa cells and the effect on pY174 of 
various tyrosine kinase inhibitors. In untransfected cells, PP1 reduced pY174 in K1 and 
TPC1, while gefitinib also reduced pY174 in K1 and HeLa cells. β actin is shown as a loading 
control. 
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8.3.4 PP1 treatment leads to a significant reduction in pY174 expression in human 
primary thyroid cultures 
The above experiments were carried out on transformed cells lines, all of which behave 
in different ways depending on their particular cancer genotype, and may have aberrantly 
activated kinase pathways. While this is useful for initially testing hypotheses, a more 
physiological model is to use normal human thyroid tissue. The inhibitor experiments were 
therefore repeated using human primary thyroid cultures, where the tissue was taken from 
macroscopically normal thyroid. As pY174 was easier to detect in primary thyroid tissue, 
these cells were left untransfected in order to reduce the amount of cell death and therefore 
maximise yield. As would be expected, human thyroid tissue demonstrated a large variation 
in culture across different preps, which affected statistical analysis. However, across a number 
of cultures, gefitinib and PP1 yielded the greatest reduction in pY174, with PP1 having the 
largest effect (Figure 8.9A). PP1 was therefore examined in isolation compared to treatment 
with DMSO alone. PP1 led to an 81.1 ± 7.8% reduction in pY174 (p < 0.001, n = 5), 
demonstrating that in both transformed cell lines and primary cultures, it is the most potent 
inhibitor of PBF phosphorylation at Y174 (Figure 8.9B). 




Figure 8.9 Effect of TKIs on pY174 in human primary thyroid cultures. A: Western blot 
analysis demonstrating that treatment with gefitinib and PP1 led to a reduction in pY174. B: 
Scanning densitometry revealed an 81.1 ± 7.8% reduction in pY174 (p < 0.001, n = 5) with 
PP1 treatment compared to DMSO alone (n=3). 
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8.3.5 Effect of PBF and SRC on 125I uptake 
8.3.5.1 Determination of uptake efficiency in different cell lines 
Work within our group has demonstrated that over-expression of PBF significantly 
reduces 125I uptake in both murine and human primary thyroid cultures (Read et al. 2011). In 
order to explore the relationship between PBF phosphorylation and 125I uptake, the human 
primary thyroid model was validated and the cell lines assessed for uptake experiments. When 
measured on a gamma counter, untransfected and untreated human primary thyrocytes and 
FRTL5 cells both had counts in excess of 15,000 cpm per 3.7 cm2 of culture. The K1, TPC1 
and HeLa cells all had low counts, the highest being in the TPC1 cells where the average 
count was just over 500 cpm (n = 3) (Figure 8.10). While this was to be expected in the HeLa 
cells which do not express NIS, the low uptake in the thyroid cell lines was an indicator of 
their degree of de-differentiation from normal thyroid tissue and their lack of functional NIS. 
Given that these counts were low in the absence of treatment or transfection, it was thought 
unlikely that they would be suitable for further uptake experiments as the cell death that 
inevitably occurs would render the counts too low to be meaningful, and further uptake 
experiments were subsequently conducted on the primary cultures and FRTL5s, discounting 
the other cell lines. 




Figure 8.10 3 hour 125I uptake in cell lines. FRTL5 and human primary thyrocytes exhibit 
significantly higher uptake when compared to K1, TPC1 and HeLa cells (SEM = standard 
error of the mean, uptake in counts per million counted over 60 secs). 
8.3.5.2 There is significant variation in 125I uptake between primary thyroid 
cultures 
Although from macroscopically normal thyroid tissue, each primary thyroid culture 
came from a different patient, yielding significant variation in the behaviour of the cells. 
Therefore, for each preparation the culture had to be assessed to ensure that it was functional 
in terms of iodide uptake. Untransfected cells showed wide variation; although most cultures 
had uptake counts of greater than 15,000 cpm, some exhibited little or no uptake and these 
were discarded from subsequent analysis. In addition, cells should exhibit the typical dose-
response effect with TSH, whereby uptake increases up to around 0.3 Units, then falls off as 
the dose increases further (Pratt et al. 1989). In Figure 8.11A and C, this was demonstrated 
across 4 cultures. Figure 8.11A demonstrates the uptake of the preps, and it can be seen that 
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Prep 1 has a much lower uptake that the other 3, therefore would not be usable once 
transfected and treated. Despite this, Prep 1 showed a typical TSH response, although Prep 3 
did not show any change in uptake with changing TSH concentration (Figure 8.11B). 
Therefore, of the 4 preps, only Preps 2 and 4 would be used in uptake experiments. 
The response of preps to transfection was also varied; Figure 8.11C shows the different 
uptake profile of 3 separate cultures, all of which were transfected with blank vector, with 
average counts ranging from 700 to 2450 cpm. Cultures where the average count after 
transfection with blank vector was less than 300 cpm were not used for analysis, as at these 
lower values the intra-culture variation meant that significant results were unlikely to be 
obtained.  
To eliminate variation caused by errors inherent to the gamma counter itself, each 
sample was counted at least twice in different wells of the counter, and the machine calibrated 
on a regular basis. The variation between counts in a representative prep is shown in Figure 
8.11D; although most samples had a less than 15% difference between the 2 counts, those 
exhibiting a greater variation were re-counted twice in different wells. If the variation was still 
greater than 15% the samples were discounted.  




Figure 8.11 Variation in iodide uptake between different patient cultures. A: Uptake from 4 
preps demonstrated poor uptake in Prep 1, and some variation in the uptake in the other 
preps. B: TSH response curves for the same 4 preps; Prep 3 did not exhibit the 
physiologically correct response and was therefore discarded. C: Iodide uptake in a separate 
3 preps following transfection with blank vector; uptake was generally lower than observed in 
untransfected preps - Preps 5 and 7 demonstrated a more marked reduction. D: Variation in 
count obtained when measuring the same sample in different wells of the gamma counter. Red 
lines indicate a 15% difference between the 2; results outside these lines were re-counted and 
if still variable then discarded. 
 
Provided the samples met the initial criteria for uptake and TSH response, they were 
then assessed for their response to PBF over-expression. Some cultures did not show any 
change in 125I uptake with PBF over-expression. In some cases this was due to lack of 
transfection, although in others it appeared that PBF did not affect 125I uptake at all (Figure 
8.12). As the aim of these experiments was to attempt to modulate the effect that PBF had on 
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125I uptake, and because several publications have now confirmed that PBF represses iodide 
uptake in vitro and in vivo (Smith et al. 2009; Read et al. 2011), only those that demonstrated 
a significant reduction in uptake with PBF over-expression were used.  
 
Figure 8.12 Relative 125I uptake by human primary thyrocytes in a single prep. This prep did 
not demonstrate any change in uptake with PBF transfection and was therefore not used (1.05 
± 0.05 fold change, p = ns). 
8.3.5.3 PBF and SRC inhibit 125I uptake in human primary thyroid cultures 
For those thyroid cultures which adhered to the criteria described in the previous section, 
over-expression of PBF-HA led to a 60 ± 8% reduction in iodide uptake (p < 0.05, n = 4). 
When untagged PBF was transfected, there was a similar, albeit smaller, reduction in uptake 
(45 ± 17% decrease compared to VO, p = ns, n = 4), although there was no significant 
difference between the two (Figure 8.13A). This was in keeping with previously published 
data from our group (Smith et al. 2009; Read et al. 2011). 
To assess the relationship between SRC over-expression and 125I uptake in the context of 
PBF expression, PBF and SRC were co-transfected into human primary thyroid cultures, with 
blank vector used as a control (n = 3) (Figure 8.13B). Despite the fact that when co-
transfecting, half the amount of cDNA was used for each vector, there was still a 52.4 ± 
16.4% reduction in 125I uptake when PBF was over-expressed compared to blank vector at 48 
hours post-transfection. When SRC alone was transfected, a similar reduction in uptake was 
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seen (48.6 ± 16.7%), although interestingly when PBF and SRC were co-transfected the 
subsequent reduction in 125I uptake was no different (46.2 ± 9.8%), i.e. there was no 
cumulative effect of the dual transfection. Unfortunately, given the variable nature of thyroid 
preps, in particular the variability when transfecting in blank vector, none of these results 
reached statistical significance (Figure 8.13B). 
 
Figure 8.13 Iodide uptake in human primary thyrocytes following transfection. A: 
Transfection with PBF-HA resulted in a 60 ± 8% fall in uptake (p < 0.05, n = 4); untagged 
PBF transfection resulted in a 45 ± 17% fall (p = ns, n = 4). B: Co-transfection of PBF and 
SRC caused uptake to fall by 46.2 ± 9.8%, which was no different to when PBF and VO (52.4 
± 16.4%) or SRC and VO (48.6 ± 16.7%) were transfected (for all compared to VO: p = ns, n 
= 3). * = p < 0.01, ns = not significant. 




8.3.6 Effect of TKIs on iodide uptake 
8.3.6.1 Treatment for 30 minutes does not alter 125I uptake 
Having demonstrated that PBF and SRC both cause a reduction in 125I uptake in human 
primary thyrocytes, and having previously shown that SRC leads to an increase in pY174, 
experiments were performed to determine if this reduction in uptake could be reversed by 
targeting the phosphorylation of PBF at Y174. The uptake in primary thyrocytes transfected 
with PBF, SRC, or both was measured after 30 minutes treatment with the inhibitors 
previously shown to have the most effect on PBF phosphorylation: SU11274, gefitinib and 
PP1, with PP3 acting as a negative control. As previously observed, both PBF and SRC over-
expression led to a reduction in 125I uptake when compared to blank vector transfection, both 
independently and when co-transfected, although this did not reach statistical significance 
(Figure 8.14). However, following treatment with the panel of TKIs for 30 minutes, there was 
no difference in the uptake when compared to either DMSO or PP1 treatment, thus indicating 
that treatment with these inhibitors and for this time period had no effect on the PBF induced 
repression of iodide uptake. 
 




Figure 8.14 125I uptake of human primary thyrocytes after treatment with 10 µM TKI for 30 
minutes. A: Cells transfected with PBF-HA showed a reduction in uptake but no reversal after 
treatment with TKIs. B: Cells transfected with SRC also exhibited a reduced 125I uptake which 
was not reversed by any TKI. C: The reduced uptake observed after co-transfection with 
PBF-HA and SRC was not reversed by treatment with TKIs. There was no statistically 
significant difference between these results (n = 3). 
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8.3.6.2 PP1 increases 125I  uptake 
Despite the fact that PBF phosphorylation was significantly reduced by the TKIs (Figure 
8.4), there was no apparent effect on 125I uptake after 30 minutes treatment (Figure 8.14). 
Given that we have shown PBF to internalise NIS and reduce its expression (Smith et al. 
2009), it was felt likely that 30 minutes treatment may be too short a time to reverse this 
process and therefore facilitate an increase in uptake.  
To test this theory, untransfected human primary thyrocytes were treated with PP1 for 24 
hours, with control wells treated with DMSO only. The PP1-treated cells demonstrated a 65% 
± 15% increase in 125I uptake compared to DMSO treated cells (p < 0.001, n = 3) (Figure 
8.15).  
 
Figure 8.15 125I uptake in untransfected human primary thyrocytes treated with DMSO or 
PP1 for 24 hours. PP1 treatment resulted in a 65 ± 15% increase in iodide uptake (p < 0.001, 
n = 3). 
Alongside this experiment, FRTL5 cells were transfected with PBF or blank vector and 
treated with PP1 or DMSO for 24 hours. In both the VO and PBF samples, uptake was 
increased by PP1 treatment (19.1 ± 5.2%, p < 0.05 and 31.1 ± 9.2%, p < 0.01 respectively, n = 
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3). However, no difference was observed between the VO and PBF transfected cells as a 
whole (Figure 8.16). When examined by Western blotting, the FRTL5 cells were shown not 
to have transfected efficiently, essentially leading to no genotypic difference between the two 
groups and hence the similarity in uptake profile (data not shown). Despite this lack of 




Figure 8.16  125I uptake in FRTL5 cells treated with either DMSO or PP1 for 24 hours. PP1 
increased uptake in both VO and PBF transfected cells (19.1 ± 5.2%, p < 0.05 and 31.1 ± 
9.2%, p < 0.01 respectively). There was no difference in uptake between the DMSO treated 
VO and PBF transfected cells (2.4 ± 5.1%, p = ns), although subsequent analysis showed that 
these cells had not taken up the transfection (n = 3). 
 
8.3.6.3 PP1 reverses the PBF induced repression of iodide uptake 
To examine the effect of PP1 in the most physiologic in vitro setting, primary human 
thyrocytes were transfected with either blank vector or PBF-HA, and subsequently treated for 
24 hours with PP1 or DMSO (n = 5). In these cultures, treating blank vector transfected cells 
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with DMSO made no difference to the iodide uptake (7.4 ± 9.9% increase, p = ns). 
Transfection with PBF-HA resulted in a 47.3 ± 7.3% reduction in 125I uptake compared with 
blank vector (p < 0.01). Most importantly, this effect was completely reversed by treatment 
with PP1, with PBF-HA transfected cells treated with PP1 showing no significant difference 
to blank vector transfected cells receiving only DMSO treatment (4.1 ± 17.7% difference 
from VO, p = ns) (Figure 8.17). Therefore, treatment of human primary thyrocytes with PP1 
for 24 hours led to a full recovery from PBF-mediated iodide uptake repression.  
 
Figure 8.17 125I uptake in human primary thyrocytes transfected with either VO or PBF-HA 
and treated for 24 hours with DMSO or PP1. PBF-HA transfection led to a 47.3 ± 7.3% (p < 
0.01, n = 5) reduction in uptake compared to VO transfection. PP1 treatment was able to 
reverse this, with PBF-HA transfected cells treated with PP1 having a significantly higher 
uptake than those treated with DMSO (82.8 ± 33.6%, p < 0.05, n = 5). This abrogation of the 
PBF response resulted in treated cells exhibiting no differnce in uptake compared to VO 
untreated cells (4.1 ± 17.7% reduction compared to VO, p = ns, n = 5). 
 
 




PBF is a phosphoprotein, with a potential site of tyrosine phosphorylation identified as 
Y174 (see Section 1.4.1.4.2). Phosphorylation prediction software identified SRC as a 
potential tyrosine kinase at this site, and the identification of SRC in the MS/MS dataset of 
Chapter 4 was therefore interesting, especially as targeting tyrosine kinases is a rapidly 
emerging field in the treatment of aggressive cancers. The previous chapter validated the 
interaction between PBF and SRC, with evidence of co-localisation within intra-cellular 
vesicles and at the plasma membrane; this chapter sought to further explore this interaction in 
relation to PBF phosphorylation and implications for iodide uptake in thyroid cells. 
A specific antibody to pY174 PBF was already in use within our group and had recently 
been validated by Western blotting (data not shown); Chapter 7 validated its use for 
fluorescence immunocytochemistry. Using this antibody, SRC over-expression was shown to 
significantly increase the amount of pY174 in HeLa cells, although not to alter the sub-
cellular localisation of PBF. SRC acts within a number of signalling networks and therefore it 
could not be determined from this experiment whether SRC was acting as the kinase itself or 
if it was part of a cascade that resulted in PBF phosphorylation. Given the multiple ways SRC 
may affect PBF, a panel of inhibitors that are currently in use in trials/clinical care was tested 
to determine whether any of these (which all target a kinase linked to SRC) could reduce PBF 
phosphorylation. The most successful of these was SU11274, a potent and selective inhibitor 
of MET (Wang et al. 2003). MET is the receptor for hepatocyte growth factor (HGF), 
activation of which leads to increased cellular proliferation, survival, motility and invasion. 
Inhibition of MET using small molecule inhibitors has been shown to reduce SRC 
phosphorylation and kinase activity in breast cancer cells (Mueller et al. 2008), and this 
corresponds well with the observed result. Having identified SU11274 as the most potent 
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inhibitor of the panel in HeLa cells, the optimum dose and treatment time was then 
established. Various studies using TKIs have reported results with concentrations ranging 
from 0.5 to 10 µM and treatment times from 15 minutes to 24 hours. In these experiments, no 
further reduction in pY174 was identified on Western blotting with a treatment time of longer 
than 30 minutes and an inhibitor concentration greater than 2 µM, and therefore these were 
the conditions used.   
In addition to the panel of TKIs tested, the SRC family kinase specific inhibitor PP1 was 
also tested for its ability to inhibit pY174. PP1, first described in 1996 (Hanke et al. 1996) is a 
potent selective inhibitor for the SRC family, and is often used when studying both SRC 
individually as well as the family as a whole. As a negative control, PP3 (which has a similar 
structure to PP1 but does not affect SRC kinase activity) was used. If SRC was part of a 
kinase cascade that at some point resulted in PBF phosphorylation, then given the overlaps 
that exist in such pathways, inhibition of SRC would not result in a complete loss of pY174. 
However, if SRC was the kinase responsible for Y174 phosphorylation it would be expected 
that levels of pY174 would be almost undetectable. In the first experiments, PP1 was assessed 
with both endogenous and over-expressed SRC. When the two conditions were directly 
compared, SRC once again led a large increase in pY174, and this could be reversed to some 
extent by PP1 (although not by PP3). pY174 was not reduced to the levels observed with 
endogenous SRC, which was most likely due to the excess of SRC resulting from 
transfection. To compare the effect of PP1 with the other TKIs, in particular SU11274, and 
also to assess its efficacy with endogenous levels of SRC, pY174 was measured in K1, TPC1 
and HeLa cells. In all 3 cell lines, PP1 had an effect on pY174 expression. In TPC1 and K1 
cells, PP1 inhibited pY174 the most, although in HeLas SU11274 and gefitinib appeared the 
most potent. The reason for the discrepancy in the HeLa results is unclear; and may be a 
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consequent of constitutively altered and therefore different kinase activation in this cell line. 
This is a problem that is inherent to using transformed cancer cell lines, as each will have 
varying mutations that affect the cell’s basic physiological processes.  
To combat this factor, human primary thyrocytes were used. These cultures were taken 
from macroscopically normal thyroid tissue and were therefore as close to physiologically 
normal cells as possible. As in vivo, there were differences in the behaviour of the cultures 
between different patients. This, at times, resulted in wide variation and therefore reduced the 
significance of some results. 
With normal human tissue now the subject of analysis, the panel of inhibitors was once 
again tested in untransfected cells. pY174 was much easier to detect in primary cells than for 
the cell lines, which resulted in the ability to assess the response of pY174 to the TKIs in a 
more physiological setting, as a precursor to the model of PBF over-expression found in 
thyroid cancers. In these circumstances, PP1 resulted in an almost complete abrogation of 
pY174, with reduction also observed with gefitinib and SU11274. A second experiment, 
treating cells with only PP1 or DMSO, confirmed this as a significant 81% reduction. 
Having established that PBF phosphorylation was modulated by SRC, and that 
phosphorylation could be affected by PP1, the next process was to assess the physiological 
impact of both this phosphorylation and its inhibition in the context of radio-iodide uptake. 
Iodide uptake is a key feature of thyroid epithelial cells, and forms an essential aspect of post-
surgical treatment of thyroid cancer. Previous work within our group had demonstrated that 
PBF represses NIS and thereby reduces iodide uptake (Smith et al. 2009), and that the murine 
transgenic model of thyroidal over-expression of PBF similarly demonstrates reduced iodide 
uptake in vivo (Read et al. 2011). Vitally, this phenotype could be rescued by PBF 
knockdown in primary cultures of murine thyrocytes (Read et al. 2011). The aim of these 
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experiments was thus to further elucidate a mechanism for this process, and if possible to 
target PBF-induced repression using a chemical inhibitor. 
Firstly, it was necessary to select the most appropriate model for experimentation. Both 
TPC1 and K1 cell lines had a low 125I uptake. Both cell lines are de-differentiated to a degree; 
the K1 line is known to have poor NIS expression (Petrich et al. 2002) and both have low 
expression of TSHR, which in turn reduces NIS expression (Meireles et al. 2007), and 
therefore these cell lines would not be suitable. The uptake in the non-thyroidal HeLa cell line 
was, as expected, poor and all three cell lines were therefore discounted from iodide uptake 
studies. 
As a result, human primary thyroid cultures were deemed to be the most appropriate 
cells on which to examine iodide uptake in the context of PBF phosphorylation, despite the 
high degree of variation between individual cultures. A number of validatory steps had to be 
performed for each culture before it was included in iodide uptake assays. The cells had to be 
shown to respond to TSH in the physiologically normal manner, indicating that the cellular 
processes governing TSH response, iodide uptake and thyroid hormone synthesis were 
functioning correctly. In addition to these normal functions of thyrocytes, the cells had to 
demonstrate a reduction in 125I uptake with PBF transfection. The purpose of these 
experiments was to attempt to reverse the reduction in iodide uptake demonstrated by tumours 
with high levels of PBF. Experiments on thyroid cancers not displaying a PBF response 
would still be valid, but were beyond the scope of this project. 
Both PBF-HA and untagged-PBF reduced iodide uptake in human primary thyroid 
cultures, further validating the work previously performed in our group (Smith et al. 2009). 
Interestingly, SRC also had a negative effect on uptake, independent of PBF transfection. 
However, no cumulative increase was observed when SRC and PBF were co-transfected. One 
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explanation for this is that SRC, in isolation, increases phosphorylation of endogenous PBF 
and this represses NIS to similar levels as seen when PBF is over-expressed, i.e. the total 
amount of pY174 is similar in the 2 settings. When they are co-transfected, pY174 repression 
of NIS is already at a maximum and therefore increasing the amount of SRC/PBF is unable to 
drive the response further.   
Following on from this, primary thyrocytes were therefore co-transfected with PBF or 
SRC for the purpose of assessing the effect of TKIs on 125I uptake. Initially, the panel of 
inhibitors was used at the dose (2 µM) and timepoint (30 minutes) shown to have significant 
effect on pY174 at the protein level as determined by Western blotting. However, none of the 
inhibitors, including PP1, had any effect on uptake following treatment. pY174 was 
appropriately repressed as measured by Western blotting (data not shown) but this did not 
translate into a measurable effect on uptake. A hypothesis to explain this finding was that the 
30 minute treatment was not sufficient to allow the relocation of NIS to the cell membrane. 
Indeed other studies examining iodide uptake in response to various treatments have used 24 
hours as a timepoint (Kogai et al. 2006). Therefore the further experiments were carried out 
with a treatment time of 24 hours.  
Initially, the response of untransfected cells to PP1 for 24 hours was assessed. There was 
a significant 65% increase in 125I uptake in the treated cells compared to those treated with 
DMSO, indicating that this was a more suitable time-point for this assay. To measure the 
ability of PP1 to reverse the PBF response, endogenous as opposed to over-expressed SRC 
was used. This had the added advantage of allowing for a more realistic disease model; we 
have demonstrated that PBF expression is increased in thyroid cancer (Stratford et al. 2005), 
but there is no evidence that SRC is regularly over-expressed or aberrantly activated alongside 
PBF in differentiated thyroid cancers. As a cell line that had previously shown high levels of 
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iodide uptake, the rat follicular cell-derived line FRTL5 was also employed at this point. PP1 
again led to a significant increase in iodide uptake but unfortunately the cells were not 
amenable to transfection and there was therefore no difference in uptake between blank vector 
and PBF transfected cells. 
The most important model, therefore, was one consisting of multiple cultures of human 
thyrocytes, transfected with either blank vector or PBF and treated for 24 hours with PP1. 
Compared to the untransfected cells, there was no significant increase in uptake in the vector 
only transfected cells with PP1 treatment. Most important was the finding that treating PBF-
HA transfected cells with PP1 led to a complete reversal in the repression of iodide uptake, 
returning levels back to those apparent with vector only transfection. 
 
Concluding remarks 
This chapter has demonstrated that SRC over-expression leads to an increase in PBF 
phosphorylation at Y174, an effect which could be reversed by the SRC family kinase 
inhibitor PP1, the latter with both endogenous and over-expressed levels of SRC. This effect 
was also observed in human primary thyrocytes at the protein level. These data suggested that 
SRC is the likely kinase responsible for phosphorylating PBF. 
Functionally, PBF and SRC both (although not cumulatively) reduced iodide uptake in 
human primary thyrocytes. Treatment of thyrocytes over-expressing PBF, as found in human 
thyroid cancer, with PP1 significantly increased their avidity for iodide, thus providing a 








Chapter 9 Final conclusions and future 
directions 
  




The work presented in this thesis described investigations into the binding partners of 
the product of the proto-oncogene PBF, in particular in relationship to thyroid disease. This 
was based on previous work detailing the important role PBF has in thyroid cancer; increased 
expression is observed in cancers compared to normal tissues, and high levels of PBF are 
independently associated with distant metastases, tumour multicentricity, advanced TNM 
stage, loco-regional recurrence and disease-specific mortality (Stratford et al. 2005; Hsueh et 
al. 2013). PBF is known to interact with a number of cellular proteins. It was first described as 
interacting with PTTG (Chien and Pei 2000), a process which was essential for the 
transactivation of FGF2. Subsequently PBF has been identified as a binding partner for NIS 
(Smith et al. 2009) and MCT8 (Smith et al. 2012); both of these interactions result in the 
internalisation of the transporter into the cell, from its usual location at the cell membrane. In 
the case of NIS, this leads to a reduction in iodide uptake into the thyroid cell. The effects of 
the internalisation of MCT8 are less well characterised, but it does appear to lead to an 
increase in intra-thyroidal thyroid hormone levels (Smith et al. 2012), and PBF-transgenic 
mice exhibit large, macro-follicular goitres (Read et al. 2011). Additional work carried out 
involving the PBF-Tg mouse model demonstrated that by knocking-down PBF in mouse 
primary thyroid cultures, iodide uptake could be restored to wild-type levels (Read et al. 
2011). 
 
Mapping the PBF interactome 
 
The above research highlighted PBF as a novel and important protein in the thyroid 
cancer pathway, and also as a potential therapeutic target in the treatment of thyroid cancer as 
an adjunct to surgery. Although the peptide structure of the protein is known, and several 




putative functional domains have been identified, the exact mechanism by which PBF exerts 
the above effects is not yet known. Tandem mass spectrometry has emerged in the past 
decade as   a   powerful   and   efficient   tool   with   which   to   determine   the   range   of   a   protein’s  
interactions within a cell (Downard 2006), and this information may facilitate the 
identification  of  methods  to  alter  that  protein’s  function (Sharma et al. 2012). The technique 
has drawbacks, however, in relation to its sensitivity and the subsequently large datasets 
generated. Therefore, initial experiments focussed on optimising the protocol for MS/MS, 
using K1 papillary thyroid cancer cells transfected with PBF-HA as a model to reduce 
contamination and non-specific binding, and then spreadsheet algorithms to determine the 
most relevant proteins from the software output. 
Following optimisation, PBF from K1 and TPC1 cells was immunoprecipitated, using 
either over-expressed (HA-tagged / untagged), or endogenous PBF. After HPLC and MS/MS, 
the results from the different runs were combined and analysed according to the parameters 
set out in Chapter 3. This generated a list of proteins with which PBF may interact and was, as 
expected, extensive. This list inevitably contained false positives, and by the nature of 
MS/MS would also have omitted some true binding partners, but would contain a substantial 
number of binding partners for consideration in future research. This list is presented in 
Appendix 1. 
For the purposes of this work, however, the list was further scrutinised to produce a 
shortlist of 9 proteins which were thought most likely to interact with PBF, based upon on 
their score across several runs as well as the number of peptides identified. The proteins 
included were cortactin, HSP90, thyroglobulin, Src family kinases, LRRK1/2, FAK1, UACA, 
adenomatous polyposis coli protein, and citron kinase. All of these potential binding proteins 




merit further investigation, although only three could be taken forward for further research; 
these were thyroglobulin, cortactin and the Src family kinases. 
 
Investigating the interaction between PBF and thyroglobulin 
 
The first protein to be assessed was thyroglobulin. This large protein is the precursor to 
the thyroid hormones T3 and T4; given the phenotype of the PBF transgenic mouse thyroid, 
an interaction with PBF may alter the metabolic pathway of thyroid hormones within the 
gland. Attempts at validation using GST pull-down assays were unsuccessful, likely due to 
the large protein size and multi-step process in the cell which results in its finished form. Co-
immunoprecipitation was also technically challenging in the thyroid cell lines, complicated by 
the multiple subunits identified on Western blotting. When the experiments were repeated in 
primary cultures and in homogenised thyroid tissue, the MS/MS findings of an interaction 
were supported. Preliminary studies then highlighted areas of potential co-localisation in 
intra-cellular vesicles, although these were inconclusive. Future work exploring this 
interaction and its functional consequences will need to address the problems of protein 
translation and cell line phenotype; the use of primary thyroid cultures and / or tissue will be 
key to studying any translational and physiological effects. 
 
Cortactin may be responsible for PBF membrane trafficking and secretion 
 
Cortactin was the highest scoring of the short-listed proteins and has been the focus of 
increasing research with regards its role in cell invasion and metastases in cancer (Kirkbride 
et al. 2011). It interacts with the actin cytoskeleton and has an important role in membrane 




trafficking, regulating both clathrin-dependent and -independent endocytosis (Weaver et al. 
2001; Cao et al. 2003; Kirkbride et al. 2011). It is a commonly used marker to characterise 
invadopodia - cytoplasmic projections from the cell membrane from which ECM-degrading 
proteins are secreted (Clark and Weaver 2008). 
As for thyroglobulin, independent experiments were first undertaken to validate the 
findings of MS/MS. Unfortunately, pull-down assays again failed to demonstrate an 
interaction, and therefore co-immunoprecipitation was performed. Initially, these studies were 
unsuccessful, due to heavy immunoglobulin / non-specific binding on Western blotting. 
However, when Myc-tagged cortactin was over-expressed, an interaction was supported. 
Western blotting did not demonstrate any change in expression of PBF with increased levels 
of cortactin, and in the reverse experiment cortactin levels remained constant with over-
expressed PBF-HA. To begin to determine the functional significance of the interaction 
between cortactin and PBF, immunofluorescence was performed and demonstrated potential  
co-localisation within intra-cellular vesicles. This would support a hypothesis that cortactin is 
responsible for the membrane shuttling of PBF; whether this is an endocytic or exocytic 
process could not be determined from these experiments. Immunofluorescence studies with a 
more sensitive anti-HA antibody did indicate what appeared to be membrane protrusions from 
cells transfected with PBF-HA; however this assay was not specific enough to determine if 
these were invadopodia, or in fact if they represented a step in the secretory mechanism of 
PBF. Secretion assays were therefore undertaken to investigate if cortactin played a part in 
PBF export, a process previously explored by our group (Watkins 2010). Initial attempts at 
this were unsuccessful, and failed to detect any evidence of secreted PBF on Western blotting. 
However, this study involved endogenous as opposed to over-expressed PBF (as previous 
work had done), and it is probable, therefore, that the quantity of PBF was below the 




detection limit for Western blotting. To overcome this problem, the experiment was repeated 
but with ELISA as the detection technique. This proved more successful, and identified 
secreted PBF in the media, but failed to demonstrate any change with either cortactin over-
expression or knock-down. This may be due to the fact that cortactin is not involved in PBF 
secretion, or that it does have a role but the time frame required to demonstrate an effect was 
not met in these experiments. These data do, however, further increase our understanding of 
how PBF may be transported around the cell, and work is now on-going to further explore the 
role of PBF in invadopodia formation, and whether cortactin expression affects PBF 
secretion. 
 
SRC phosphorylates PBF and reduces iodide uptake 
 
The final protein to be examined was SRC. The Src-family kinases are a group of non-
receptor tyrosine kinases which share a significant homology (Aleshin and Finn 2010). LYN 
and SRC were both identified by MS/MS, and closer inspection of the peptides identified 
them within a homologous part of the sequence. As phosphorylation is a modification often 
necessary for a protein to carry out a particular function, and as SRC had been identified by 
phosphorylation prediction software as a likely kinase for PBF Y174, this was pursued. 
In this case, GST pull-down assay as well as forward and reverse co-
immunoprecipitation supported an interaction between PBF and SRC, although SRC was 
over-expressed in the cells due to endogenous levels being poorly detected by Western 
blotting. Using fluorescence immunocytochemistry, co-localisation was observed at the cell 
membrane and within intra-cellular vesicles. SRC is active at the cell membrane and it is 
therefore at this site that phosphorylation of PBF would be  most likely to occur. There did 




not appear to be any alteration in the sub-cellular localisation of PBF when SRC was over-
expressed compared to endogenous levels of the kinase, although further quantitative studies 
would be needed to formally determine this.  
Having confirmed an interaction, experiments were then undertaken to assess the effect 
of SRC on PBF phosphorylation. An antibody specific to PBF phosphorylated at Y174 
(pY174) was already in use within our group and validated for Western blotting. After 
confirming its suitability also for immunocytochemistry, Western blot studies demonstrated a 
significant increase in pY174 expression when SRC was over-expressed; supporting the 
hypothesis that SRC phosphorylates PBF. In HeLa cells, the effect of a panel of TKIs on this 
finding was tested, with SU11274 and gefitinib significantly reducing this phosphorylation. 
SU11274 was then shown to have a dose- and time-dependent effect on PBF phosphorylation, 
as demonstrated by both Western blotting and immunofluorescence. An explanation for the 
reduction in pY174 observed with both gefitinib and SU11274 (and to a non-significant 
degree with the other TKIs), was the cross over in signalling pathways that exists within cells 
and which may be aberrantly activated in transformed cell lines.  To further investigate the 
specificity of SRC as the kinase responsible for phosphorylating PBF, cells were treated with 
a specific SRC inhibitor, PP1, and its inactive counterpart, PP3. PP1 treatment resulted in a 
significant reduction in pY174 in cells over-expressing SRC and PBF-HA, an effect 
replicated in untransfected cells across all 3 cell lines used. Finally, human primary cell 
cultures were assessed for a response to the TKI panel; a significant reduction in pY174 was 
observed with PP1 treatment. Taken together, these data provide strong evidence that PBF is 
phosphorylated by SRC, and that this process can be inhibited by treatment with a specific 
SRC inhibitor. 




To measure the effect of this functionally, iodide uptake assays were then performed. 
The efficacy of the various cell lines, including with transfection of NIS, was examined, and 
found to be too low to allow reproducible, reliable data. Experiments were therefore carried 
out on human primary thyrocytes; these also exhibited significant variation in both uptake and 
response to TSH, and therefore each prep underwent viability testing prior to uptake studies. 
PBF and SRC both reduced iodide uptake in primary thyrocytes, although this effect was not 
cumulative for co-transfection, perhaps an indication that NIS repression is already maximal 
with either of the genes over-expressed, and therefore no addition reduction can be obtained. 
To determine if these findings had a clinical relevance to a potential therapeutic strategy, 
primary thyrocytes were transfected as above and treated with the TKIs. The only inhibitor 
that caused a significant increase in iodide uptake was PP1. In those cells that underwent 
PBF-HA transfection and subsequent treatment with PP1, iodide uptake was identical to those 
that were transfected with blank vector. The potential translational implications of this are 
important: by inhibiting SRC in thyroid tissue over-expressing PBF, NIS repression may be 
overcome and iodide uptake restored, potentially increasing the tissue sensitivity to 
radioiodine. 
 
 A novel therapeutic strategy for thyroid cancer: Final remarks and future directions 
 
This thesis has generated data that improve the current level of understanding regarding 
the role of PBF in normal thyroid physiology and in thyroid cancer. The interaction with 
thyroglobulin (although as yet poorly characterised), and how this may relate to the transgenic 
mouse phenotype, is the focus of further study within our group. Perhaps the most exciting 
aspects of this research are the potential roles of cortactin in PBF transport and secretion, and 




the ability of SRC inhibition to increase iodide uptake in thyroid tissue over-expressing PBF. 
Although further studies are required, a working hypothesis can be generated against which to 
test future experiments (Figure 9.1). These will seek to further define the data described 
above, using in vitro techniques such as cell surface biotinylation, invadopodia assays and 
PBF mutant analysis to further probe the PBF / cortactin relationship, as well as detailed 
inhibitor studies to determine the efficacy of SRC inhibitors as therapeutic modalities and 
potentially progressing to clinical trials. SRC inhibitors are the subject of intensive clinical 
research, and recent studies have highlighted the potential for SRC inhibitors in subsets of 
thyroid cancer treatment (Chan et al. 2012). This would be the final translational step and one 
which has personalised medicine at its base – by   studying   a   patient’s   thyroid   tumour  
following surgery, if PBF is found to be over-expressed then adjuvant SRC inhibitor 
treatment could be delivered with radioiodine remnant ablation, thus increasing the efficacy of 
the therapy and reducing tumour recurrence and subsequent survival. 





Figure 9.1  Hypothesis regarding the secretion and phosphorylation of PBF. A – PBF 
interacts with cortactin and is transported to cell membrane invadopodia, where it is secreted 
into the ECM (Secretory pathway). Alternatively, PBF is transported to the cell membrane 
where it interacts with Src (Kinase pathway). B – PBF is phosphorylated by Src at Y174 and, 
now activated, binds NIS or MCT8 at the cell membrane. C – PBF now internalises NIS and 
MCT8, thereby repressing their function. 
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11.1 List of potential interacting partners identified by MS/MS 
 
The following is a list of proteins identified as potential binding partners during the 
MS/MS analysis in Chapter 4. All proteins with an Average Score per Peptide (ASP) less than 
20 and a total number of peptides less than 4 were discarded. 




ELAV-like protein 1 64.3 
Protein LYRIC 61.0 
Splicing factor, arginine/serine-rich 1 60.5 
Eukaryotic translation initiation factor 4 gamma 1 56.5 
Complement C1q subcomponent subunit B 55.5 
Lamin-B1 55.0 
TATA-binding protein-associated factor 2N 54.9 
Pituitary tumor-transforming gene 1 protein-interacting protein 53.9 
EF-hand domain-containing protein KIAA0494 53.2 
Intraflagellar transport protein 140 homolog 53.1 
Thioredoxin 50.5 
G-protein coupled receptor 39 49.9 
Heat shock 70 kDa protein 1 49.6 
Nuclease-sensitive element-binding protein 1 49.5 
Desmocollin-1 48.5 
Cell division control protein 2 homolog 48.3 
PH and SEC7 domain-containing protein 4 48.1 
Importin-7 47.8 
Tolloid-like protein 1 47.7 
Heat shock 70 kDa protein 1A 46.9 
Adenomatous polyposis coli protein 2 46.3 
Actin-related protein 2/3 complex subunit 3 45.3 
NHP2-like protein 1 45.2 
Lysozyme C 45.0 
Neurofilament heavy polypeptide 45.0 
Actin-related protein 2/3 complex subunit 5 44.7 
Histone H2A type 2-C 44.2 
Tubulin-specific chaperone E 44.2 
Cystatin-A 43.9 
Protein ASP 
Macrophage migration inhibitory factor 43.7 
Supervillin 43.6 
Histone H2B type 1-K 43.3 
Protein-glutamine gamma-glutamyltransferase 2 43.0 
PHD and RING finger domain-containing protein 1 42.9 
Targeting protein for Xklp2 42.9 
Actin-related protein 3 42.7 
ADP-ribosylation factor 5 42.1 
Calnexin 41.6 
Intracellular hyaluronan-binding protein 4 41.0 
Endonuclease VIII-like 3 41.0 
Trinucleotide repeat-containing gene 18 protein 40.6 
Bullous pemphigoid antigen 1, isoform 7 (Fragment) 40.5 
Choline transporter-like protein 4 40.4 
Uncharacterized protein C1orf125 homolog 40.2 
Src substrate cortactin 40.0 
Lysosomal-trafficking regulator 39.9 
Stress-70 protein, mitochondrial 39.7 
SLIT and NTRK-like protein 4 39.7 
G patch domain-containing protein 8 39.5 
Histone H2B type 3-A 39.5 
Peptidyl-prolyl cis-trans isomerase-like 1 39.3 
Prohibitin-2 39.0 
Apolipoprotein A-I 38.8 
Filamin-C 38.8 
Ribosome-binding protein 1 38.8 
Heat shock protein HSP 90-beta 38.6 
Peroxisome proliferator-activated receptor gamma coactivator  38.6 
Poly [ADP-ribose] polymerase 1 38.3 




Survival motor neuron protein 38.1 
Peptidoglycan recognition protein 1 37.7 
Hemoglobin subunit alpha-A 37.6 
High mobility group protein HMG-I/HMG-Y 37.4 
Ras GTPase-activating protein-binding protein 2 37.3 
Zinc finger protein 407 36.8 
Plexin-A1 36.5 
Cysteine-rich protein 2 36.4 
Syntaxin-binding protein 5 36.3 
Replicase polyprotein 1ab 36.3 
Transformation/transcription domain-associated protein 36.0 
Kinectin 35.6 
T-cell surface glycoprotein CD1b-2 35.5 
Fibrillin-1 35.4 
Ankyrin repeat and KH domain-containing protein 1 35.2 
Heterogeneous nuclear ribonucleoprotein G 35.2 
Synaptopodin-2 35.2 
Ubiquitin carboxyl-terminal hydrolase 25 35.2 
Beta-type platelet-derived growth factor receptor precursor 35.1 
Protein SFI1 homolog 35.1 
Myelin transcription factor 1-like protein 35.0 
Pericentrin 35.0 
Coatomer subunit gamma 34.7 
HHIP-like protein 2 34.7 
Pyrroline-5-carboxylate reductase 1, mitochondrial 34.7 
Inactive ubiquitin carboxyl-terminal hydrolase 54 34.7 
Uncharacterized protein C2orf71 homolog 34.5 
Phosphatidylinositol-4-phosphate 3-kinase C2 domain-
containing beta polypeptide 34.4 
Protein ASP 
StAR-related lipid transfer protein 9 34.3 
Basic helix-loop-helix domain-containing protein KIAA2018 34.3 
Nucleolysin TIAR 34.2 
Peroxisomal biogenesis factor 19 34.2 
Coagulation factor X 34.1 
Transcription factor 20 34.1 
Probable D-lactate dehydrogenase, mitochondrial 33.8 
EH domain-containing protein 4 33.7 
Actin-related protein 2/3 complex subunit 4 33.6 
Vacuolar protein sorting-associated protein 13A 33.5 
Thyroglobulin 33.5 
Transient receptor potential cation channel subfamily M 
member 6 33.4 
Tyrosine-protein kinase SgK223 33.4 
BEN domain-containing protein 3 33.3 
Dehydrogenase/reductase SDR family member 4 33.3 
Granulins 33.3 
Rho guanine nucleotide exchange factor 1 33.2 
Actin-related protein 2/3 complex subunit 2 33.2 
Hydrocephalus-inducing protein homolog 33.2 
Pleckstrin homology domain-containing family H member 1 33.2 
Coiled-coil domain-containing protein 46 32.9 
Protein TFG 32.9 
Elongation factor G 1, mitochondrial 32.9 
IQ motif and SEC7 domain-containing protein 3 32.9 
Polyadenylate-binding protein 4 32.8 
Zinc finger protein GLI1 32.8 
FH1/FH2 domain-containing protein 1 32.7 
Polypeptide N-acetylgalactosaminyltransferase 5 32.6 




Tetratricopeptide repeat protein 30B 32.5 
Fatty acid-binding protein, epidermal 32.4 
Protein MICAL-2 32.4 
Coiled-coil domain-containing protein 36 32.3 
Transketolase-like protein 2 32.2 
Glutathione S-transferase P 32.2 
Cytochrome P450 20A1 32.2 
Centromere protein F 32.1 
FK506-binding protein 15 32.0 
Multidrug resistance-associated protein 1 31.9 
Proline-rich protein 11 31.9 
ATP-citrate synthase 31.9 
E3 ubiquitin-protein ligase HUWE1 31.9 
Murinoglobulin-1 precursor 31.8 
CLIP-associating protein 1 31.6 
Histone H2A.V 31.6 
A disintegrin and metalloproteinase with thrombospondin 
motifs 4 31.6 
Tudor domain-containing protein 6 31.6 
Schlafen family member 5 31.5 
Aryl hydrocarbon receptor nuclear translocator 31.5 
ADP-ribosylation factor-like protein 2-binding protein-like 
protein 31.4 
Prolactin-inducible protein homolog 31.3 
Heparin cofactor 2 31.3 
ESF1 homolog 31.2 
Cullin-9 31.1 
Caspase-7 31.1 
Latent-transforming growth factor beta-binding protein 2 31.0 
Protein ASP 
Antigen WC1.1 31.0 
Methionine aminopeptidase 1D, mitochondrial 30.9 
Hemoglobin subunit alpha-2 30.9 
Integrin beta-2 30.8 
TRAF-interacting protein 30.8 
Zinc finger protein 766 30.8 
Neurogenic differentiation factor 6 30.8 
Testis-specific gene 13 protein 30.8 
Multisynthetase complex auxiliary component p43 30.7 
Fidgetin-like protein 1 30.7 
Heterogeneous nuclear ribonucleoprotein A1 30.6 
Inositol 1,4,5-trisphosphate receptor type 2 30.6 
Pleckstrin homology-like domain family B member 1 30.5 
Lactotransferrin precursor 30.5 
Zinc finger protein 608 30.5 
Histone H1.2 30.5 
ATP-binding cassette sub-family A member 2 30.4 
Protein KIAA0284 30.4 
Transcription initiation factor TFIID subunit 3 30.3 
Metastasis-associated protein MTA1 30.2 
Twist-related protein 2 30.2 
Interleukin-3 30.0 
Thrombospondin-4 30.0 
Metabotropic glutamate receptor 5 30.0 
Peroxidasin homolog 30.0 
Putative uncharacterized protein C12orf63 29.9 
Olfactory receptor 52E2 29.9 
TNFAIP3-interacting protein 3 29.8 
CCAAT/enhancer-binding protein zeta 29.7 




Huntingtin-interacting protein 1 29.7 
Plexin-B1 29.7 
ATP synthase subunit beta, mitochondrial 29.6 
Renalase 29.6 
TRIO and F-actin-binding protein 29.6 
Protein virilizer homolog 29.5 
Glycerol-3-phosphate acyltransferase 3 29.5 
Receptor-type tyrosine-protein phosphatase S 29.5 
LON peptidase N-terminal domain and RING finger protein 3 29.4 
Vasodilator-stimulated phosphoprotein 29.4 
ADP/ATP translocase 2 29.4 
Nucleosome-remodeling factor subunit BPTF 29.4 
Voltage-dependent T-type calcium channel subunit alpha-1G 29.4 
Peptidyl-prolyl cis-trans isomerase B 29.4 
Lamin-B2 29.3 
Uncharacterized protein C1orf62 29.2 
Src Family kinase 29.1 
HEAT repeat-containing protein 5B 29.1 
Protein TANC1 29.1 
Complement C4-B 29.1 
Histone H2A type 1-H 29.0 
JmjC domain-containing histone demethylation protein 1D 29.0 
KN motif and ankyrin repeat domain-containing protein 2 29.0 
Ras GTPase-activating-like protein IQGAP3 29.0 
WD repeat-containing protein 51B 29.0 
Cytospin-A 28.9 
BAT2 domain-containing protein 1 28.9 
Myb-binding protein 1A 28.9 
Tubby-related protein 1 28.9 
Protein ASP 
Interleukin-18 receptor 1 precursor 28.9 
Multimerin-1 28.9 
Calcineurin-binding protein cabin-1 28.8 
Calpain-1 catalytic subunit 28.8 
Utrophin 28.8 
Signal recognition particle receptor subunit alpha 28.8 
Uncharacterized coiled-coil domain-containing protein KIAA1984 28.7 
Putative tubulin-like protein alpha-4B 28.7 
Serine/threonine-protein kinase Nek4 28.7 
Peroxisomal membrane protein 11B 28.7 
Mutated melanoma-associated antigen 1 28.7 
Trans-acting transcriptional protein ICP0 28.7 
Lipid phosphate phosphatase-related protein type 3 28.7 
VPS10 domain-containing receptor SorCS1 28.7 
AF4/FMR2 family member 2 28.6 
Bromodomain and WD repeat-containing protein 3 28.6 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 2 28.6 
HAUS augmin-like complex subunit 6 28.5 
Meiosis-specific nuclear structural protein 1 28.5 
Centrosomal protein of 120 kDa 28.5 
Ninein-like protein 28.5 
Deformed epidermal autoregulatory factor 1 homolog 28.5 
Transferrin receptor protein 1 28.5 
Transcriptional regulator ATRX 28.4 
Cadherin-like protein 26 28.4 
Putative adenosylhomocysteinase 3 28.4 
Thioredoxin domain-containing protein 2 28.4 
Protein orai-2 28.4 




Cubilin precursor 28.3 
Voltage-dependent R-type calcium channel subunit alpha-1E 28.3 
Pecanex-like protein C14orf135 28.2 
Dachshund homolog 2 28.2 
Protein cramped-like 28.2 
Hyaluronan synthase 3 28.2 
Protein Dok-7 28.2 
FRAS1-related extracellular matrix protein 1 precursor 28.2 
MAP7 domain-containing protein 3 28.2 
Myeloid/lymphoid or mixed-lineage leukemia protein 2 28.1 
Fructose-bisphosphate aldolase B 28.1 
Emerin 28.1 
Fanconi anemia group M protein 28.1 
CD225 family protein FLJ76511 28.1 
Armadillo repeat-containing protein 5 28.1 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 2 28.1 
Fibrous sheath-interacting protein 2 28.1 
CLIP-associating protein 2 28.0 
Complement C1q subcomponent subunit C 28.0 
Syncoilin 28.0 
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 28.0 
Contactin-2 28.0 
Nucleoside-triphosphatase C1orf57 27.9 
Polymerase delta-interacting protein 3 27.9 
Protein LOC339766 27.9 
Ankyrin repeat domain-containing protein 7 27.9 
Protocadherin Fat 3 27.9 
G protein-coupled receptor kinase 5 27.9 
Protein ASP 
RIB43A-like with coiled-coils protein 1 27.9 
Uncharacterized protein C6orf174 27.8 
Syntaxin-4 27.8 
T-cell surface protein tactile 27.8 
Cell cycle checkpoint control protein RAD9B homolog 27.8 
Sodium bicarbonate cotransporter 3 27.8 
Sciellin 27.8 
Cell growth-regulating nucleolar protein 27.8 
Forkhead-associated domain-containing protein 1 27.7 
E3 ubiquitin-protein ligase RNF149 27.7 
Breast cancer type 1 susceptibility protein homolog 27.7 
ADP-ribosylation factor-like protein 8A 27.7 
P2X purinoceptor 5 27.7 
Uncharacterized protein KIAA0552 27.7 
Cell division cycle protein 123 homolog 27.7 
Cancer-associated gene 1 protein homolog 27.6 
Membrane primary amine oxidase 27.6 
Proto-oncogene tyrosine-protein kinase ROS precursor 27.6 
Transcription cofactor vestigial-like protein 3 27.6 
SH3 and multiple ankyrin repeat domains protein 1 27.6 
Leucine-rich repeat flightless-interacting protein 27.5 
Kappa-casein 27.5 
Macrophage receptor MARCO 27.5 
Retinoic acid-induced protein 1 27.5 
Transient receptor potential cation channel subfamily M 
member 1 27.4 
Uncharacterized protein C19orf21 homolog 27.4 
E3 ubiquitin-protein ligase Praja1 27.4 
Spermatid nuclear transition protein 3 27.4 




SPATS2-like protein 27.3 
Sodium channel protein type 11 subunit alpha 27.3 
Gephyrin 27.3 
Probable carboxypeptidase PM20D1 27.3 
Poly [ADP-ribose] polymerase 4 27.3 
Plasminogen activator inhibitor 2, macrophage 27.2 
Angiopoietin-2 27.2 
Plasmalemma vesicle-associated protein 27.2 
Serine/threonine-protein kinase VRK2 27.2 
Sodium channel protein type 10 subunit alpha 27.2 
Vesicle transport through interaction with t-SNAREs homolog 1B 27.2 
Probable 10-formyltetrahydrofolate dehydrogenase ALDH1L2 27.1 
Protein FAM83G 27.1 
Rho GTPase-activating protein 18 27.1 
Sperm motility kinase 4a 27.1 
Stanniocalcin-2 27.1 
Phosphatidylinositol 4-kinase alpha 27.1 
Toll-like receptor 5 27.1 
Protein-glutamine gamma-glutamyltransferase E 27.0 
Disks large homolog 4 27.0 
Integrin alpha-11 27.0 
Corneodesmosin 27.0 
T-box transcription factor TBX22 26.9 
Importin subunit alpha-6 26.9 
Oxygen-regulated protein 1 26.9 
Nucleoporin NUP85 26.9 
Putative methyltransferase METT10D 26.8 
Leiomodin-2 26.8 
Uncharacterized protein C9orf102 homolog 26.8 
Protein ASP 
Receptor-type tyrosine-protein phosphatase delta 26.7 
Katanin p60 ATPase-containing subunit A-like 1 26.7 
Uncharacterized protein C1orf26 homolog 26.7 
Centrosome-associated protein 350 26.7 
Uncharacterized protein C6orf170 26.7 
Zinc finger protein with KRAB and SCAN domains 2 26.7 
Regulator of G-protein signaling 3 26.7 
ATPase WRNIP1 26.7 
Coiled-coil domain-containing protein 40 26.7 
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-
2 26.7 
Xylosyltransferase 1 26.6 
Low-density lipoprotein receptor-related protein 2 26.6 
Eosinophil peroxidase 26.6 
Ubiquitin carboxyl-terminal hydrolase 29 26.6 
Zinc finger protein 322A 26.6 
Cholinephosphotransferase 1 26.6 
Heterogeneous nuclear ribonucleoprotein A3 26.6 
Angiopoietin-4 26.6 
B-cell receptor CD22 26.6 
EH domain-binding protein 1 26.6 
Lactation elevated protein 1 26.6 
Ubiquitin carboxyl-terminal hydrolase 49 26.6 
Ferritin heavy chain 26.5 
Phosphoglycerate mutase family member 5 26.5 
FCH and double SH3 domains protein 2 26.5 
Transcription factor HIVEP3 26.4 
Alanine--glyoxylate aminotransferase 2-like 1 26.4 
SCL-interrupting locus protein homolog 26.4 




IQ and ubiquitin-like domain-containing protein 26.4 
Dynamin-2 26.4 
Tubulin beta-1 chain 26.4 
Uncharacterized protein C3orf63 homolog 26.4 
Heat shock-related 70 kDa protein 2 26.4 
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase 26.3 
Tenascin-X 26.3 
Peroxisomal acyl-coenzyme A oxidase 2 26.3 
Zinc finger homeobox protein 4 26.3 
Protein kinase C theta type 26.3 
Histone H1t 26.3 
Eukaryotic translation initiation factor 2-alpha kinase 4 26.2 
Rho GTPase-activating protein 20 26.2 
Protocadherin gamma-B6 26.2 
Ubiquitin carboxyl-terminal hydrolase 34 26.2 
B-cell receptor-associated protein 29 26.2 
C4b-binding protein alpha chain 26.2 
RING finger protein 31 26.2 
Stonin-2 26.2 
Structural maintenance of chromosomes protein 1B 26.2 
Zinc finger protein 638 26.2 
Prostacyclin synthase 26.2 
Arginine-glutamic acid dipeptide repeats protein 26.2 
Protein sidekick-2 26.2 
cAMP-specific 3',5'-cyclic phosphodiesterase 4B 26.1 
Dehydrogenase/reductase SDR family member on chromosome 
X 26.1 
Peripheral-type benzodiazepine receptor-associated protein 1 26.1 
Protein ASP 
5'-nucleotidase domain-containing protein 3 26.1 
Antigen peptide transporter 1 26.1 
Proliferating cell nuclear antigen 26.0 
Fibrocystin 26.0 
Protein RMD5 homolog A 26.0 
Desmin 26.0 
Mitochondrial intermediate peptidase 26.0 
Serine/threonine-protein kinase MRCK alpha 26.0 
Intersectin-2 25.9 
Peptidylprolyl isomerase domain and WD repeat-containing 
protein 1 25.9 
Ankyrin repeat domain-containing protein 56 25.9 
Actin filament-associated protein 1-like 1 25.9 
Bestrophin-1 25.9 
Coiled-coil domain-containing protein 146 25.9 
Eukaryotic translation initiation factor 3 subunit E 25.9 
Heterogeneous nuclear ribonucleoprotein A0 25.9 
TRAF family member-associated NF-kappa-B activator 25.9 
RING finger protein 113A 25.8 
Probable helicase with zinc finger domain 25.8 
Ankyrin-2 25.8 
Multiple epidermal growth factor-like domains 8 25.7 
Transmembrane protein C15orf27 25.7 
Dedicator of cytokinesis protein 1 25.7 
Fanconi anemia group A protein 25.7 
Proto-oncogene serine/threonine-protein kinase mos 25.6 
Neuron navigator 2 25.6 
Pulmonary surfactant-associated protein D precursor 25.6 
2',3'-cyclic-nucleotide 3'-phosphodiesterase 25.6 




Phosphatase and actin regulator 4 25.6 
Signal recognition particle 68 kDa protein 25.6 
Rab3 GTPase-activating protein non-catalytic subunit 25.6 
Cyclin-J 25.6 
B-cell lymphoma 6 protein 25.5 
Fatty acid-binding protein, adipocyte 25.5 
Pleckstrin homology-like domain family B member 2 25.5 
Alpha-enolase 25.5 
Uncharacterized protein KIAA1671 25.5 
Splicing factor 3B subunit 3 25.5 
Pecanex-like protein 1 25.5 
AT-rich interactive domain-containing protein 5A 25.4 
Huntingtin 25.4 
Protein QN1 homolog 25.4 
ATP-binding cassette sub-family A member 3 25.4 
Coiled-coil domain-containing protein 45 25.4 
Ras GTPase-activating protein 3 25.4 
Seminal vesicle major clotting proteins 25.4 
Probable Coiled-coil domain-containing protein 8 25.4 
Ubiquitin carboxyl-terminal hydrolase 4 25.4 
Antigen KI-67 25.3 
Protein AHNAK2 25.3 
Ankyrin repeat domain-containing protein 43 25.3 
Coiled-coil domain-containing protein 18 25.3 
Uncharacterized protein C14orf80 homolog 25.3 
Protocadherin gamma-C3 25.3 
DALR anticodon-binding domain-containing protein 3 25.3 
Lamina-associated polypeptide 2, isoforms alpha/zeta 25.2 
Uncharacterized protein KIAA0947 25.2 
Protein ASP 
RUN and FYVE domain-containing protein 1 25.2 
Tetratricopeptide repeat protein 3 25.2 
Protein BAT2-like 25.2 
Calpain-7 25.2 
G2/mitotic-specific cyclin-B1 25.2 
Voltage-gated potassium channel subunit beta-1 25.2 
Bile acid receptor 25.1 
Nuclear pore complex protein Nup205 25.1 
SH3 and multiple ankyrin repeat domains protein 3 25.1 
Uncharacterized protein ENSP00000382514 homolog 25.1 
Probable E3 ubiquitin-protein ligase HERC1 25.1 
Macrophage scavenger receptor types I and II 25.1 
Proto-oncogene tyrosine-protein kinase Fes/Fps 25.1 
HIRA-interacting protein 3 25.1 
Nesprin-2 25.0 
Transcription factor HIVEP2 25.0 
Cell cycle progression protein 1 25.0 
Replication initiator 1 25.0 
Proto-oncogene vav 25.0 
WD repeat-containing protein 64 25.0 
Disintegrin and metalloproteinase domain-containing protein 28 25.0 
Uncharacterized protein C15orf42 25.0 
Integrator complex subunit 4 25.0 
Proprotein convertase subtilisin/kexin type 7 25.0 
Uncharacterized protein C14orf166B homolog 24.9 
Protein argonaut 24.9 
GTP-binding protein GUF1 homolog 24.9 
Prominin-2 24.9 
Suprabasin 24.9 




Serine--pyruvate aminotransferase, mitochondrial 24.9 
Uncharacterized protein C12orf55 24.9 
ATPase family AAA domain-containing protein 3 24.9 
Uncharacterized protein C20orf79 homolog 24.9 
Low-density lipoprotein receptor-related protein 1B precursor 24.9 
Complement C1q subcomponent subunit A 24.8 
Probable global transcription activator SNF2L2 24.8 
Cytochrome P450 3A17 24.8 
Lethal(3)malignant brain tumor-like 3 protein 24.8 
Mitogen-activated protein kinase 12 24.8 
Monocarboxylate transporter 10 24.8 
Multidrug resistance-associated protein 7 24.8 
Long-chain-fatty-acid--CoA ligase ACSBG2 24.7 
Catalase 24.7 
Coiled-coil domain-containing protein 55 24.7 
CD59 glycoprotein 24.7 
Uncharacterized protein C18orf34 24.7 
Protein dispatched homolog 1 24.7 
GAS2-like protein 2 24.7 
Putative glycerophosphodiester phosphodiesterase 5 24.7 
Raftlin 24.7 
Synaptotagmin-15 24.7 
SET and MYND domain-containing protein 3 24.7 
UHRF1-binding protein 1-like 24.7 
Metabotropic glutamate receptor 3 24.7 
Heterogeneous nuclear ribonucleoprotein M 24.6 
Ubiquitin carboxyl-terminal hydrolase 40 24.6 
Microtubule-associated protein tau 24.6 
Spermatogenesis-associated serine-rich protein 2 24.6 
Protein ASP 
Spindle and kinetochore-associated protein 3 24.6 
UPF0606 protein C11orf41 24.6 
Protein MON2 homolog 24.6 
Tyrosine-protein kinase RYK 24.6 
Inverted formin-2 24.5 
Liprin-alpha-2 24.5 
Kinetochore protein Nuf2 24.5 
B-cell CLL/lymphoma 9 protein 24.5 
Uncharacterized protein C12orf41 homolog 24.5 
Protein Hook homolog 2 24.5 
Phosphotidylinositol phosphatase PTPRQ 24.5 
Carbohydrate kinase domain-containing protein 24.5 
Beta-klotho 24.5 
Lysine-specific demethylase 3A 24.4 
SH2 domain-containing protein 4A 24.4 
GRB2-associated-binding protein 3 24.4 
Lipid phosphate phosphatase-related protein type 4 24.4 
Tetratricopeptide repeat protein 30A2 24.4 
Taste receptor type 1 member 1 24.4 
Vascular endothelial growth factor receptor 2 24.4 
Putative uncharacterized protein FLJ32790 24.4 
Zinc finger protein 350 24.4 
Echinoderm microtubule-associated protein-like 4 24.4 
Zinc finger protein 22 24.4 
Zinc finger SWIM domain-containing protein 1 24.4 
Ryanodine receptor 1 24.3 
Endoplasmic reticulum aminopeptidase 1 24.3 
Protein FAM81B 24.3 
Hemicentin-1 24.3 




Zinc finger protein basonuclin-1 24.3 
Cyclin-A1 24.3 
Ran-binding protein 10 24.3 
Protein asteroid homolog 1 24.3 
Focal adhesion kinase 1 24.3 
Caspase recruitment domain-containing protein 10 24.3 
Probable serine protease HTRA3 24.3 
Cytoplasmic protein NCK2 24.3 
Protein C16orf88 24.2 
UPF0723 protein C11orf83 homolog 24.2 
Band 4.1-like protein 1 24.2 
Signal transducer and activator of transcription 2 24.2 
T-cell surface antigen CD2 24.2 
Uncharacterized protein C14orf145 24.2 
Fer-1-like protein 4 24.2 
Inositol 1,4,5-trisphosphate receptor type 3 24.1 
Polycystic kidney disease and receptor for egg jelly-related 
protein 24.1 
PDZ domain-containing protein 2 24.1 
Cullin-4B 24.1 
Glycine cleavage system H protein, mitochondrial 24.1 
Glycine receptor subunit alpha-4 24.1 
Mitochondrial inner membrane protein 24.1 
Potassium voltage-gated channel subfamily H member 5 24.1 
Leucine-rich repeat-containing protein 7 24.1 
Ligand-dependent nuclear receptor corepressor-like protein 24.1 
Uncharacterized protein C12orf35 24.0 
Sickle tail protein 24.0 
Calpain-13 24.0 
Protein ASP 
Uncharacterized protein C6orf203 homolog 24.0 
Septin-9 24.0 
Serine palmitoyltransferase 1 24.0 
Ubiquitin-conjugating enzyme E2 E2 24.0 
Inner centromere protein 24.0 
Sentrin-specific protease 6 24.0 
Regulating synaptic membrane exocytosis protein 2 23.9 
Protocadherin Fat 1 precursor 23.9 
U4/U6 small nuclear ribonucleoprotein Prp3 23.9 
Telomere length regulation protein TEL2 homolog 23.9 
NFX1-type zinc finger-containing protein 1 23.9 
Ninein 23.9 
Cytokine-inducible SH2-containing protein 23.9 
Tyrosine-protein phosphatase non-receptor type 20 23.9 
Somatoliberin 23.9 
Arf-GAP, Rho-GAP domain, ANK repeat and PH domain-
containing protein 2 23.8 
Rho guanine nucleotide exchange factor 10-like protein 23.8 
Dihydrodipicolinate synthase-like, mitochondrial 23.8 
Uncharacterized protein C15orf33 homolog 23.8 
Tripartite motif-containing protein 9 23.8 
Lung squamous cell carcinoma-related protein 1 23.8 
A disintegrin and metalloproteinase with thrombospondin 
motifs 15 23.8 
Protein FAM135A 23.8 
Glutamate [NMDA] receptor subunit epsilon-4 23.8 
RANBP2-like and GRIP domain-containing protein 4 23.8 
PH and SEC7 domain-containing protein 3 23.7 
Endonuclease/exonuclease/phosphatase family domain- 23.7 




containing protein 1 
Haptoglobin 23.7 
Ribonucleoside-diphosphate reductase subunit M2 23.7 
Semaphorin-7A 23.7 
Syntaxin-binding protein 2 23.7 
Probable E3 ubiquitin-protein ligase TRIP12 23.7 
Heat shock protein 75 kDa, mitochondrial 23.7 
ATP-binding cassette sub-family B member 6, mitochondrial 23.6 
ATP synthase subunit g, mitochondrial 23.6 
C2 domain-containing protein 3 23.6 
Nuclear pore complex protein Nup214 23.6 
Heat shock protein beta-1 23.6 
E3 ubiquitin-protein ligase TRIM33 23.6 
Cullin-7 23.5 
Semaphorin-3B 23.5 
Lipopolysaccharide-binding protein 23.5 
Transmembrane protein 131 23.5 
Nance-Horan syndrome protein 23.5 
Serine-protein kinase ATM 23.5 
Uncharacterized protein C22orf30 23.5 
Cohesin subunit SA-2 23.5 
Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 2 23.4 
Melanoma inhibitory activity protein 3 23.4 
Mucin-16 23.4 
Peroxiredoxin-5, mitochondrial precursor 23.4 
Transcription initiation factor TFIID subunit 1 23.4 
Tetratricopeptide repeat protein 18 23.4 
Toll-like receptor 9 23.4 
Protein ASP 
Rab GDP dissociation inhibitor alpha 23.4 
Tumor suppressor p53-binding protein 1 23.4 
Signal recognition particle 54 kDa protein 23.3 
Thrombospondin type-1 domain-containing protein 7A 23.3 
Cathepsin D 23.3 
Cytochrome c oxidase subunit 6A2 23.3 
Plasminogen activator inhibitor 1 23.3 
Receptor-type tyrosine-protein phosphatase U 23.3 
Transforming acidic coiled-coil-containing protein 2 23.3 
Zinc finger C3H1 domain-containing protein 23.3 
Uncharacterized protein C3orf17 23.3 
Acyl-coenzyme A oxidase-like protein 23.3 
BCL-6 corepressor 23.3 
Integrator complex subunit 3 23.3 
Leucine-rich repeat-containing protein 33 23.3 
TNF receptor-associated factor 6 23.3 
LIM domain only protein 7 23.2 
Large proline-rich protein BAT2 23.2 
Uncharacterized protein KIAA1797 23.2 
Ankyrin repeat and LEM domain-containing protein 2 23.2 
Circadian locomoter output cycles protein kaput 23.2 
Basic fibroblast growth factor receptor 1 23.2 
Mitogen-activated protein kinase kinase kinase 4 23.2 
Testis-expressed sequence 10 protein 23.2 
Voltage-dependent L-type calcium channel subunit alpha-1F 23.2 
HERV-K_8p23.1 provirus ancestral Gag polyprotein 23.2 
Glutamate [NMDA] receptor subunit epsilon-3 23.2 
Fibrocystin-L 23.2 
Tubulin alpha chain-like 3 23.2 




Transcription intermediary factor 1-beta 23.1 
Alpha-protein kinase 2 23.1 
Bromodomain testis-specific protein 23.1 
cAMP-specific 3',5'-cyclic phosphodiesterase 4A 23.1 
Interferon beta 23.1 
Uncharacterized protein KIAA0467 23.1 
Arachidonate 12-lipoxygenase, 12S-type 23.1 
Nipped-B-like protei 23.1 
Phosphoribosylformylglycinamidine synthase 23.1 
Protein ALEX 23.1 
Zinc finger protein 24 23.1 
Tetratricopeptide repeat protein 21A 23.1 
Histone H1oo 23.1 
Gamma-interferon-inducible protein Ifi-16 23.1 
Type I iodothyronine deiodinase 23.1 
Lebercilin 23.1 
ADP/ATP translocase 4 23.1 
Ribosome biogenesis protein BMS1 homolog 23.1 
Induced myeloid leukemia cell differentiation protein Mcl-1 
homolog 23.1 
Midasin 23.0 
Tight junction protein ZO-2 23.0 
C-myc promoter-binding protein 23.0 
Trinucleotide repeat-containing gene 6B protein 23.0 
Bromodomain adjacent to zinc finger domain protein 1A 23.0 
Protein DERPC 23.0 
Latent-transforming growth factor beta-binding protein 1 23.0 
Mitogen-activated protein kinase-binding protein 1 23.0 
Papilin 23.0 
Protein ASP 
Serine/threonine-protein kinase 36 23.0 
WD repeat and FYVE domain-containing protein 3 23.0 
Apolipoprotein A-IV 23.0 
Histone acetyltransferase MYST4 23.0 
LAS1-like protein 23.0 
Proline dehydrogenase, mitochondrial 23.0 
Coiled-coil domain-containing protein 60 23.0 
Canalicular multispecific organic anion transporter 2 22.9 
Thymidine phosphorylase 22.9 
Protein CASC5 22.9 
Lutropin-choriogonadotropic hormone receptor 22.9 
E3 ubiquitin-protein ligase UBR4 22.9 
Caspase recruitment domain-containing protein 9 22.9 
Interleukin-1 receptor-associated kinase-like 2 22.9 
Leukocyte cell-derived chemotaxin-2 22.9 
Mucin-2 22.9 
Pantothenate kinase 1 22.9 
Superoxide dismutase [Cu-Zn] 22.9 
LINE-1 reverse transcriptase homolog 22.9 
Nucleolar protein 11 22.9 
Acyl-CoA dehydrogenase family member 10 22.9 
Death domain-containing protein CRADD 22.9 
ERV-FRD provirus ancestral Env polyprotein 22.9 
Platelet receptor Gi24 22.9 
Ras-interacting protein 1 22.9 
Leucine-rich repeat protein SHOC-2 22.9 
Tetratricopeptide repeat protein 23-like 22.9 
Small subunit processome component 20 homolog 22.9 
Interferon gamma 22.9 




Thioredoxin reductase 3 22.8 
Galectin-1 22.8 
Uncharacterized protein C1orf103 22.8 
Transmembrane protein 175 22.8 
Protein CREG2 22.8 
Lactase-phlorizin hydrolase 22.8 
Msx2-interacting protein 22.8 
SNF-related serine/threonine-protein kinase 22.8 
Zinc finger MYM-type protein 3 22.8 
Transcription factor GATA-5 22.8 
Myopalladin 22.8 
Rho guanine nucleotide exchange factor 15 22.7 
Myocardin 22.7 
A disintegrin and metalloproteinase with thrombospondin 
motifs 13 22.7 
Ankycorbin 22.7 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 22.7 
Rho-related GTP-binding protein RhoG 22.7 
Uncharacterized protein C14orf38 22.7 
Low-density lipoprotein receptor-related protein 5 22.7 
Transmembrane protein 41B 22.7 
Zinc finger protein 280D 22.7 
Arachidonate 5-lipoxygenase 22.7 
E3 ubiquitin-protein ligase UBR3 22.7 
Uncharacterized protein C10orf95 22.7 
UPF0518 protein FAM160A2 22.7 
Protein FAM44A 22.7 
Kin of IRRE-like protein 1 22.7 
Ly6/PLAUR domain-containing protein 3 22.7 
Protein ASP 
PEST proteolytic signal-containing nuclear protein 22.7 
Protein SMG7 22.7 
Zinc finger protein 18 22.7 
Bactericidal/permeability-increasing protein-like 1 22.7 
Zinc finger protein DZIP1 22.6 
Protein KRBA1 22.6 
Otogelin 22.6 
V-type proton ATPase subunit C 2 22.6 
Centrosomal protein of 170 kDa 22.6 
Protein SHQ1 homolog 22.6 
Dystroglycan 22.6 
Glucocorticoid receptor 22.6 
Protein NDRG1 22.6 
2',5'-phosphodiesterase 12 22.6 
Polymerase delta-interacting protein 2 22.6 
Ankyrin repeat domain-containing protein 34C 22.6 
Autophagy-related protein 2 homolog B 22.6 
Hemoglobin subunit gamma 22.6 
ADP-ribosylation factor GTPase-activating protein 3 22.6 
Core histone macro-H2A.1 22.6 
Phosphorylase b kinase regulatory subunit beta 22.6 
SCO-spondin 22.6 
Dual specificity protein kinase TTK 22.6 
Structural maintenance of chromosomes protein 3 22.5 
Apolipoprotein O-like 22.5 
Steroid 21-hydroxylase 22.5 
Zinc finger protein 227 22.5 
ATP-binding cassette sub-family G member 2 22.5 
Cytosolic carboxypeptidase 2 22.5 




DENN domain-containing protein 4C 22.5 
Leucine-rich repeat serine/threonine-protein kinase 2 22.5 
NADH dehydrogenase [ubiquinone] 1 beta  22.5 
Uncharacterized protein FLJ44066 22.5 
Centromere protein H 22.5 
Calcium-activated chloride channel regulator 4 22.5 
Receptor-type tyrosine-protein phosphatase eta 22.5 
WSC domain-containing protein 1 22.5 
Epiplakin 22.4 
GAS2-like protein 1 22.4 
Protein ALO17 22.4 
2,4-dienoyl-CoA reductase, mitochondrial 22.4 
Protein SLC7A6OS 22.4 
Troponin I, cardiac muscle 22.4 
Tripartite motif-containing protein 72 22.4 
GDP-L-fucose synthetase 22.4 
Eukaryotic translation initiation factor 3 subunit K 22.4 
Sphingosine-1-phosphate lyase 1 22.4 
E3 ubiquitin-protein ligase LRSAM1 22.4 
Netrin-3 22.4 
Splicing factor, arginine/serine-rich 7 22.4 
Zinc finger protein 106 22.4 
Sucrase-isomaltase, intestinal 22.4 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 1 22.4 
Leucine-rich repeat-containing protein 17 22.4 
Suppressor of G2 allele of SKP1 homolog 22.4 
Tribbles homolog 3 22.4 
Alpha-1-antiproteinase 22.4 
Protein ASP 
Alstrom syndrome protein 1 22.3 
Bromodomain adjacent to zinc finger domain protein 2A 22.3 
Disintegrin and metalloproteinase domain-containing protein 5 22.3 
Growth hormone receptor 22.3 
Protein phosphatase inhibitor 2 22.3 
Protein Shroom4 22.3 
Alcohol dehydrogenase class-3 22.3 
Fer-1-like protein 6 22.3 
M-phase phosphoprotein 9 22.3 
Pentatricopeptide repeat-containing protein 2 22.3 
Solute carrier family 26 member 9 22.3 
Tudor domain-containing protein 5 22.3 
Glutathione S-transferase Yb-3 22.3 
Nitric oxide synthase, endothelial 22.3 
Beta-actin-like protein 3 22.2 
Synaptonemal complex protein 1 22.2 
Toll-like receptor 1 22.2 
Protein FAM118B 22.2 
Potassium voltage-gated channel subfamily B member 1 22.2 




Deoxyribonuclease gamma 22.2 
Sodium/glucose cotransporter 1 22.2 
Ubiquitin-conjugating enzyme E2 O 22.2 
Elongation factor Ts, mitochondrial 22.2 
Probable G-protein coupled receptor 156 22.2 
Septin-7 22.2 




WD repeat-containing protein 35 22.2 
Alkyldihydroxyacetonephosphate synthase, peroxisomal 22.2 
UPF0580 protein C15orf58 homolog 22.1 
Transmembrane protease, serine 13 22.1 
Rho-associated protein kinase 2 22.1 
Armadillo repeat-containing protein 3 22.1 
Uncharacterized protein C4orf37 homolog 22.1 
Centrosomal protein of 68 kDa 22.1 
Cytochrome P450 4B1 22.1 
Symplekin 22.1 
Mitochondrial brown fat uncoupling protein 1 22.1 
Death-inducer obliterator 1 22.1 
FLYWCH-type zinc finger-containing protein 1 22.1 
NADH-ubiquinone oxidoreductase chain 5 22.1 
Brefeldin A-inhibited guanine nucleotide-exchange protein 3 22.1 
Cathepsin L1 22.1 
Hyccin 22.1 
S100P-binding protein 22.1 
Janus kinase and microtubule-interacting protein 2 22.0 
Protein bassoon 22.0 
Putative uncharacterized protein ENSP00000382790 22.0 
Ankyrin repeat domain-containing protein 6 22.0 
Transcription elongation factor B polypeptide 3 22.0 
Ribonucleases P/MRP protein subunit POP1 22.0 
RIMS-binding protein 2 22.0 
Carnitine O-palmitoyltransferase 1, liver isoform 22.0 
Alpha-catulin 22.0 
Retrotransposon gag domain-containing protein 1 22.0 
N-acetyltransferase ESCO1 22.0 
Protein ASP 
Amine oxidase [flavin-containing] B 22.0 
Brefeldin A-inhibited guanine nucleotide-exchange protein 1 22.0 
Protein DGCR14 22.0 
Complement component C9 21.9 
Protein dopey-1 21.9 
Oxoeicosanoid receptor 1 21.9 
Zinc finger protein 40 21.9 
Trichohyalin 21.9 
B-lymphocyte antigen CD20 21.9 
Dynamin-3 21.9 
Ecotropic viral integration site 5 protein 21.9 
Exophilin-5 21.9 
Transcription factor Dp-1 21.9 
Sorbin and SH3 domain-containing protein 1 21.9 
Leucine-rich repeat and IQ domain-containing protein 1 21.9 
Intestinal alkaline phosphatase 1 21.9 
Perforin-1 21.9 
StAR-related lipid transfer protein 13 21.9 
Cholinesterase 21.9 
RING finger protein 180 21.9 
10-formyltetrahydrofolate dehydrogenase 21.8 
Golgin subfamily A member 2 21.8 
Limbin 21.8 
U2-associated protein SR140 21.8 
Uncharacterized protein C19orf47 21.8 
Leucine-rich repeat and WD repeat-containing protein 21.8 
Roundabout homolog 4 21.8 
Plexin-B3 21.8 
Protein RRP5 homolog 21.8 




Fanconi anemia group I protein homolog 21.8 
Partitioning defective 3 homolog 21.8 
PMS1 protein homolog 1 21.8 
Small G protein signaling modulator 1 21.8 
Protein unc-45 homolog A 21.7 
Rootletin 21.7 
Tight junction-associated protein 1 21.7 
E3 ubiquitin-protein ligase MARCH6 21.7 
Trinucleotide repeat-containing gene 6A protein 21.7 
Protein Daple 21.7 
Neuronal PAS domain-containing protein 1 21.7 
Brain-specific angiogenesis inhibitor 1-associated protein 2 21.7 
Protein FAM161B 21.7 
Huntingtin-interacting protein 1-related protein 21.7 
Origin recognition complex subunit 6 21.7 
Peptidyl-glycine alpha-amidating monooxygenase 21.7 
AF4/FMR2 family member 4 21.7 
Beta-galactosidase-1-like protein 3 21.7 
Centrosomal protein of 78 kDa 21.6 
Dual oxidase 1 21.6 
Deubiquitinating protein VCIP135 21.6 
Armadillo repeat-containing protein 6 21.6 
L-amino-acid oxidase 21.6 
Rho GTPase-activating protein 27 21.6 
RING finger protein 213 21.6 
Calpain-12 21.6 
Zinc finger protein 167 21.6 
Nuclear fragile X mental retardation-interacting protein 1 21.6 
Teashirt homolog 2 21.6 
Protein ASP 
Magnesium transporter MRS2 homolog, mitochondrial 21.5 
Splicing factor, arginine/serine-rich 5 21.5 
UPF0704 protein C6orf165 homolog 21.5 
SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A-like protein 1 21.5 
Interleukin-21 21.5 
Uncharacterized protein C15orf52 21.5 
Eukaryotic translation initiation factor 2-alpha kinase 1 21.5 
SEL1-like repeat-containing protein KIAA0746 21.5 
Uncharacterized protein LOC340228 homolog 21.5 
p130Cas-associated protein 21.5 
YLP motif-containing protein 1 21.5 
Amyloid beta A4 precursor protein-binding family B member 3 21.5 
Bromodomain-containing protein 4 21.5 
Nuclear receptor coactivator 2 21.4 
Uncharacterized protein C12orf40 21.4 
Disintegrin and metalloproteinase domain-containing protein 7 21.4 
Plastin-2 21.4 
Reticulon-4 21.4 
Pulmonary surfactant-associated protein A 21.4 
Stonin-1 21.4 
T-box transcription factor TBX19 21.4 
Tetratricopeptide repeat protein 24 21.4 
Pancreatic triacylglycerol lipase 21.4 
Sodium channel protein type 9 subunit alpha 21.4 
Fanconi anemia group D2 protein 21.4 
Nuclear pore complex protein Nup98-Nup96 21.4 
C-type lectin domain family 4 member F 21.4 
Ankyrin repeat and zinc finger domain-containing protein 1 21.4 




Uncharacterized protein C1orf77 21.4 
Cathepsin S 21.4 
Chitotriosidase-1 21.4 
Cytochrome P450 2C19 21.4 
Lactadherin 21.4 
Nuclear pore membrane glycoprotein 210 21.4 
Protein FAM63A 21.4 
Ankyrin repeat domain-containing protein 24 21.3 
Armadillo repeat-containing X-linked protein 1 21.3 
D-beta-hydroxybutyrate dehydrogenase, mitochondrial 21.3 
RING finger protein 112 21.3 
Protein furry homolog-like 21.3 
Amyloid protein-binding protein 2 21.3 
Dual specificity tyrosine-phosphorylation-regulated kinase 4 21.3 
Otoancorin precursor 21.3 
Zinc finger protein 187 21.3 
ATP-dependent Clp protease ATP-binding subunit clpX-like, 
mitochondrial 21.3 
Disco-interacting protein 2 homolog B 21.3 
Far upstream element-binding protein 2 21.3 
Versican core protein 21.3 
A disintegrin and metalloproteinase with thrombospondin 
motifs 12 21.3 
Cell division cycle-associated protein 2 21.3 
Disco-interacting protein 2 homolog A 21.3 
Extracellular matrix protein FRAS1 21.3 
RAB6-interacting golgin 21.3 
Leiomodin-1 21.3 
Solute carrier family 43 member 3 21.3 
Protein ASP 
Structural maintenance of chromosomes protein 1A 21.3 
COP9 signalosome complex subunit 7a 21.3 
Centrosomal protein of 135 kDa 21.2 
Solute carrier family 22 member 6 21.2 
Ankyrin-3 21.2 
Uveal autoantigen with coiled-coil domains and ankyrin repeats 21.2 
GTPase IMAP family member 8 21.2 
Potassium voltage-gated channel subfamily H member 2 21.2 
Na(+)/H(+) exchange regulatory cofactor NHE-RF3 21.2 
Uncharacterized protein C3orf32 homolog 21.2 
Protein Shroom2 21.2 
Voltage-dependent T-type calcium channel subunit alpha-1I 21.2 
Cadherin-23 21.2 
Protein phosphatase 1 regulatory subunit 14A 21.2 
Leucine-rich repeat and WD repeat-containing protein 1 21.1 
Ankyrin repeat domain-containing protein 17 21.1 
Rho-guanine nucleotide exchange factor 21.1 
Tctex1 domain-containing protein 3 21.1 
Tetratricopeptide repeat protein 16 21.1 
Alpha-L-iduronidase 21.1 
Adenomatous polyposis coli protein 21.1 
Histone H2B type 1-C/E/F/G/I 21.1 
Protein phosphatase 1 regulatory subunit 3A 21.1 
Autophagy-related protein 2 homolog A 21.1 
Advillin 21.1 
Fibrinogen-like protein 1 21.1 
Methylthioribose-1-phosphate isomerase 21.1 
Lysyl oxidase homolog 4 21.1 
Cerebellar degeneration-related protein 2 21.1 




Ephrin type-A receptor 8 21.1 
Serine/threonine-protein phosphatase 1 regulatory subunit 10 21.1 
Tyrosine-protein kinase-protein kinase SgK269 21.1 
Carboxypeptidase A5 21.1 
Serine protease inhibitor Kazal-type 2 21.1 
Ewing's tumor-associated antigen 1 homolog 21.0 
Uncharacterized protein C6orf222 homolog 21.0 
Coagulation factor VII 21.0 
Calmodulin-regulated spectrin-associated protein 1-like protein 
1 21.0 
Centrosomal protein of 57 kDa 21.0 
Tyrosine-protein phosphatase non-receptor type 2 21.0 
Teneurin-1 21.0 
Nicotinamide phosphoribosyltransferase 21.0 
Zinc finger protein 512 21.0 
Coiled-coil domain-containing protein 61 21.0 
E1A-binding protein p400 21.0 
Matrix-remodeling-associated protein 5 21.0 
Protein SDA1 homolog 21.0 
Sodium/potassium-transporting ATPase subunit alpha-2 21.0 
Cytochrome c oxidase subunit 4 isoform 1 21.0 
Mesoderm posterior protein 1 21.0 
Mucosal pentraxin 21.0 
Inhibin beta B chain 21.0 
Major facilitator superfamily domain-containing protein 2 21.0 
Tudor domain-containing protein 7 21.0 
Calpain-3 20.9 
Long palate, lung and nasal epithelium carcinoma-associated 
protein 3 20.9 
Protein ASP 
Phosphoinositide 3-kinase regulatory subunit 4 20.9 
Protein phosphatase Slingshot homolog 1 20.9 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac 
exchanger 1 protein 20.9 
Cytochrome c oxidase subunit 5A, mitochondrial 20.9 
UPF0501 protein KIAA1430 homolog 20.9 
Netrin-4 precursor 20.9 
Vomeronasal type-1 receptor 2 20.9 
Thyroid adenoma-associated protein homolog 20.9 
Uncharacterized protein C12orf24 homolog 20.9 
Neurobeachin-like protein 2 20.9 
Rho GTPase-activating protein 23 20.9 
Secernin-3 20.9 
Rab3 GTPase-activating protein catalytic subunit 20.9 
Glutaminase kidney isoform, mitochondrial 20.9 
Proteasome subunit beta type-10 20.9 
Translocation protein SEC63 homolog 20.9 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 20.8 
Semenogelin-2 20.8 
THO complex subunit 2 20.8 
Leucine-rich repeat and death domain-containing protein  20.8 
Mitochondrial Rho GTPase 1 20.8 
Tubulin beta-6 chain 20.8 
Toll-like receptor 2 20.8 
Secretory phospholipase A2 receptor 20.8 
Alanine aminotransferase 1 20.8 
Coiled-coil domain-containing protein 125 20.8 
Hepatocyte growth factor receptor 20.8 
Sterol regulatory element-binding protein 2 20.8 




Polycomb group RING finger protein 6 20.8 
Scavenger receptor class A member 3 20.8 
Ankyrin repeat domain-containing protein 13A 20.7 
Protein Shroom1 20.7 
Uncharacterized protein C9orf79 20.7 
Coiled-coil domain-containing protein 154 20.7 
Semaphorin-6D 20.7 
Cysteine and histidine-rich domain-containing protein 1 20.7 
Ubiquinone biosynthesis methyltransferase COQ5, 
mitochondrial 20.7 
Glutathione S-transferase A2 20.7 
IQ domain-containing protein H 20.7 
WD repeat-containing protein 78 20.7 
Protein capicua homolog 20.7 
Fetal and adult testis-expressed transcript protein homolog 20.7 
AP-3 complex subunit beta-1 20.7 
Probable G-protein coupled receptor 150 20.7 
Orexigenic neuropeptide QRFP 20.7 
PAXIP1-associated protein 1 20.7 
Serpin B7 20.6 
Rho GTPase-activating protein 24 20.6 
Clusterin 20.6 
Glutathione synthetase 20.6 
F-box only protein 30 20.6 
Dynamin-1 20.6 
Mucin-5B 20.6 
Proteasome-associated protein ECM29 20.6 
Coiled-coil domain-containing protein 64A 20.6 
Coiled-coil and C2 domain-containing protein 2A 20.6 
Protein ASP 
Golgi integral membrane protein 4 20.6 
NACHT, LRR and PYD domains-containing protein 1 20.6 
Tetratricopeptide repeat protein 21B 20.5 
Microtubule-associated serine/threonine-protein kinase-like 20.5 
Niemann-Pick C1 protein 20.5 
Transmembrane protein 131-like 20.5 
Cell division cycle-associated protein 3 20.5 
Importin subunit alpha-4 20.5 
Laminin subunit beta-2 20.5 
Serine/threonine-protein kinase Nek9 20.5 
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic 
phosphodiesterase 8A 20.5 
Tubulin beta-5 chain 20.5 
Usherin 20.5 
Coiled-coil and C2 domain-containing protein 1B 20.5 
NADH-ubiquinone oxidoreductase chain 4L 20.5 
Proprotein convertase subtilisin/kexin type 6 20.5 
Phospholipase B1, membrane-associated 20.5 
Signal-induced proliferation-associated 1-like protein 1 20.4 
Probable E3 ubiquitin-protein ligase HERC2 20.4 
Neurolysin, mitochondrial 20.4 
Leucine-rich repeats and immunoglobulin-like domains protein 20.4 
TIR domain-containing adapter molecule 1 20.4 
General transcription factor IIH subunit 2 20.4 
Liprin-alpha-4 20.4 
Pyruvate kinase isozyme R 20.4 
Fibrillin-2 20.4 
Eukaryotic translation initiation factor 3 subunit H 20.4 
Fibronectin type 3 and ankyrin repeat domains 1 protein 20.4 





Serum amyloid A protein 20.4 
CD160 antigen 20.4 
Serine/threonine-protein kinase N1 20.4 
Protein EMSY 20.3 
Cadherin EGF LAG seven-pass G-type receptor 3 20.3 
Putative Polycomb group protein ASXL3 20.3 
Protein FAM81A 20.3 
Gamma-aminobutyric acid receptor subunit theta precursor 20.3 
Glycine receptor subunit alpha-3 20.3 
Leucine-rich repeat and coiled-coil domain-containing protein 1 20.3 
TBC1 domain family member 4 20.3 
Cytoskeleton-associated protein 2-like 20.3 
Nuclear receptor corepressor 1 20.3 
Centrobin 20.3 
Oligophrenin-1 20.3 
Putative CDC37-like protein ENSP00000350273 20.3 
Werner syndrome ATP-dependent helicase homolog 20.2 
Zinc finger protein DZIP1L 20.2 
5-aminolevulinate synthase, erythroid-specific, mitochondrial 20.2 
Agrin 20.2 
MACRO domain-containing protein 1 20.2 
Lupus brain antigen 1 homolog 20.2 
InaD-like protein 20.2 
Retinol-binding protein 3 20.2 
Sterol regulatory element-binding protein 1 20.2 
Telomeric repeat-binding factor 2 20.2 
Disintegrin and metalloproteinase domain-containing protein 20 20.2 




Protein Niban 20.2 
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
delta-4 20.2 
Aminopeptidase N 20.2 
Cyclin-dependent kinase inhibitor 2A, isoform 1 20.2 
Fc receptor-like B 20.2 
Formimidoyltransferase-cyclodeaminase 20.2 
Nucleolar complex protein 3 homolog 20.2 
Pancreatic lipase-related protein 1 20.1 
Argininosuccinate lyase 20.1 
Enoyl-CoA hydratase domain-containing protein 1 20.1 
Rab GDP dissociation inhibitor beta 20.1 
Guanine nucleotide-binding protein-like 3 20.1 
Putative E3 ubiquitin-protein ligase SH3RF1 20.1 
Apoptosis regulatory protein Siva 20.1 
Spermatogenesis-associated protein 7 homolog 20.1 
Myomesin-1 20.1 
Microtubule-associated serine/threonine-protein kinase 4 20.1 
Polyamine-modulated factor 1-binding protein 1 20.1 
Beta-crystallin A1 20.1 
ATP-binding cassette sub-family A member 5 20.1 
Disintegrin and metalloproteinase domain-containing protein 20.1 
Ras-related protein Rab-3C 20.1 
ATP-binding cassette transporter sub-family C member 8 20.0 
Protein MAK10 homolog 20.0 
Probable urocanate hydratase 20.0 
Protein MICAL-3 20.0 




Uncharacterized protein C10orf88 homolog 20.0 
Dimethylaniline monooxygenase [N-oxide-forming] 4 20.0 
Follitropin subunit beta 20.0 
Solute carrier organic anion transporter family member 1B2 20.0 
Paired amphipathic helix protein Sin3b 20.0 
Vinculin 20.0 
Eukaryotic translation initiation factor 4B 20.0 
Sex-determining region Y protein 20.0 
Interferon-induced very large GTPase 1 19.9 
Nuclear mitotic apparatus protein 1 19.9 
Coagulation factor V 19.9 
Protocadherin Fat 2 19.9 
Junction-mediating and -regulatory protein 19.9 
Uncharacterized protein KIAA1680 19.9 
Microtubule-associated protein 4 19.8 
Zinc finger ZZ-type and EF-hand domain-containing protein 1 19.8 
Uncharacterized protein C19orf44 homolog 19.8 
Synaptonemal complex central element protein 1 19.7 
Poly(ADP-ribose) glycohydrolase 19.6 
Coiled-coil domain-containing protein 57 19.6 
Threonine synthase-like 1 19.6 
Centromere-associated protein E 19.6 
E3 ubiquitin-protein ligase MARCH7 19.5 
Telomere-associated protein RIF1 19.5 
Stress-induced-phosphoprotein 1 19.5 
Sodium/potassium-transporting ATPase subunit beta-2 19.4 
Voltage-dependent L-type calcium channel subunit alpha-1C 19.4 
Sulfide:quinone oxidoreductase, mitochondrial 19.4 
Leukocyte receptor cluster member 1 homolog 19.3 
Protein ASP 
Citron Rho-interacting kinase 19.2 
Afadin 19.2 
Dimethylaniline monooxygenase [N-oxide-forming] 5 19.2 
Nuclear autoantigenic sperm protein 19.1 
Toll-like receptor 4 19.1 
Cystic fibrosis transmembrane conductance regulator 19.1 
EF-hand calcium-binding domain-containing protein 5 19.1 
Neurogenic locus notch homolog protein 3 19.1 
Fibrinogen alpha chain 19.1 
Uncharacterized protein KIAA1310 homolog 19.0 
Sperm flagellar protein 2 19.0 
Leucine-rich repeat-containing protein 18 19.0 
Methionine synthase 19.0 
Uncharacterized protein C18orf19 homolog 19.0 
UPF0681 protein KIAA1033 18.9 
Coiled-coil domain-containing protein 54 18.9 
Cytochrome b 18.8 
Disco-interacting protein 2 homolog C 18.8 
Disintegrin and metalloproteinase domain-containing protein 2 18.7 
Amyloid beta A4 precursor protein-binding family A member 3 18.7 
Nestin 18.7 
Kinetochore protein NDC80 homolog 18.7 
Putative COBW domain-containing protein 7 18.6 
RE1-silencing transcription factor 18.6 
Protein FAM65C 18.6 
Hornerin 18.6 
A-kinase anchor protein 9 18.5 
Chromobox protein homolog 2 18.5 
Talin-2 18.5 




14-3-3 protein zeta/delta 18.5 
Peroxiredoxin-2 18.4 
Microtubule-actin cross-linking factor 1 18.4 
Proteoglycan 4 18.4 
Spermatogenesis-associated protein 17 18.3 
Ryanodine receptor 2 18.3 
Taste receptor type 1 member 2 18.3 
Vacuolar protein sorting-associated protein 13B 18.3 
Fatty acid synthase 18.2 
Serine/threonine-protein kinase 10 18.2 
Serine/threonine-protein kinase MRCK beta 18.2 
Guanylate-binding protein 6 18.1 
Neurogenic locus notch homolog protein 4 18.0 
Serotransferrin precursor 18.0 
Mucin-5AC 18.0 
Mitogen-activated protein kinase kinase kinase 12 18.0 
Probable methylcytosine dioxygenase TET2 17.9 
Enhancer of polycomb homolog 1 17.9 
Receptor-type tyrosine-protein phosphatase N2 17.9 
Dedicator of cytokinesis protein 9 17.9 
Uncharacterized protein FLJ44048 homolog 17.9 
Uncharacterized protein KIAA1109 17.8 
Gag-Pro-Pol polyprotein 17.8 
NADH-ubiquinone oxidoreductase chain 2 17.8 
Ankyrin repeat domain-containing protein 30A 17.8 
UDP-glucose:glycoprotein glucosyltransferase 1 17.8 
Capsid polyprotein 17.7 
EH domain-binding protein 1-like protein 1 17.7 
Cell division cycle-associated 7-like protein 17.7 
Protein ASP 
Acetyl-CoA carboxylase 2 17.7 
Tetratricopeptide repeat protein 28 17.7 
Voltage-dependent N-type calcium channel subunit alpha-1B 17.7 
Tudor and KH domain-containing protein 17.7 
Thrombospondin type-1 domain-containing protein 7B 17.7 
Coiled-coil domain-containing protein 138 17.6 
Protein disulfide-isomerase A4 17.6 
UPF0474 protein C5orf41 17.6 
Ankyrin repeat domain-containing protein 31 17.5 
Talin-1 17.4 
Protein tyrosine kinase 2 beta 17.4 
Protein KIAA1881 17.4 
Fibulin-7 17.4 
Meiotic recombination protein REC8 homolog 17.3 
Sulfotransferase 1C2 17.3 
Coiled-coil alpha-helical rod protein 1 17.2 
Histone deacetylase 9 17.1 
Interleukin-10 17.0 
Carnitine O-palmitoyltransferase 1, muscle isoform 17.0 
Stabilin-1 16.9 
Lebercilin-like protein 16.9 
Nuclear receptor coactivator 6 16.9 
Strumpellin 16.8 
Intraflagellar transport protein 172 homolog 16.8 
Centrosomal protein of 164 kDa 16.8 
Uncharacterized protein KIAA0556 16.7 
Macoilin 16.7 
Cytosolic carboxypeptidase 3 16.6 
Dapper homolog 2 16.6 




von Willebrand factor A domain-containing protein 3A 16.6 
Phosphoserine phosphatase 16.5 
Apolipoprotein B-100 16.4 
Synaptonemal complex protein 2 16.4 
Intersectin-1 16.3 
Tumor necrosis factor receptor superfamily member 8 16.1 
Rho GTPase-activating protein 22 16.1 
LYR motif-containing protein 1 16.0 
Follicle-stimulating hormone receptor 15.9 
Guanine nucleotide exchange factor VAV3 15.9 
WD repeat-containing protein 62 15.9 
Lipopolysaccharide-responsive and beige-like anchor protein 15.8 
Retinitis pigmentosa 1-like 1 protein 15.8 
Putative glycerol kinase 5 15.7 
Coiled-coil domain-containing protein 74A 15.7 
Transcription elongation factor SPT6 15.6 
Zinc finger protein 536 15.5 
USP6 N-terminal-like protein 15.5 
WD repeat-containing protein 48 15.4 
Vasopressin V1a receptor 14.3 
Transcription factor TFIIIB component B'' homolog 14.0 
WD repeat-containing protein 19 13.6 
Protein unc-45 homolog B 13.6 
Uncharacterized protein FLJ40521 13.0 
Vascular endothelial growth factor receptor 1 12.9 
Ufm1-specific protease 2  12.7 
Coiled-coil domain-containing protein 52 12.3 
Zinc finger CCCH domain-containing protein 13 12.2 
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PTTG-Binding Factor (PBF) Is a Novel Regulator of the
Thyroid Hormone Transporter MCT8
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R. I. Seed, P. Kwan, G. Ryan, H. Mehanna, S. Y. Chan, V. M. Darras,
K. Boelaert, J. A. Franklyn, and C. J. McCabe
School of Clinical and Experimental Medicine (V.E.S., M.L.R., N.S., G.D.L., J.C.W.F., R.I.S., P.K., G.R.,
S.Y.C., K.B., J.A.F., C.J.M.), Institute of Biomedical Research, and School of Cancer Sciences (A.S.T.),
University of Birmingham, B15 2TT, United Kingdom; Institute of Head and Neck Studies and Education
(H.M.), University Hospitals Coventry and Warwickshire National Health Service Trust, Coventry, CV2
2DX, United Kingdom; and Laboratory of Comparative Endocrinology, Animal Physiology, and
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Within the basolateralmembrane of thyroid follicular epithelial cells, two transporter proteins are
central to thyroid hormone (TH) biosynthesis and secretion. The sodium iodide symporter (NIS)
delivers iodide from thebloodstream into the thyroid, andafter THbiosynthesis,monocarboxylate
transporter 8 (MCT8) mediates TH secretion from the thyroid gland. Pituitary tumor-transforming
gene-binding factor (PBF; PTTG1IP) is a protooncogene that is up-regulated in thyroid cancer and
thatbindsNIS andmodulates its subcellular localizationand function.Wenowshowthat PBFbinds
MCT8 in vitro, eliciting amarked shift inMCT8 subcellular localization and resulting in a significant
reduction in the amount of MCT8 at the plasma membrane as determined by cell surface bioti-
nylation assays. Colocalization and interaction between PBF andMct8 was also observed in vivo in
a mouse model of thyroid-specific PBF overexpression driven by a bovine thyroglobulin (Tg) pro-
moter (PBF-Tg). ThyroidalMct8mRNAandprotein expression levelswere similar towild-typemice.
Critically, however, PBF-Tg mice demonstrated significantly enhanced thyroidal TH accumulation
and reduced TH secretion upon TSH stimulation. Importantly, Mct8-knockout mice share this phe-
notype. Thesedata showthatPBFbindsandalters the subcellular localizationofMCT8 in vitro,with
PBF overexpression leading to an accumulation of TH within the thyroid in vivo. Overall, these
studies identify PBF as the first protein to interact with the critical TH transporter MCT8 and
modulate its function in vivo. Furthermore, alongsideNIS repression, PBFmay thus represent anew
regulator of TH biosynthesis and secretion. (Endocrinology 153: 3526–3536, 2012)
Pituitary tumor-transforming gene (PTTG)-bindingfactor (PBF; PTTG1IP) (1) is a protooncogene impli-
cated in endocrine cancer. Widely expressed in normal
tissue (1, 2), PBF is overexpressed in a number of tumors
including thyroid (3), pituitary (4), and breast (5). In thy-
roid cancer, higher PBF expression is independently asso-
ciated with early tumor recurrence (3).
The primary function of PBF remains unknown. How-
ever, some functional information has been obtained
through its interactions with other proteins. PBF was first
identified through its interaction with the human securin
PTTGand is thought to promote the nuclear translocation
of PTTG in a manner dependent upon the nuclear local-
ization signal at the C-terminal end of PBF (2).
More recently, we have demonstrated an interaction
with the sodium iodide symporter (NIS), an integralmem-
braneglycoprotein located in thebasolateral plasmamem-
brane of thyroid follicular epithelial cells (6). NIS is re-
sponsible formediating iodide uptake and is consequently
essential for thyroid hormone (TH) synthesis. Although
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radioiodine has long been used to successfully image and
treat tumors of the thyroid and their metastases, many of
these cancers demonstrate reduced iodide uptake and
those with reduced NIS activity are generally associated
with a poor prognosis (7).
Through investigating the mechanisms underlying the
repression of NIS activity, we found that PBF inhibited
iodide uptake and NIS expression in vitro (8). Further-
more, we elucidated a posttranslational mechanism of NIS
repression bywhich PBF bindsNIS and alters its subcellular
localization, thereby regulating its ability to uptake iodide
(6).Thesedatawere recently recapitulated in vivo in amouse
model of thyroid-specific PBF overexpression driven by a
bovine thyroglobulin (Tg) promoter (PBF-Tg), where Nis
mRNAexpressionwas significantly reducedbyapproximately
50% and iodide uptake in primary thyroid cell cultures was
down-regulated by approximately 70% (9).
These studies led us to question whether other mem-
brane transporters could be similarly regulated by PBF.
Monocarboxylate transporter 8 (MCT8) is a highly spe-
cific TH transporter (10, 11). Patients with inactivating
mutations in the gene encoding MCT8 present with neu-
rological abnormalities including severe psychomotor im-
pairment, strongly suggesting that TH uptake via MCT8,
particularly in the brain, is of critical importance. These
patients typically have abnormal tests of thyroid function,
with high serum free and total T3, low free and total T4,
low rT3, and normal-high TSH concentrations (12, 13).
MCT8 is highly expressed in the human thyroid gland
(14) and is the most abundant TH transporter in both the
human and mouse thyroid (15, 16). Like NIS, MCT8 is
expressed in the basolateral membrane of thyroid follic-
ular epithelial cells (15–17). Recent evidence suggests that
MCT8 is involved in the secretion of TH from the thyroid
after biosynthesis (15, 17). However, there is still little
known about the regulation of MCT8 expression and ac-
tivity (18).
Due to the similarity between MCT8 and NIS in terms
of thyroidal subcellular localization and a role in TH bio-
synthesis and secretion, we investigated a potential rela-
tionship between MCT8 and PBF. A physical interaction
betweenMCT8 and PBF was observed in vitro. PBF over-
expression in vitro resulted in a shift inMCT8 subcellular
localization from the plasma membrane into intracellular
vesicleswhere the two proteins colocalized bothwith each
other and the late endosome marker CD63. Colocaliza-
tion between Mct8 and PBF was also observed in vivo in
the significantly enlarged thyroid gland of the PBF-Tg
mouse, and coimmunoprecipitation assays in these thy-
roid glands revealed an interactionbetweenPBFandMct8
in vivo. The PBF-Tg mouse bears a phenotypic resem-
blance to theMct8-knockout (KO)mouse that, as a result
of the loss of Mct8-mediated TH secretion, displays en-
larged thyroid follicles due to TH accumulation (15, 17).
In keeping with this, thyroidal T3 and T4 content were
significantly elevated and TSH-stimulated T4 secretion
was significantly reduced in ourmousemodel of thyroidal
PBF expression. These studies thus suggest that PBF is a
novel interacting partner of MCT8 that may regulate its
localization and therefore its function.
Materials and Methods
Cell lines and plasmids
The COS-7 African green monkey kidney epithelial cell line
was maintained in DMEM (Life Technologies, Inc., Paisley,
Scotland, UK) supplemented with 10% fetal bovine serum, pen-
icillin (105 U/liter), and streptomycin (100 mg/liter).
Plasmids containing the full-lengthPBF cDNAwith andwith-
out ahemagglutinin (HA) taghavepreviously beendescribed (3).
The expression vector for human MCT8 with a C-terminal
HA tag (MCT8-HA) has been described previously (19). MCT8
cDNA was also subcloned into the EcoRI and XhoI restriction
sites of the pcDNA3.1! vector (Invitrogen, Carlsbad, CA) with
the addition of the Myc epitope at the 3" end using the forward
primer GCCGAATTCATGGCGCTGCAAAGC and reverse
primer CGG CTC GAG TCA GGA TCC CAG GTC CTC CTC
GGA AAT CAG CTT CTG CTC GAT TGG TTC CTC AGG
GTT GG (MCT8-MYC).
Cells were transfected using Fugene 6 reagent (Roche, Indi-
anapolis, IN) following the manufacturer’s instructions at a 3:1
reagent to DNA ratio. For cell surface biotinylation assays, im-
munofluorescence staining and coimmunoprecipitation assays,
cells were seeded in six-well plates, six-well plates with sterile
coverslips, and T25 flasks, respectively, and transfected with 2
!g (six-well) or 5 !g (T25) DNA after 24 h.
In vitro transcription: translation and glutathione-
S-transferase (GST) pull-down assays
The TNT coupled reticulocyte lysate system (Promega,Mad-
ison, WI) was used to express protein from theMCT8-HA plas-
mid, and PBF was expressed as a fusion protein with GST from
a pGEX plasmid (Amersham Biosciences, Little Chalfont, Buck-
inghamshire, UK) as described previously (6). Along with a GST
protein-only control, 20 !g GST-tagged PBF protein was com-
bined with 10 !l of the L-"-[35S]methionine-labeledMCT8 pro-
tein and incubated for 1 h on ice. After the addition of 400 !l of
a low-salt buffer [50mMTris (pH 7.4), 150mMNaCl, 1%Non-
idet P-40], 40!l packed glutathione agarose beads was added to
each reaction,whichwas subsequently incubatedwith end-over-
endmixing using a rotator for 90min at 4 C. After washingwith
the low-salt buffer, bound GST-PBF protein was eluted with 40
!l 25 mM glutathione in 50 mM Tris (pH 8) on ice for 1 h. The
protein samples were then analyzed by SDS-PAGE, using a 12%
acrylamide gel, along with 1 !l L-"-[35S]methionine-labeled
MCT8 protein in 20 !l Laemmli sample buffer (Bio-Rad Labo-
ratories, Hercules, CA) with 5% (vol/vol) #-mercaptoethanol,
used as a control demonstrating 10% input. After electropho-
resis, the gel was fixed and stained. The gel was then immersed
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in Amplify fluorographic reagent (Amersham) to increase the
sensitivity of signal detection, dried at 65 C for 2 h, and finally,
exposed to autoradiographic film at #20 C.
Coimmunoprecipitation assays
COS-7 cells in T25 flasks were transiently transfected with
MCT8-MYC and pCI-neo vector only (VO), PBF-HA and
pcDNA3.1! (VO), or MCT8-MYC and PBF-HA. Cells were
harvested in 500 !l RIPA buffer [50 mMTris-HCl (pH 7.4), 150
mM NaCl, 1% vol/vol Igepal CA-630, 6 mM sodium deoxy-
cholate, 1 mM EDTA] containing protease inhibitor cocktail
(Sigma, Poole, Dorset, UK). After a brief sonication step, cell
lysates were centrifuged at 13,000 rpm for 20 min and trans-
ferred to a cleanmicrocentrifuge tube. Each lysatewas incubated
with 10 !l mouse monoclonal anti-Myc-Tag (9B11) antibody
(Cell Signaling Technology, Inc., Danvers,MA) at 4 C overnight
with end-over-end rotating. After the addition of 25 !l packed
beads prepared from protein G Sepharose 4 Fast Flow (Amer-
sham), the samples were incubated for another 2 h at 4 C with
end-over-end rotating. Protein G Sepharose beads were centri-
fuged and, after the removal of any unbound protein, washed
four times with 500!l RIPA buffer. Bound protein was eluted in
50 !l Laemmli sample buffer containing 5% (vol/vol) #-mer-
captoethanol and1%(wt/vol) sodiumdodecyl sulfate at 37C for
30 min.
Proteins were separated by SDS-PAGE using a 12% acryl-
amide gel and transferred to polyvinylidene difluoride mem-
brane. The membrane was blocked with 5% milk in Tris-buff-
ered saline containing 0.025% Tween 80, and PBF-HA protein
was probed with mouse monoclonal anti-HA.11 antibody (Co-
vance Research Products, Emeryville, CA) at a concentration of
1:1000 in blocking buffer. After incubation with 650 ng/ml
horseradish peroxidase-conjugated polyclonal rabbit antimouse
Ig (Dako, Glostrup, Denmark) as secondary antibody, the anti-
gen-antibody complexes were detected using the ECL-Plus
chemiluminescence detection system (Amersham). Total protein
cell lysate (20!g) taken before the coimmunoprecipitation steps
was also separated by SDS-PAGE using 12% acrylamide gels to
confirm MCT8-MYC and PBF-HA expression. PBF-HA was
probed in the same way as the coimmunoprecipitation samples,
andMCT8-MYCwasdetectedwithmouseanti-Mycantibodyat
a concentration of 1:1000. #-Actin expression was assessed as a
loading control for each protein.
The reciprocal experimentwas performed in the sameway by
precipitating PBF-HA with 10 !l rabbit polyclonal anti-HA
(Y-11) antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
and probing for coimmunoprecipitated MCT8-MYC with
mouse anti-Myc antibody.
Mouse thyroid glands were homogenized in 350 !l RIPA
buffer and centrifuged at 13,000 rpm for 10 min. Lysate was
pooled from eight wild-type (WT) and six PBF-Tg thyroid
glands, and protein concentration was measured using the bi-
cinchoninic acid assay (Pierce, Rockford, IL). Using the method
described abovewith an additional preclearing step consisting of
a 2-h incubation at 4 C with 100 !l protein G Sepharose 4 Fast
Flow/ml lysate, endogenousMct8was immunoprecipitatedwith
5 !l rabbit anti-MCT8 antibody (Atlas, Stockholm, Sweden)
from 0, 0.3, 0.5, and 1 mg WT and PBF-Tg protein lysate. Co-
immunoprecipitation of PBF-HAwas detected throughWestern
blotting using the mouse monoclonal anti-HA.11 antibody (Co-
vance Research Products).
Immunofluorescence staining
Immunofluorescence staining using COS-7 cells was as car-
ried out as described previously (6). The following antibodies
were used: mouse monoclonal anti-HA.11 antibody (Covance
Research Products), rabbit polyclonal anti-HA (Y-11) antibody
(Santa Cruz Biotechnology), rabbit polyclonal anti-PBF anti-
body [made byEurogentec (Seraing, Belgium) for our laboratory
using the full-length PBF protein as an epitope], and mouse
monoclonal anti-CD63 antibody (kindly provided by Fedor
Berditchevski, School of Cancer Sciences, University of Birming-
ham, Birmingham, UK).
For the preparation of frozen tissue sections, thyroid glands
were excised fromWT and PBF-Tg mice and fixed in 4% form-
aldehyde. After cryoprotection of the tissue using an increasing
sucrose gradient (10–30%), the tissues were embedded in OCT
(Thermo Fisher Scientific,Waltham,MA) and frozen on dry ice.
Sections of 6 !m were prepared on a cryostat.
Before staining, theOCTwasdissolved inPBS for10min, and
tissue was permeabilized with 0.1% Triton X-100 (Sigma) for 5
min. After blocking in 10% normal calf serum (NCS) for 1 h,
tissues were incubated overnight at 4 C with rabbit anti-MCT8
antibody (Atlas) at 1:500 in 1%BSA. Incubationwith secondary
antibody Alexa Fluor 594-conjugated goat antirabbit IgG (In-
vitrogen) was performed at room temperature for 1 h at 1:500 in
1% BSA, with 2% NCS and Hoechst stain for nuclei (1:1000).
PBF-HA was stained using mouse monoclonal anti-HA.11 an-
tibody (Covance Research Products) at 1:500 and theMouse on
Mouse (M.O.M.) fluorescein immunodetection kit (Vector Lab-
oratories Inc., Burlingame, CA) following the manufacturer’s
instructions.
Epifluorescent microscopy was performed using a $40 ob-
jective on a Zeiss Axioplan fluorescent microscope (Zeiss,
Oberkochen, Germany). A Zeiss confocal LSM 510 microscope
with a$63 objective was used to perform confocal microscopy.
Cell surface biotinylation
MCT8-MYC and either pCI-neo (VO) or PBF plasmids were
transiently transfected into COS-7 cells. Forty-eight hours after
transfection, the cell surface protein isolation kit (Pierce) was
used to biotinylate and isolate membrane-associated proteins as
described previously (6)with someminormodifications. Briefly,
cells were exposed to 2$ 1ml EZ-Link Sulfo-NHS-SS-Biotin for
25 min at 4 C followed by 2$ 2 ml 100 mM glycine for 20 min
at 4 C. Cells from each of two wells of a six-well plate were
combined in 700 !l lysis buffer (1% Triton X-100 in PBS) con-
tainingprotease inhibitor cocktail (Sigma) andvortexed every15
min for an hour on ice. The lysate was centrifuged at 13,000 $
g for 15min at 4 C, and 40!l of the supernatant was retained as
whole-cell lysate. The remaining cell lysate was incubated with
immobilizedNeutrAvidin gel overnight at 4Cwith end-over-end
mixing using a rotator, and after washing away unbound pro-
tein, membrane proteins were eluted in 100 !l SDS-PAGE sam-
ple buffer [62.5 mM Tris-HCl (pH 6.8), 3% sodium dodecyl
sulfate, 10% glycerol] containing 70mM dithiothreitol for 1 h at
room temperature with end-over-end rotating.
MCT8-MYC was detected in the membrane protein and
whole-cell lysate fractions through immunoblotting. Proteins
were separated by SDS-PAGE using a 10% acrylamide gel, and
MCT8 protein was probed with mouse monoclonal anti-Myc-
Tag (9B11) antibody at a concentration of 1:1000, followed by
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secondary antibody, 650 ng/ml horseradish peroxidase-con-
jugated polyclonal rabbit antimouse Ig (Dako). Membranes
were subsequently reprobed with mouse monoclonal anti-flo-
tillin-1 antibody (BD Biosciences, Franklin Lakes, NJ) at
1:1000 to determine equal protein loading (6). Experiments
were carried out on three separate occasions, and scanning
densitometry used to quantitate mean changes in expression
vs. flotillin controls.
Mct8 mRNA and protein expression measurement
Total RNA was extracted from mouse thyroids using the
RNeasy Micro Kit (QIAGEN, Hilden, Germany) and reverse
transcribed using the reverse transcription system (Promega), as
previously described (9). Expression of Mct8 mRNAwas deter-
mined by quantitative PCR (8) using the TaqMan gene expres-
sion assay Mm00486202_m1 with analysis on the 7500 real-
time PCR system (Applied Biosystems, Foster City, CA). Mct8
mRNA expression was normalized to the expression of the
housekeeping gene 18s by subtracting the 18s cycle threshold
(Ct) values from theMct8 Ct values for each sample (%Ct). Pro-
tein extracted from homogenized thyroid glands in RIPA buffer
was analyzed by Western blotting using the rabbit anti-MCT8
antibody (Atlas) at 1:500.
Thyroidal TH content analysis
WT and transgenic PBF-Tg (thyroid-targeted expression of
PBF-HA)micewere bred at theUniversity of Birminghamand all
experiments performed in accordance with United Kingdom
Home Office regulations. The generation of the transgenic
PBF-Tg line has been described previously (9).
Thyroid glands were harvested from 8-wk-old WT and
PBF-Tg mice. After weighing, glands were frozen and stored at
#80 C until analysis of non-Tg-bound and total hormone con-
tent as described before (17). Thyroid glands were homogenized
in 500 !l ice-cold barbital buffer (0.05 M, pH 8.6) using a glass/
Teflon Potter tissue grinder system. This first step was followed
by additional ultrasonic homogenization (twice for 25 sec). Ho-
mogenates were then centrifuged and supernatants were trans-
ferred to new tubes. Part of the supernatant was directly frozen
and stored at#20 C, and 150!l of the supernatant was used for
enzymatic degradation of Tg by addition of 150 !l protease
[SigmaP-5147, 6.25mgprotease, and3.13mg2-thiouracil in 10
ml Tris-HCl buffer 0.75 M (pH 8.8)] and 15 !l toluol. Tubes
were stoppered and incubated for 2 d in a shaking water bath
at 37 C. Finally, tubes were placed in boiling water for 2 min
to inactivate the Pronase enzyme, frozen, and stored at#20C.
T4 and T3 concentrations were measured by RIA (20) in di-
lutions of untreated homogenates (non-Tg hormone levels)
and enzymatically digested homogenates (total hormone lev-
els) and non-Tg and total hormone content were calculated
per thyroid gland.
T4 and T3 concentrations were also measured in serum ob-
tained from the same mice using 25 and 100 !l serum, respec-
tively, by RIA (MP Biomedicals, Santa Ana, CA).
TSH stimulation test
WT (n & 10) and PBF-Tg (n & 14) mice were treated with
daily ip injections of 5 !g L-T3 (Sigma) for 4 d to suppress en-
dogenous TSH and basal T4 concentration. Blood was obtained
from the tail vein to provide a basal level of T4 before adminis-
tration of 50 mU bovine TSH (Sigma) via ip injection. Both L-T3
and TSH were administered in PBS with 0.02% BSA. After 3 h,
blood was obtained via cardiac puncture, and all animals were
euthanized humanely. T4 concentrations were measured using
25 !l serum using RIA (MP Biomedicals).
Results
PBF binds MCT8 in vitro
To investigate PBF andMCT8 bind-
ing in vitro, pull-down assays were per-
formed with in vitro-translated L-"-
[35S]methionine-labeled MCT8 and
GST-tagged PBF. Binding reactions
consistently demonstrated an interac-
tion between labeled MCT8 and GST-
PBF but not with a GST protein-only
control (Fig. 1A).
Coimmunoprecipitation assays were
subsequently used to assess this inter-
action in a more physiological, cellular
environment, given that in vitro-trans-
latedMCT8may not be processed cor-
rectly. After the transient transfection
of HA-tagged PBF (PBF-HA) and
MYC-tagged MCT8 (MCT8-MYC)
into COS-7 cells, MCT8-MYC was
precipitated from the cell lysatewith an
anti-MYC antibody. Probing with an
FIG. 1. PBF binds MCT8 in vitro. A, Pull-down assay showing in vitro-translated L-"-
[35S]methionine-labeled MCT8 binding GST-tagged PBF vs. a GST-only control. B,
Coimmunoprecipitation assays in COS-7 cells transfected with MCT8-MYC and VO, MCT8-
MYC and PBF-HA, or PBF-HA and VO. i, After immunoprecipitation (IP) with the anti-MYC
antibody, a band corresponding to PBF (arrows and asterisk) was observed at approximately
30 kDa in lysates transfected with both MCT8-MYC and PBF-HA but was not present when
either MCT8-MYC or PBF-HA was transfected with VO. Analysis of total protein cell lysate
shown below demonstrates the presence of MCT8-MYC or PBF-HA in each sample along with
a #-actin loading control. IgG is light-chain Ig. (ii) Reciprocal assay whereby MCT8-MYC was
coprecipitated along with PBF-HA and detected as a band at approximately 65 kDa (arrows
and asterisk).
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anti-HA antibody after Western blotting established that
PBF-HAhad coprecipitated alongwithMCT8-MYC (Fig.
1Bi). In contrast, PBF remained undetected in controls in
which MCT8-MYC and VO or PBF-HA and VO were
transfected (Fig. 1Bi). The reciprocal coimmunoprecipi-
tation assay, in which PBF-HAwas precipitated using the
anti-HA antibody, confirmed coimmunoprecipitation of
MCT8-MYC after immunoblotting with the anti-MYC
antibody (Fig. 1Bii). Finally, amass spectrometry screen to
detect binding partners of PBF in K1 thyroid carcinoma
cells also detected coimmunoprecipitation ofMCT8 (data
not shown). Thus, GST pull-down assays, coimmunopre-
cipitation assays, and mass spectrometry experiments all
demonstrated that PBF and MCT8 bind in vitro.
MCT8 colocalizes with PBF in vitro
We have demonstrated previously that HA-tagged
MCT8 (MCT8-HA) showed intense cell surface expres-
sion after transient transfection into the pluripotent hu-
man central nervous system precursor NT2 cell line and
colocalized with the plasmamembrane marker CD8 (19).
In the present studies, the subcellular localization of ex-
ogenous MCT8-HA and PBF was analyzed using immu-
nofluorescent staining in COS-7 cells, which are highly
amenable to immunofluorescent studies. As seen in NT2
cells, MCT8-HA was observed predominantly at the
plasmamembrane (Fig. 2A). As shown previously (6), en-
dogenous PBFwas expressed at relatively low levels in the
nucleus, whereas the majority of PBF protein was concen-
trated within intracellular vesicles in the cytoplasm (Fig.
2A).When PBFwas cotransfected alongwithMCT8-HA,
there was an apparent increase in MCT8 staining within
intracellular vesicles anda concomitant reduction inmem-
brane staining (Fig. 2B). Merged images demonstrated
strong colocalization between PBF and MCT8-HA, par-
ticularly within vesicles (Fig. 2B).
PBF alters the subcellular localization of MCT8
Given the apparent alteration in MCT8 localization,
we next investigated by quantitative means whether PBF
overexpressionwas associatedwith diminishedMCT8 lo-
calization at the cell membrane, where it serves as a func-
tional transporter. COS-7 cells were transfected with
MCT8-MYC and either VO control or PBF, and cell sur-
face biotinylation assayswere performed. Comparedwith
VO treatment, there was a significant reduction inMCT8
expression at the plasmamembrane after PBF transfection
(56 ' 7% reduction, P & 0.005, n & 3) (Fig. 3A). Total
MCT8-MYC expression was not significantly altered by
PBFoverexpressioncomparedwithVO
(10' 7% reduction, P& 0.245, n& 3)
(Fig. 3B), confirming an alteration in
localization rather than an overall re-
duction in MCT8 expression. Hence,
plasma membrane expression of
MCT8 was significantly reduced with
PBF overexpression in COS-7 cells.
MCT8 colocalization with CD63
We have previously demonstrated
colocalization of both PBF and NIS
with endogenous expression of the late
endosome marker CD63, a member of
the tetraspanin family that is com-
monly associated with clathrin-depen-
dent trafficking (6). Upon transfection
of PBF-HA into COS-7 cells, we again
showed a high degree of colocalization
between PBF and CD63 (Fig. 4A).
When MCT8-HA was transfected into
COS-7 cells, there was no apparent as-
sociation between MCT8 and CD63
staining (Fig. 4Bi). However, after
cotransfection of PBF, the vesicles in
which MCT8 was now detected
showed strong colocalization with en-
dogenous CD63 (Fig. 4Bii). This sug-
FIG. 2. MCT8 and PBF localization in COS-7 cells. A, Confocal images of MCT8-HA after
cotransfection with a VO control into COS-7 cells, and endogenous PBF, both detected by
immunofluorescent analysis. MCT8-HA (green) was located predominantly within the plasma
membrane, whereas endogenous PBF (red) was found in the nucleus and within intracellular
vesicles. B, Representative fluorescent immunocytochemistry experiments examining staining
of PBF (red) and MCT8-HA (green) after transient cotransfection into COS-7 cells using both
epifluorescent (i) and confocal (ii) microscopy. PBF was predominantly expressed within
cytoplasmic vesicles. MCT8-HA demonstrated increased staining within intracellular vesicles
where it strongly colocalized with PBF, as seen in yellow in the merged images. Scale bars, 20 !m.
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gests that the vesicles in which MCT8 was observed are
late endosomes and that the mechanism by which PBF
alters the subcellular localization of MCT8 may involve
clathrin-dependent endocytosis.
Mct8 expression in an in vivo model of thyroidal
PBF overexpression
Given that PBF binds MCT8 and alters its subcellular
localization, we next investigated Mct8 expression and
function in vivo in a mouse model in which HA-tagged
PBF overexpression is targeted specifically to the thyroid
gland (PBF-Tg) (9). Compared with WT mice, thyroidal
Mct8 mRNA expression was unaltered in PBF-Tg mice
(mean %Ct: PBF-Tg & 10.49 ' 0.13; cf. WT & 10.35 '
0.13,P&0.482, n&6) (Fig. 5Ai). ThyroidalMct8protein
expression, as determined by Western blot analysis, was
also similar in WT and PBF-Tg mice (0.98 ' 0.07-fold,
P& 0.878, n& 8) (Fig. 5Aii). Thus, in keeping with the in
vitro data above, high expression of PBF in vivo did not
alter Mct8 expression in the thyroid.
PBF and Mct8 colocalization and interaction in vivo
To further investigate an association between PBF and
Mct8 in vivo, frozen sections of thyroid glands taken from
PBF-Tgmicewere immunofluorescently labeled usingHA
andMCT8 antibodies. PBF-HAandMct8 showed intense
areas of colocalization, predominantly within the cyto-
plasm of the thyroid follicular epithelial cells of the
PBF-Tg mice (Fig. 5B). To determine whether these pro-
teins interactwithin these regions of co-
localization, coimmunoprecipitation
assays were performed on protein ly-
sate extracted from mice thyroid
glands. After the immunoprecipitation
of endogenous Mct8, a band of rising
intensity corresponding to PBF-HA
was detected in increasing amounts of
protein lysate from PBF-Tg thyroid
glands but not in equivalent amounts of
lysate taken from WT thyroids (Fig.
5C). In addition, examination of Mct8
localization in the thyroid follicular ep-
ithelial cells ofWTmice revealed strong
basolateral membrane expression (Fig.
5Di) that is in agreement with pub-
lished data (15–17) and that appeared
markedly reduced in the PBF-Tg thy-
roid cells (Fig. 5Dii). Hence, PBF and
Mct8 colocalize and interact within the
thyroid in vivo and, in keepingwith our
in vitro data, there appears to be a shift
in the subcellular localization of Mct8
in the presence of PBF overexpression.
Increased TH levels in the PBF-Tg thyroid glands
Given the reduction in cell surface MCT8 expression
after PBF overexpression in vitro, we hypothesized that
increased levels of PBF might result in diminished TH se-
cretion from the thyroid. To test this, thyroidal TH con-
tent was analyzed in 8-wk-old WT (n & 8) and PBF-Tg
(n & 10) mice. Mean thyroid weight for these WT and
PBF-Tg mice were 2.25 ' 0.12 and 5.54 ' 0.26 mg, re-
spectively. Thyroidal non-Tg-bound TH content in the
PBF-Tg mice was significantly higher compared with WT
mice. Non-Tg-T3 content in the PBF-Tg thyroid glands
was 1.9-fold higher than in WT thyroids (11.5 ' 1.2 vs.
6.2 ' 0.7 $mol/thyroid, P & 0.004) (Fig. 6Ai), and non-
Tg-T4 content was increased 2.4-fold (339.5 ' 41.8 vs.
144.3 ' 25.8 $mol/thyroid, P & 0.002) (Fig. 6Aii). Tg-
bound T3 content was increased 1.9-fold in PBF-Tg thy-
roid glands, although this was not significantly higher
than in theirWT counterparts (567.8' 113.9 vs. 293.2'
62.7 $mol/thyroid,P&0.100) (Fig. 6Bi). Thyroidal Tg-T4
content was 4.2-fold higher in PBF-Tg mice than in WT
mice (8349.5' 1966.2 vs. 1968.2' 412.2 $mol/thyroid,
P & 0.019) (Fig. 6Bii). In addition, TH concentrations
were also measured in the sera of these mice. Mean serum
T3 concentrations for the WT and PBF-Tg mice were
165.3 ' 8.6 and 150.1 ' 10.4 ng/dl, respectively, and
serum T4 levels were 2.9 ' 0.1 and 3.6 ' 0.2 !g/dl, re-
spectively. Subsequently, when the ratio of total thyroid
FIG. 3. PBF alters the subcellular localization of NIS. Cell surface biotinylation assays in COS-7
cells transfected with a VO control or with human PBF. A, Representative immunoblot analysis
of surface-biotinylated proteins precipitated with streptavidin-agarose beads and probed with
anti-MYC antibody, which revealed MYC-tagged human MCT8 detection at around 60 kDa.
Flotillin-1 was used as a marker of membrane protein expression to determine loading
between samples. Bottom panel, Three separate experiments were performed, with scanning
densitometry used to quantify mean differences in cell surface expression of MCT8, relative to
alterations in flotillin-1 expression. B, Representative immunoblot analysis of total MCT8-MYC
protein expression with results of densitometry shown below, demonstrating no significant
alteration in expression after PBF overexpression. Data are presented as mean ' SEM. **, P (
0.01; ns, not significant.
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THcontent (picomoles per thyroid) to circulatingTHcon-
centration (nanograms per deciliter) was assessed in each
mouse, a significantly higher ratiowasobserved inPBF-Tg
mice comparedwithWTmiceboth forT3 (2.2-fold increase;
P & 0.046) and T4 (3.2-fold increase; P & 0.029) (Supple-
mentalFig.1,publishedonTheEndocrineSociety’s Journals
Online web site at http://endo.endojournals.org).
Decreased TSH-stimulated T4 secretion from the
PBF-Tg thyroid gland
To further investigate whether a reduction in Mct8
function, and hence TH secretion, was at least partly re-
sponsible for the accumulation in TH within the thyroid
glands of PBF-Tgmice,wemeasured the release ofT4 after
TSHstimulation.To suppress the basal serumT4andTSH
concentrations, WT (n & 10) and PBF-Tg (n & 14) mice
were treated daily with 5 !g L-T3 for 4 d before adminis-
tration of 50 mU bovine TSH. After TSH stimulation, a
significant increase in serum T4 was observed inWTmice
(1.59' 0.17 vs. 1.37' 0.03 !g/dl, P& 0.007) (Fig. 6Ci).
In contrast, no increase in serum T4 was detected in
PBF-Tg mice (1.35 ' 0.10 vs. 1.36 ' 0.05 !g/dl, P &
0.629). Basal serum T4 levels were not significantly dif-
ferent between WT and PBF-Tg mice (1.37 ' 0.03 vs.
1.36'0.05!g/dl,P&0.884),whereas
after TSH administration, significantly
less serum T4 was present in PBF-Tg
compared with WT mice (1.35 ' 0.10
vs. 1.59' 0.17 !g/dl, P& 0.013) (Fig.
6Ci). Furthermore, when differences in
serum T4 levels before and after TSH
stimulation (%T4) were calculated for
each individual animal, there was a sig-
nificant decrease in %T4 in PBF-Tg
compared with WT mice (0.00 ' 0.06
vs. 0.22' 0.05 !g/dl, P& 0.021) (Fig.
6Cii).
Taken together, these data implicate
PBF as a novel interacting partner of
MCT8, which regulates MCT8 local-
ization, hence altering TH secretion
from the thyroid.
Discussion
Little is known about the regulation of
the critical TH transporterMCT8 (18).
Studies of the mouse Mct8 gene have
demonstrated cell-specific induction of
Mct8 expression by retinoic acid (21),
although the effect onMct8 expression
in the thyroid remains unknown.Given
its recentlydiscovered role inmediatingTHsecretion from
the thyroid gland (15, 17), we investigated a role for PBF
in MCT8 regulation.
We have previously described a posttranslational
mechanismofNIS regulation bywhich PBF bindsNIS and
modulates its subcellular localization, thereby down-reg-
ulating NIS activity (6). In the present study, we have ad-
dressed the hypothesis that PBF can regulate other mem-
brane transporters in addition to NIS and, through
investigation of a possible relationship between PBF and
MCT8, we have identified a novel mode of posttransla-
tional regulation for MCT8.
MCT8 was confirmed as a novel binding partner for
PBF through in vitro pull-down and coimmunoprecipita-
tion assays in COS-7 cells and mass spectrometry exper-
iments in K1 thyroid carcinoma cells. As observed with
NIS in previous experiments (6), PBF overexpression in
vitro resulted in an increase in MCT8 expression within
intracellular vesicles where it colocalized with PBF. Im-
portantly, increased expression of PBF was accompanied
by a significant reduction in MCT8 expression at the
plasma membrane, as determined through cell surface bi-
otinylation assays. Thus, MCT8 and PBF colocalize and
FIG. 4. Colocalization of PBF and MCT8 with CD63 in vitro. A, Confocal images of PBF-HA,
after transfection into COS-7 cells, and endogenous CD63. PBF-HA (red) and endogenous
CD63 (green) colocalized within late endosomes. B, Representative confocal images
examining staining of MCT8-HA (red) after transient transfection into COS-7 cells and
endogenous CD63 (green). i, With cotransfection of VO control, MCT8-HA was
predominantly expressed in the plasma membrane and showed no colocalization with CD63.
ii, In contrast, cotransfection of PBF resulted in the appearance of MCT8-HA within
intracellular vesicles (arrows) where it strongly colocalized with CD63, as seen in yellow in the
merged images. Scale bars, 20 !m.
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FIG. 5. Mct8 expression and localization in the PBF-Tg mouse. Ai, Relative Mct8 mRNA expression in thyroid glands of PBF-Tg mice compared
with WT mice (n & 6); ii, representative immunoblot demonstrating similar thyroidal Mct8 protein levels in PBF-Tg mice compared with WT mice,
using #-actin as a loading control (n & 8). Results of densitometry are presented as mean ' SEM. B, Immunostaining of frozen sections of PBF-Tg
thyroid. PBF-HA (blue) and Mct8 (red) were labeled using HA and MCT8 antibodies, respectively, and demonstrated intense areas of
colocalization (magenta) detected using confocal microscopy. Scale bars, 20 !m. C, Western blot analysis showing the detection of PBF-HA
coimmunoprecipitation after the immunoprecipitation (i.p) of endogenous Mct8 in increasing amounts of protein lysate taken from PBF-Tg mice.
Whole-cell (w.c.) lysate (30 !g) controls on the right show the relative expression levels of PBF-HA and Mct8 in WT (n & 8) and PBF-Tg (n & 6)
mice, and #-actin was used as a loading control. IgG is light-chain Ig. D, Confocal images of endogenous Mct8 expression in frozen sections of
mouse thyroid gland. Mct8 (red) demonstrated intense basolateral membrane expression in WT thyroid cells (i), which was diminished in the PBF-
Tg thyroid (ii). Scale bars, 20 !m.
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bind each other, and PBF is able to alter the subcellular
localization of MCT8 in vitro. In addition, having previ-
ously demonstrated that PBF and NIS are associated with
endogenous expression of the late endosome marker
CD63 (6), we have now shown that MCT8 is also found
in late endosomes after PBF overexpression. Thus, the
mechanism by which PBF internalizes both MCT8 and
NIS is likely to involve clathrin-dependent endocytosis re-
sulting in the enrichment of these transporters within late
endosomes.
To investigate the physiological relevance of these ob-
servations, we used our recently constructed PBF-Tg
transgenic mouse model in which PBF is specifically over-
expressed in the thyroid gland (9). Although Nis mRNA
and protein expression was significantly repressed in the
PBF-Tg thyroid, bothMct8mRNAand
protein expression were similar to WT
mice. Although PBF does not appear to
regulate Mct8 transcription, the pres-
ence of a posttranslational mechanism
of regulation in vivo was supported
through immunofluorescent studies of
PBF-Tg thyroid sections where PBF co-
localized with Mct8, particularly
within the cytoplasm of the follicular
epithelial cells. Furthermore, an in vivo
interaction between PBF andMct8was
demonstrated within thyroid glands
taken from PBF-Tg mice, and compar-
ison ofMct8 localization in thyroid fol-
licular cells in PBF-Tg mice indicated a
decrease in the clearly defined basolat-
eral membrane expression that is seen
in WT mice.
In addition to the reduced thyroidal
Nis expression and iodide uptake, the
PBF-Tg mouse has a notable pheno-
type. PBF-Tg mice have significantly
enlarged thyroid glands (with 100%
penetrance) that are associatedwithhy-
perplastic lesions (9). Interestingly,
these characteristics are sharedwith the
Mct8-KO mouse (15, 16). At 14 wk of
age, the thyroid glands of Mct8-KO
mice weigh around 4.1 mg compared
with a mean thyroid weight of 2.6 mg
for WT mice (15). This 1.6-fold in-
crease is comparable to the increase in
PBF-Tgmean thyroidweight compared
with WT mice of a similar age (9). The
thyroidal enlargement in the PBF-Tg
andMct8-KOmicewas largely due to a
significant (1.5-fold) increase in mean follicle size accom-
panied by the development of macrofollicles (9, 15–17).
The reduction in TH secretion in the Mct8-KO mice
resulted in an accumulation of TH within the thyroid
gland, which was both Tg and non-Tg bound (15, 17). To
assess the effect of PBF overexpression onMct8-mediated
secretion, TH content was measured in the PBF-Tg mice.
Both Tg and non-Tg-bound TH were significantly in-
creased in the PBF-Tg thyroid compared with WT mice.
Furthermore, T4 secretion after TSH stimulation was sig-
nificantly impaired in PBF-Tg mice compared with WT
mice. Lack of TH secretion from the Mct8-KO mouse
thyroid gland partially contributes to the abnormal serum
TH profile that reproduces the high T3 and low T4 levels
seen in human subjects with mutations in theMCT8 gene
FIG. 6. Thyroidal TH content and TSH-stimulated TH secretion in the PBF-Tg mouse.
Comparison of non-Tg-bound (A) and Tg-bound (B) TH content within the thyroid glands of
WT (n & 8) and PBF-Tg (n & 10) mice. Levels of non-Tg-T3 and Tg-T3 (i) and non-Tg-T4 and
Tg-T4 (ii) are presented as mean ' SEM. Ci Serum T4 levels before and 3 h after the
administration of 50 mU TSH in WT (n & 10) and PBF-Tg (n & 14) mice; ii, for each individual
animal, the difference in T4 concentration before and after TSH stimulation was calculated
and expressed as %T4. Presentation of the mean ' SEM %T4 illustrates a significant reduction in
T4 secretion in the PBF-Tg mice compared with WT. **, P ( 0.01; *, P ( 0.05.
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(15, 17). In contrast, despite the strikingly enlarged thy-
roid, PBF-Tgmicehavenormal serumTSHandcirculating
TH concentrations (9). There are a number of differences
between the PBF-Tg and Mct8-KO mice that could ex-
plain the variation in serum TH profile. In the Mct8 total
KO mouse, there would be no TH secretion via Mct8
whatsoever, whereas PBF overexpression is likely to only
partially prevent Mct8-mediated secretion. Furthermore,
the loss of Mct8 in the peripheral tissues and the subse-
quent alteration of deiodinase activity are known to sig-
nificantly contribute to the abnormal TH profile of the
Mct8-KO mouse (22–24), but Mct8 would still be fully
functional within these tissues in the PBF-Tg mouse. PBF
may also regulate the activity of other transporters such as
Mct10, another TH transporter expressed in both mouse
and human thyroid glands (14, 17).
In addition, although iodide uptake is normal in the
Mct8-KOmouse (17), the reduction inNis expression and
iodide uptake in the PBF-Tgmouse adds further complex-
ity (9). It might be expected that the reduction in Nis ac-
tivity would result in diminished TH synthesis. However,
although serum TSH concentrations are normal, the thy-
roid glands are significantly enlarged and appear to fully
compensate for this lack of iodide uptake, with mainte-
nance of normal serum TH concentrations. One potential
mechanism for this may be the reported increase in TSH
receptor expression (9),whichmay result in increased sen-
sitivity to TSH. Importantly, the ratio of total thyroidal
TH to total circulating TH is significantly increased in the
PBF-Tg mouse, further suggesting that TH secretion is
perturbed. Future studies will endeavor to elucidate the
contributionof reducedTHsecretionviaMct8 to theover-
all thyroid phenotype of the PBF-Tg mouse.
Overall, the present studies have identified a mecha-
nism of posttranslational regulation of MCT8 by which
PBF binds and alters its subcellular localization in vitro,
with PBF overexpression resulting in a reduction in TH
secretion and an accumulation of TH within the thyroid
gland in vivo. These data add to the recent increase in our
understanding of the final stages of TH synthesis and se-
cretion andhighlight PBF as an important regulator of this
process.
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